CA2369263A1 - Methods and compositions for enhancing delivery of therapeutic agents to tissues - Google Patents
Methods and compositions for enhancing delivery of therapeutic agents to tissues Download PDFInfo
- Publication number
- CA2369263A1 CA2369263A1 CA002369263A CA2369263A CA2369263A1 CA 2369263 A1 CA2369263 A1 CA 2369263A1 CA 002369263 A CA002369263 A CA 002369263A CA 2369263 A CA2369263 A CA 2369263A CA 2369263 A1 CA2369263 A1 CA 2369263A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- apoptosis inducing
- apoptosis
- therapeutic agent
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 358
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 154
- 238000000034 method Methods 0.000 title claims abstract description 150
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 230000002708 enhancing effect Effects 0.000 title abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 388
- 230000006907 apoptotic process Effects 0.000 claims abstract description 258
- 229940079593 drug Drugs 0.000 claims abstract description 203
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 189
- 230000001939 inductive effect Effects 0.000 claims abstract description 168
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 135
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 132
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 132
- 239000007787 solid Substances 0.000 claims abstract description 23
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 146
- 210000001519 tissue Anatomy 0.000 claims description 142
- 210000004027 cell Anatomy 0.000 claims description 99
- 229960004679 doxorubicin Drugs 0.000 claims description 73
- 210000004881 tumor cell Anatomy 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 53
- 239000011859 microparticle Substances 0.000 claims description 43
- 238000009472 formulation Methods 0.000 claims description 37
- 239000002105 nanoparticle Substances 0.000 claims description 32
- 239000002246 antineoplastic agent Substances 0.000 claims description 31
- 229940127089 cytotoxic agent Drugs 0.000 claims description 28
- 239000003937 drug carrier Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000001415 gene therapy Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 230000009467 reduction Effects 0.000 claims description 18
- 208000023958 prostate neoplasm Diseases 0.000 claims description 16
- 210000002307 prostate Anatomy 0.000 claims description 15
- 230000002611 ovarian Effects 0.000 claims description 14
- 210000004185 liver Anatomy 0.000 claims description 13
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 210000003932 urinary bladder Anatomy 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 11
- 210000000481 breast Anatomy 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 206010046766 uterine cancer Diseases 0.000 claims description 10
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 208000037841 lung tumor Diseases 0.000 claims description 9
- 208000025421 tumor of uterus Diseases 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 8
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 7
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 238000001476 gene delivery Methods 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 230000035515 penetration Effects 0.000 abstract description 67
- 229920002521 macromolecule Polymers 0.000 abstract description 10
- 239000002609 medium Substances 0.000 description 53
- 150000001875 compounds Chemical class 0.000 description 47
- 230000035508 accumulation Effects 0.000 description 41
- 238000009825 accumulation Methods 0.000 description 41
- 201000011510 cancer Diseases 0.000 description 34
- 239000001963 growth medium Substances 0.000 description 27
- 230000001640 apoptogenic effect Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- -1 S-fluorouracil Chemical compound 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 239000002245 particle Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000000512 collagen gel Substances 0.000 description 13
- 238000012377 drug delivery Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 208000014829 head and neck neoplasm Diseases 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- RJYQLMILDVERHH-UHFFFAOYSA-N 4-Ipomeanol Chemical compound CC(O)CCC(=O)C=1C=COC=1 RJYQLMILDVERHH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229960001674 tegafur Drugs 0.000 description 4
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000002691 unilamellar liposome Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010002156 Depsipeptides Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 229960002727 cefotaxime sodium Drugs 0.000 description 3
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000011613 copenhagen rat Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000005567 liquid scintillation counting Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 2
- ICAYNKLSQSKOJZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]butan-1-one Chemical compound C=1C=C(F)C=CC=1C(O)C(CC1)CCN1CCCC(=O)C1=CC=C(F)C=C1 ICAYNKLSQSKOJZ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- JARCFMKMOFFIGZ-UHFFFAOYSA-N 4,6-dioxo-n-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide Chemical compound O=C1NC(=S)NC(=O)C1C(=O)NC1=CC=CC=C1 JARCFMKMOFFIGZ-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 2
- 229950008427 acivicin Drugs 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229950005033 alanosine Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229940088954 camptosar Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960005304 fludarabine phosphate Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229940087857 lupron Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229950006050 spiromustine Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003723 tiazofurine Drugs 0.000 description 2
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010019393 Fibrin Foam Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 101710132316 Transactivation protein Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002236 cellular spheroid Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 1
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention, at least in part, is directed to methods for enhancing delivery of therapeutic agents, such as macromolecules and drugs, into the interior of tissues, such as solid tissues or tumors. The method initially uses an apoptosis inducing agent, such as paclitaxel, in doses which create channels within the tissues, and enhance the penetration of therapeutic agents to the interior of the tissue. Current methods of treating tissues are often not effective because the therapeutic agents are not delivered to the interior of the tissue. By using the methods and the compositions of the current invention, therapeutic agents can be delivered to the interior of the tissue.
Description
WO 00/61141 PCT/US00l09329 METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF
THERAPEUTIC AGENTS TO TISSUES
Background Paclitaxel, one of the most important anticancer drugs developed in the past two decades, is active against multiple types of human solid tumors (Rowinsky EK
(1993) J
Natl Cancer ~nst Monogr 15:25-37). Paclitaxel has pleiotropic effects; for example, it enhances tubulin polymerization, promotes microtubule assembly, binds to microtubules, stabilizes microtubule dynamics, induces mitotic block at the metaphase/anaphase transition, and induces apoptosis (Parness J and Horwitz SB
(1981) JCell Biol 91:479-487;.Manfredi JJ et al. (1982) JCell Biol. 94:688-696; Jordan MA, et al. (1993) Proc Natl Acad Sci USA 90:9552-9556; Jordan MA et al. (1996) Cancer Res 56:816-825; Derry WB et al. (1996) Biochemistry 34:2203-2211). The intracellular concentration of paclitaxel is critical for its pharmacological effect; drug resistance in several resistant sublines is correlated with reduced intracellular drug accumulation compared with the sensitive parent cell lines (Lopes NM et al.
(1993) Cancer Chemother Pharmacol 32:235-242; Bhalla K et al. (1994) Leukemia 8: 466-476; Jekunen AP et al. (1994) Br J Cancer 69:299-306; Riou JF et al. (1994) Proc Am Assoc Cancer Res 36:160; Speicher LA et al. (1994) JNatl Cancer Inst 86:688-694).
Doxorubicin is an anticancer drug with a wide spectrum of clinical activities.
It has been used clinically to treat leukemias, lymphomas, and solid tumors including breast, lung, prostate, and ovarian cancers and sarcomas (Oesterling et al.
(1997) In:
Cancer: Principles and Practice of Oncology (Eds, DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A., 1997); Doroshow, J.H. (1996) In: Cancer Chemotherapy and 26 Biotherapy: Principles and Practice (Eds, Chabner, B.A. and Longo, D.L.)).
Doxorubicin is one of the most effective agents against hormone-refractory prostate cancer (Smith, D.C. (1999) Urol. Clin. North Am. 26:323-331). It has been shown that in human prostate tumor histocultures, doxorubicin can induce complete inhibition of tumor cell growth with ICSO of 61 nM and complete tumor cell death with LCSO
of 2.1 ~.M (Chen et al., (1998) Clin. Cancer Res. 4:277-282, 1998).
Printed by VfsuaIPatent Drug delivery to the tumor core is necessary to prevent tumor regrowth (Erlanson M et al. ( 1992) Cancer Chemother Pharmacol 29:343-353; Durand RE
(1990) Cancer Chemother Pharmacol 26:198-204) and is, therefore, an important determinant of treatment efficacy (Jain RK (1996) Science 271:1079-1080).
Following a systemic intravenous injection, drug delivery to the tumor core involves three processes, i.e., distribution through vascular space, transport across microvascuiar wall, and diffusion through interstitial space in tumor tissue (Jain RK (1987) Cancer Res 47:3039-3051). When the drug is directly injected into a tumor such as by intratumoral injection or by direct instillation into peritumoral space such as in intravesical therapy of superficial bladder cancer and in the intraperitoneal dialysis of ovarian cancer, drug delivery to the tumor is primarily by diffusion through interstitial space (Nativ O et al.
(1997) Int JCancer 70:297-301; Song D et al. (1997) Cancer Chemother Pharmacol 40:285-292; Markman M (1998) Semin Oncol 25:356-360; Markman M et al. (1995) Semin Oncol 22:84-87). Movement of paclitaxel in interstitial space, in spite of its relatively low molecular weight (853 Dalton), is likely to behave as a protein because of its extensive binding to proteins in interstitial fluid (Baguley BC et al.
(1995) Clin Exp Pharmacol Physiol 22:825-828).
A recent study indicates that drug delivery to a tissue during regional therapy depends on the ability of the drug to penetrate the solid tissue. T'he study indicates that paclitaxel distribution in multicellular spheroids is limited to the periphery, but the barriers to paclitaxel penetration are not known (Nicholson et al. (1997) Eur.
J. Cancer 33:1291-1298). Accordingly, approaches to delivering therapeutic agents to tissues that allow for penetration of the drug into the tissue are still needed.
Summary This invention provides methods, and compositions for use therein, for delivering therapeutic agents to tissues, wherein the methods allaw for enhanced penetration of the therapeutic agent into the interior of multilayer tissues, such as solid tissues or tumors. The methods involve use of an apoptosis inducing agent, such as paclitaxel, in doses and for periods of time sufficient to cause apoptosis in the tissue to thereby allow for enhanced penetration of the therapeutic agent into the tissue (e.g., by creating channels within the tissues). Thus, the apoptosis inducing agent is used as a Printed by VisualPatent pretreatment before the therapeutic dose of the therapeutic agent is delivered to the tissue, and this pretreatment allows for enhanced penetration of the therapeutic agent into the tissue as compared to when the pretreatment is not used. The apoptosis inducing agent may also have therapeutic activity and thus may also be used as the therapeutic agent (i. e., the same drug may be used as the apoptosis inducing agent and the therapeutic agent). Alternatively, the apoptosis inducing agent may be used to enhance delivery of other types of drugs into tissues (i.e., the apoptosis inducing agent and the therapeutic agent may be different drugs).
Accordingly, in one embodiment, the invention pertains to a method for delivering a therapeutic agent to tissue of a patient, e.g., a mammal, e.g., a human. The method includes administering an apoptosis inducing agent to the patient, and allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the patient's tissue. The tissue can be, for example, liver, muscle (e.g., cardiac, smooth, or skeletal muscle), neuronal, skin or adipose tissue, or a tumor, such as a brain, breast, ovarian, bladder, prostate, skin, colon, lung, liver, or uterine tumor. The apoptosis agent can be administered systemically, locally, regionally, or any combination thereof, such as both locally and regionally-(locoregionally).
In a second embodiment, the invention pertains to a method for delivering a therapeutic agent to a patient's tumor (e.g., a cancerous or benign tumor).
The method includes administering a dose of an apoptosis inducing agent to a patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient. The tumor may be, for example, a brain, breast, ovarian, bladder, prostate, skin, colon, lung, liver, or uterine tumor.
Examples of the apoptosis inducing agent include paclitaxel and doxorubicin.
In yet another embodiment, the invention features a method for delivering a chemotherapeutic agent to a tumor in a patient, for example, a human (e.g., a cancer patient). The method includes administering a dose of an apoptosis inducing agent locally or regionally to a patient, allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor, and delivering a dose of a chemotherapeutic agent to said patient. In a further embodiment, the tumor is a cancerous tumor, e.g., a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
Printed by VisualPatent The invention also pertains to a composition for delivering a therapeutic agent to a patient. The composition includes a quick release formulation of an apoptosis inducing agent, a slow release formulation of a therapeutic agent, and a pharmaceutically acceptable carrier.
The invention also includes microparticles and nanoparticles comprising therapeutic or apoptosis inducing agents. It also includes methods of treating patients using the microparticles or nanoparticles.
The invention also pertains to a kit for the treatment of tumors The kit contains an apoptosis inducing agent in a pharmaceutically acceptable carrier, a therapeutic agent in a pharmaceutically acceptable carrier, a container, and directions for using the apoptosis inducing agent and the therapeutic agent for the treatment of tumors.
Brief Description of the Drawings:
Figure 1 is a line graph depicting the kinetics of paclitaxel uptake in patient and xenograft tumor histocultures. Patient head and neck tumors are represented by ~, patient ovarian tumors are represented by ~, and FaDu xenograft tumors are represented by O.
Figure 2 is a line graph depicting the kinetics of paclitaxel efflux in patient and xenograft tumor histocultures. Patient head and neck tumors are represented by ~, patient ovarian tumors are represented by ~, and FaDu xenograft tumors are represented by O.
Figure 3 is a graph depicting the accumulation of doxorubicin in tumor tissues, expressed as tissue-to-medium concentration ratio, as a function of time and initial extracellular drug concentrations. The average drug concentration in the periphery of tumor (i.e., 75 ~1VI) and in the far end of the tumor (i. e., 325 pM from the periphery of the tumor in contact with the culture medium) are shown. (A) Top panels:
patient prostate tumors. (B) Bottom panels: PC3 xenograft tumors. Tumors treated with doxorubicin are represented by 1. Tumors treated with 5 p,M doxorubicin are represented by O. Tumors treated with 20 pM doxorubicin are represented by ~.
Printed by VisualPatent WO 00/61141 PCTlUSOOI09329 Figure 4 is a graph depicting the doxorubicin concentration in tumor tissue, expressed as tissue-to-medium concentration ratio, as a function of the distance from the edge of the tumor in contact with the culture medium. (A) Top panels:
patient prostate tumors. (B) Bottom panels: PC3 xenograft tumors. Tumors were treated with 1 (right panels), 5 (middle panels) and 20 (left panels) :M doxorubicin. The treatment times are directed noted on the graph.
Figure 5 is a graph depicting the effect of cell density in the periphery of the tumor (i. e., 100 ~tm distance from the edge in contact with the culture medium). Percent cell density is the ratio between the cell density in the treated tumors and the cell density in the untreated control samples.
Detailed Description of the Invention The invention, at least in part, is directed to methods for enhancing delivery of therapeutic agents, such as macromolecules and drugs, into the interior of multilayer tissues, such as solid tissues yr tumors. The method initially uses an apoptosis inducing agent, such as paclitaxel, in doses which create channels within the tissues, and enhance the penetration of therapeutic agents to the interior of the tissue. Current methods of treating tissues are often not effective because the therapeutic agents are not delivered to the interior of the tissue. By using the methods and the compositions of the current invention, therapeutic agents can be delivered to the interior of the tissue.
At least in part, the invention pertains to the penetration of therapeutic drugs into tissues and tumors of a patient, by treating the tissue or tumor with an apoptosis inducing agent such that the permeability of the tissue or tumor to a therapeutic agent is enhanced. The therapeutic agent can be a protein bound drug, a chemotherapeutic agent, a gene therapy construct, or another agent which may be advantageously delivered to the interior of a tissue, such as a tumor.
In one embodiment, the invention pertains to a method for delivering a therapeutic agent to tissue of a patient. The method includes administering an apoptosis inducing agent to the patient, and allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
Printed by VisualPatent I DEFINITIONS
Before further description of the invention, certain terms employed in the specification, examples and appended claims are, for convenience, collected here.
The term "apoptosis inducing agent" includes agents which induce apoptosis in cells, e.g., tumor cells. Cells, including cancer cells, can be induced to undergo programmed cell death, also known as apoptosis. Apoptosis is characterized by the selective programmed destruction of cells into relatively small fragments with DNA
becoming highly fragmented (i. e. the resulting fragments typically have no more than about 200 bases). During apoptosis, cell shrinkage and internucleosomal DNA
cleavage occurs, which results in the fragmentation of the DNA. Eventually the cell disintegrates into small fragments. Examples of apoptosis inducing agents include agents such as paclitaxel, doxorubicin, vincristine, vinblastine, vindesine, vinorelbin, taxotere (DOCETAXEL), topotecan, camptothecin, irinotecan hydrochloride (CAMPTOSAR), etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, 1 S merbarone, piroxantrone hydrochloride, S-fluorouracil, methotrexate, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, cytarabine (ARA,-C), trimetrexate, gemcitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L- Asparate (PALA), pentostatin, 5-azacitidine, 5-Aza-2'-deoxycytidine, adenosine arabinoside (ARA-A), cladribine, ftorafur, UFT (combination of uracil and ftorafur), 5-fluoro-2'-deoxyuridine, fluorouridine, 5'-deoxy-5-fluorouridine, hydroxyurea, dihydrolenchlorambucil, tiazofurin, cisplatin, carboplatin, oxaliplatin, mitomycin C, BCNU
(Carmustine), melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4-ipomeanol, dihydrolenperone, spiromustine, geldanamycin, cytochalasins, depsipeptide, Lupron, ketoconazole, tamoxifen, goserelin (Zoledax), flutamide, 4'- cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide, Herceptin, anti-CD20 (Rituxan), interferon alpha, interferon beta, interferon gamma, interleukin 2, interleukin 4, interleukin 12, tumor necrosis factors, and radiation.
The language "chemotherapeutic agent" includes agents such as drugs which can advantageously be administered to the tissue, such as anti-tumor drugs such as paclitaxel, doxorubicin, and other drugs which have been known to affect tumors. It also includes agents which modulate other states which are related to tissues which can Printed by VisualPatent -be permeabilized using the methods and compositions of the invention. The chemotherapeutic agent can be, for example, a steroid, an antibiotic, or another pharmaceutical composition. Examples of chemotherapeutic agents include agents such as paclitaxel, doxorubicin, vincristine, vinblastine, vindesine, vinorelbin, taxotere (DOCETAXEL), topotecan, camptothecin, irinotecan hydrochloride (CAMPTOSAR), doxorubicin, etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, merbarone, piroxantrone hydrochloride, 5-fluorouracil, methotrexate, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, cytarabine (ARA-C), trimetrexate, gemcitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L-Asparate (PALA), pentostatin, 5-azacitidine, 5-Aza-2'-deoxycytidine, adenosine arabinoside (ARA-A), cladribine, ftorafur, UFT (combination of uracil and ftorafur), 5-fluoro-2'-deoxyuridine, 5- fluorouridine, 5'-deoxy-5-fluorouridine, hydroxyurea, dihydrolenchlorambucil, tiazofurin, cisplatin, carboplatin, oxaliplatin, mitomycin C, BCNU (Carmustine), melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4-ipomeanol, dihydrolenperone, spiromustine, geldanamycin;
cytochalasins, depsipeptide, Lupron, ketoconazole, tamoxifen, goserelin (Zoledax), flutamide, 4'- cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide, Herceptin, anti-CD20 (Rituxan), interferon alpha, interferon beta, interferon gamma, interleukin 2, interleukin 4, interleukin 12, tumor necrosis factors, and radiation.
The term "delivering" refers to making the therapeutic agent available to the interior of the tissue (e.g., tumor) to be treated such that the therapeutic agent is capable of having a therapeutic effect on the interior of the tissue and includes, for example, contacting the tissue with the agent. The term "delivering" is intended to include administering the therapeutic agent to the patient as a separate dose (after administration of the apoptosis inducing agent), as well as administering the therapeutic agent to the patient together with (i.e., at the same time as or in the same dose as) the apoptosis inducing agent, wherein the therapeutic agent is formulated such that the tissue is contacted with the therapeutic agent after the sufficient time has elapsed for apoptosis to occur in the interior of the tissue (i. e., the therapeutic agent is delivered to the tissue after sufl'icient time has elapsed for apoptosis to occur).
Printed by VisualPatent _g-The term "dose" refers to an amount of an apoptosis inducing agent or a therapeutic agent which is sufficient to perform its intended function, e.g., induce apoptosis and treat the tissue, respectively. In one embodiment, the dose of the apoptosis inducing agent may be, for example, between about 0.01 nM to about nM over about 0.01 to about 5.0 hours, between about 0.1 nM to about 500 nM
over about 0.1 to about 4.0 hours, between about 1 nM to about 250 nM over about 0.5 to about 3.0 hours, between about 10 nM to about 150 nM over about 0.5 to about 2.0 hours, between about 30 nM to about 100 nM over about 0.75 to about 1.5 hours, between about 40 nM to about 70 nM over about 1 hour, and, advantageously, about 50 nM of paclitaxel over about l hour. The dose of the therapeutic agent can be, for example, administered for three hours, starting 24 hour after administration of the apoptosis-inducing agent. The target concentration of the therapeutic agent, can be, for example, about 50 nM. In another embodiment, the dose of the apoptosis inducing agent, can be, for human patients about one-half of the usual clinical dose (135-225 mg/m2), administered by intravenous infusion over about, for example, 3 hours.
The dose of the therapeutic agent can be, far example, the remaining one-half of the usual clinical dose, and could be administered, for example, between 16 to 30 hour after administration or delivery of the dose of the apoptosis inducing agent.
The term "gene therapy construct" includes constructs useful for gene therapy purposes, in treatments for either genetic or acquired diseases, e.g. cancer.
The general approach of gene therapy involves the introduction of nucleic acid into cells such that one or more gene products encoded by the introduced genetic material are produced in the cells to restore or enhance a functional activity. For reviews on gene therapy approaches see Anderson, W.F. (1992) Science 256:808-813; Miller, A.D. (1992) Nature 357:455-460; Friedmann, T. (1989) Sciehce 244:1275-1281; and Cournoyer, D., et al. (1990) Curr. Opin. Biotech. 1:196-208.
Genes of particular interest to be expressed in cells of a subject for treatment of genetic or acquired diseases include those encoding adenosine deaminase, Factor VIII, Factor IX, dystrophin, j3-globin, LDL receptor, CFTR, insulin, erythropoietin, anti-angiogenesis factors, growth hormone, glucocerebrosidase, (3-glucouronidase, al-antitrypsin, phenylalanine hydroxylase, tyrosine hydroxylase, ornithine transcarbamylase, arginosuccinate synthetase, UDP-glucuronysyl transferase, apoAl, Printed by VisuaIPatent WO 00/61141 P'CTlUS00/09329 TNF, soluble TNF receptor, interleukins (e.g., IL-2), interferons (e.g., a- or y-IFN) and other cytokines and gmwth factors. Cells types which can be modified for gene therapy purposes include tumor cells, hematopoietic stem cells, myoblasts, hepatocytes, lymphocytes, skin epithelium and airway epithelium. For further descriptions of cell types, genes and methods for gene therapy see e.g., Wilson, J.M et al. (1988) Proc: Natl.
Acad. Sci. USA 85:3014-3018; Armentano, D. et al. (1990) Proc. Natl. Acad.
Sci. USA
87:6141-6145; Wolff, J.A. et al. (1990) Science 247:1465-1468; Ghowdhury, J.R.
et al.
(1991) Science 254:1802-1805; Ferry, N, et al. (1991) Proc. Natl. Acac~ Sci.
USA
88:83??-8381; Wilson, J.M. et al. (1992) J. Biol. Chem. 267:963-967; Quantin, B. et al.
(1992) Proc. Natl. Acad. Sci. USA 89:2581-2584; Dai, Y. et al. (1992) Proc.
Natl. Acad.
Sci. USA 89:10892-10895; van Beusechem, V.W. et al. (1992) Proc. Natl. Acad.
Sci.
USA 89:7640-7644; Rosenfeld, M.A. et al. (1992) Cell 68:143-155; Kay, M.A. et al.
(1992) Human Gene Therapy 3:641-647; Cristiano, R.J. et al. (1993) Proc. Natl.
Acad.
Sci. USA 90:2122-2126; Hwu, P. et al. (1993) J. Immunol. 150:4104-4115; and Herz, J.
and Gerard, R.D. (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816.
Gene therapy applications of particular interest in cancer treatment include overexpression of a cytokine gene (e.g., TNF-a) in tumor infiltrating lymphocytes or ectopic expression of cytokines in tumor cells to induce an anti-tumor immune response at the tumor site), expression of an enzyme in tumor cells which can convert a non-toxic agent into a toxic agent, expression of tumor specific antigens to induce an anti-tumor immune response, expression of tumor suppressor genes (e.g., p53 or Rb) in tumor cells, expression of a multidrug resistance gene (e.g., MDR1 and/or MRP) in bone marrow cells to protect them from the toxicity of chemotherapy.
Gene therapy applications of particular interest in treatment of viral diseases include expression of traps-dominant negative viral transactivation proteins, such as traps-dominant negative tat and rev mutants for HIV ar traps-dominant ICp4 mutants for HSV (see e.g., Balboni, P.G. et al. (1993) J. Med. Yirol. 41:289-295; Liem, S.E. et al.
(1993) Hum. Gene Tyrer. 4:625-634; Malim, M.H. et al. (1992) J. Exp. Med.
176:1197-1201; Daly, T.J, et al. (1993) Biochemistry 32:8945-8954; and Smith, C.A. et al. (1992) Virology 191:581-588), expression of traps-dominant negative envelope proteins, such as env mutants for HIV (see e.g., Steffy, K.R. et al. (1993) J. Virol. 67:1854-1859), intracellular expression of antibodies, or fragments thereof, directed to viral products Printed by VisuaIPatent ("internal immunization", see e.g., Marasco, W.A. et al. (1993) Proc. Natl.
Acad. Sci.
USA 90:7889-7893) and expression of soluble viral receptors, such as soluble CD4.
Additionally, the system of the invention can be used to conditionally express a suicide gene in cells, thereby allowing for elimination of the cells after they have served an intended function.
The term "liposomes" or "lipid vesicles" refer to substantially spherical structures made of materials having a high lipid content in which the lipids are organized in the form of lipid bilayers. Unilamellar vesicles have a single lipid bilayer surrounding an amorphous central cavity which can encapsulate an aqueous volume.
Uniiamellar vesicles can be prepared as either large unilamellar vesicles (LUVs; diameter greater than about l p,) or small unilamellar vesicles (SUV s; diameter less than about 0.2 pm).
Multilamellar vesicles (MLVs) have many onion-like shells of lipid bilayers.
Because of their high lipid content, MLVs have use for carrying certain small lipophilic molecules but have a low carrying capacity for aqueous material. Paucilamellar vesicles I S (PLVs) have about two-ten bilayers arranged in the form of substantially spherical shells separated by aqueous layers surrounding a central cavity free of lipid bilayers. PLVs can encapsulate both aqueous and hydrophobic material and thus can carry a wide variety of materials. Unilamellar vesicles composed of a single bilayer of phospholipids and/or glycolipids are the most commonly used lipid vesicles for modeling of cell membrane structures since phospholipids are the primary structural component of natural membranes, including the outer cell membrane. Liposomes (e.g., phospholipid vesicles) can be used as carrier vehicles for delivering biologically active materials to tissues using the methods of the invention. For reviews of phospholipid vesicle-mediated transfer of materials see Mannino, BioTechniques, 6:682 (1988);
Litzinger, D.C. Biochim. et Biophys. Acta, I 113:201 (1992). Methods for preparing liposomes as carrier vesicles for delivery of biologically active materials are known in the art (see, for example, U.S. 4,522,811).
The term "locally" includes administration, e.g., injection, directly into the tissue to be treated. Examples of local treatment include intratumoral and intralesional injection.
Printed by VisuaIPatent The term "locoregionally" includes administration both locally and regionally.
For example, the compound may be administered in the fluid surrounding the tissues and directly injected into the tissues, e.g., intraperitoneal treatment of ovarian cancer, intravesical instillation of drug into urinary bladder for the treatment of diseased bladder, intraprostatic injection, intrahepatic infusion, perfusion of isolated organs (e.g., lung), intrathecal treatment of brain tumors, implants of drug release devices in brain for the treatment of brain cancer, and intralesional injection (e.g., into a skin lesion or a tumor). Locoregional treatments may also apply to other diseases, e.g., viral or bacterial infection, interstitial cystitis.
The term "microparticles" includes particles which comprise apoptasis inducing agents, therapeutic agents or other substances which can be advantageously delivered using methods of the invention to the interior of a tissue, e.g., a tumor. The term refers to particles of about 0.1 l.un to about 100 ~.m, about 0.5 ~m to about 50 pm, 0.5 pxn to about 20 ~m in size, advantageously, particles of about 1 pm to about 10 p,m in size, about 5 pm in size, or mixtures thereof. The microparticles may comprise macromolecules, gene therapy constructs, chemotherapeutic agents, or protein bound drugs, for example. Typically microparticles can be administered locally, locoregionally, or regionally, for example.
The term "nanoparticles" includes particles which comprise apoptasis inducing agents, therapeutic agents or other substances which can be advantageously delivered using methods of the invention to the interior or a tissue, e.g., a tumor. The term refers to particles of about 0.1 nm to about 1 ~,m, 1 nm to about 1 pm, about 10 nm to about 1 Vim, about 50 nm to about l pm, about 100 nm to about 1 p,m, about 250-900 nm in size, or, advantageously, about 600-800 nm. The nanoparticles may comprise macromolecules, gene therapy constructs, chemotherapeutic agents, or protein bound drugs, for example. Typically, nanoparticles can be administered to a patient via local, locoregional, regional, or systemic administration. In one embodiment, the nanoparticles may comprise cross-linked gelatin.
The term "patient" includes animals which can be treated using the methods of the invention. Examples of animals include mammals, such as mice, rabbits, rats, horses, goats, dogs, cats, pigs, cattle, sheep, and primates (e.g., chimpanzees, gorillas;
Printed by VlsualPatent and, preferably, humans). In a further embodiment, the patient is a cancer patient, e.g., a human suffering from cancer.
The phrase "pharmaceutically acceptable carrier" is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, diluent, excipient,, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt;
gelatin; talc;
excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water;
isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions;
and other non-toxic compatible substances employed in pharmaceutical formulations. In one embodiment, the pharmaceutically acceptable carrier is suitable for intravenous administration. In another embodiment, the pharmaceutically acceptable carrier is suitable for Iocoregional injection.
The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. Hydroxyls can be converted into esters via treatment with an esterifying agent such as alkanoyl halides. The term also includes lower hydrocarbon groups capable of being solvated under physiological conditions, Printed by VfsualPatent WO 00/61141 PCTiL1S00109329 e.g., alkyl esters, methyl, ethyl and propyl esters. (See, for example, Berge et al., supra. ) The term "pharmaceutically acceptable salts" is art recognized and includes relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. {19'77) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).
The language "pharmaceutical composition" includes preparations suitable for administration to mammals, e.g., humans. When the compounds of the present invention are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a pharmaceutical composition containing, fox example, 0.1 to 99.5%
(more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
The term "protein bound drug" includes drugs bound to or capable of binding to proteins. Examples of protein bound drugs include paclitaxel, doxorubicin, cisplatin, carboplatin, oxaliplatin, vinca alkaloids, suramin, amitriptyline, amphotericin B, cefazolin, chlorothiazide, chlorpromazine, clindamycin, clofibrate, depsipeptide, desipramine, diazepam, dicloxacillin, digitoxin, doxycycline, furosemide, heparin, indomethacin, lorazepam, nafcillin, nortriptyline, phenytoin, prazosin, prednisolone, propranolol, protriptyline, rifampin, sulfisoxazole, warfarin.
The term "quick-release formulation" refers to a formulation of a drug, wherein the drug is delivered to a site of interest in an already-active form or a form that becomes active, in a relatively short period of time, e.g., within one or a few hours and includes formulations which allow the apoptosis inducing agent to be released in a dose of about 50 nM or more over about a 1 hour time. Examples of quick-release Printed by VisualPatent formulations include micro- and nanoparticle formulations. Methods used to prepare these formulation are described in Example 5.
The term "regionally" includes administration to a region of tissue where the tissue to be treated is located, e.g., intraperitoneal administration for the peritoneal organs (such as the bladder, ovaries, etc); intracranial administration for the brain; intra-spinal administration for spinal column tissue; infra peri-cordially for the cardiac tissue;
and the like.
The term "simultaneously" includes administrations which occur together. In one embodiment, the therapeutic agent and the apoptosis inducing agent are formulated together. In such an embodiment, the apoptosis agent is typically in a quick formulation and the therapeutic agent is typically in a slow release formulation, such that the therapeutic agent is released, for example, about sixteen to twenty four hours after the apoptosis inducing agent.
The term "slow-release formulation" refers to a formulation of a drug wherein 1 S the drug is delivered to a site of interest for a sustained period of time and includes formulations whichrelease the therapeutic agent after a sufficient time has elapsed for the apoptosis inducing agent to induce apoptosis. In one embodiment, the slow release formulation releases the therapeutic agent in about six to about 120 hours after administration, about six to 96 hours after administration, about six to about seventy two hours after administration, about six to about forty-eight hours after administration, about twelve to about thirty six hours after administration, about twelve to about thirty hours after administration, or, advantageously, about sixteen to about twenty four hours after administration.
The term "solid tissue cells" describes the cells that comprise a solid tumor or tissue and include, but are not limited to, "solid tumor cells." They includes cells in the outer or exterior cell layers which can be treated with an apoptosis inducing agent such that a therapeutic agent can be delivered to the interior of the tumor or tissue, and the inner cell layers of a mufti-layer tissue. Solid tumor or tissue cells can be derived from epithelial or non-epithelial lineages. The term "solid tumor cells" includes cells that comprise a solid tumor, and also includes that cells in the outer or exterior cell layers.
Printed by VlsualPatent WO 00/61141 PCTlUS00/093Z9 The term "sufficient time" includes the length of time which is necessary for the apoptosis inducing agent to induce apoptosis, such that the tissue is permeabilized to the therapeutic agent. Far example, the sufficient time may be when the density of the epithelial, exterior or solid tissue or tumor cells have.been reduced, e.g., reduced by 1%, 2%, 3%, 4%, 5%, 10%, 20 %; 25%, 30%, 35%, 40%; 45%, 50% or greater. In another example, the sufficient time may be when apoptosis has been induced in some, e.g., 1°/a, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 15%, 17%, 20% or more of the solid tissue cells. In Example 3, it has been shown that, in at least in certain situations, the sufficient time for a apoptosis inducing agent such as paclitaxel when administered at a dose of 50 nM over one hour, is about sixteen to twenty four hours.
The sufficient time may vary. 'according to the identity and the dose of the apoptosis inducing agent and can be determined using such methods as those described in the Examples.
In a further embodiment, the sufficient time is, for example, seventy two hours or more, seventy two hours or less, sixty hours or less, fifty five hours or less, fifty hours or less, forty five hours or less, forty hours or less, thirty five hours or less, thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
The language "therapeutic agent" encompasses any agent that can confer a therapeutic benefit on a patient and includes gene therapy constructs, chemotherapeutic agents, antibiotics, macromolecules, and protein bound drugs. The language also includes any agents which can be delivered to the interior of the tissue using the methods described herein. In one embodiment, the therapeutic agent is paclitaxel or doxorubicin, or analogues or derivatives thereof. In one embodiment, the therapeutic agent comprises the same active component as the apoptosis inducing agent. For example, both the apoptosis inducing agent and the therapeutic agent can be compounds such as, but not limited to, paciitaxel or doxorubicin. The therapeutic agent may be Printed by VisuaiPatent WO 00!61141 PCT/US00l09329 formulated as microparticles or nanoparticles. Other examples of therapeutic agents include macromolecules, such as, liposomes, nanoparticles, plasmid, viral vectors, non-viral vectors, chemotherapeutics, and oligonucleotides.
The term "tissue" includes both normal mammalian tissues such as liver, muscle (e.g., cardiac, skeletal; or smooth muscle), skin, neuronal, and adipose tissue, as weal as both benign and cancerous tumors.
The term "tumor" refers to abnormally growing tissue of any tissue type and includes both benign and malignant tumors, such as cancerous tumors. Examples of cancerous tumors include sarcomas, carcinomas, adenocarcinomas, lymphomas, and leukemias. The cancerous tumor may comprise metastatic lesion. It also includes any other tumors which can be advantageously treated using the methods and compositions of the invention. The cancerous tumor may be, for example, a fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesotheIioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastric cancer, esophageal cancer, colon carcinoma, rectal cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of the head and neck, skin cancer, brain cancer, squamous cell carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, non-small cell dung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, rneningioma, melanoma, neuroblastoma, retinoblastorna, leukemia, lymphoma, or Kaposi's sarcoma.
The term "tumor suppressor genes" include genes known to suppress tumors, e.g., tumors which are treatable by using the methods of the invention.
Examples of tumor suppressor genes include, for example, p53.
Printed by VisuaIPatent _ 17 .
II. METHODS OF THE INVENTION
In one embodiment, the invention pertains to a method for delivering a therapeutic agent to tissue (e.g., the interior of a multilayer tissue) of a patient, e.g., a mammal, e.g., a human. The method includes administering an apoptosis inducing agent to the patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the patient's tissue, and delivering a therapeutic agent to tlxe tissue. The tissue can be, for example, liver, muscle (e.g., cardiac, skeletal, or smooth muscle), skin, neuronal, yr adipose tissue, or a tumor, such as a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor. The apoptosis agent can be administered systemicahy, locally, regionally, or any combination thereof, such as both locally and regionally (locoregionally). In a further embodiment, the method further comprises obtaining the apoptosis inducing agent prior to administration to the patient.
In a further embodiment, the apoptosis inducing agent is paclitaxel or doxorubicin. The therapeutic agent can be a gene therapy construct, a I5 chemotherapeutic agent, a protein bound drug or an antibiotic.
In a second further embodiment, the sufficient time and/or dosage is sufficient to reduce the density of the epithelial, exterior, or solid cells of the tissue. For example, the density of the solid tissue cells may be reduced by about 1 %; 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12 %, 13%, 14%, 15%, 16%, 17,%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or greater, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In another example, the density of the solid tissue cells may be reduced by about 0.1% to about 50%, about 1% to about 45%, about 2% or about 45%, about 1% to about 40%, 5% to about 40%, 10% to about 40%, 20% or about 40%, 25% to about 40%, or about 30% to about 35%, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours Printed by VisuaIPatent or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In another, the time is sufficient to induce apoptosis in about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25% or more of the solid tissue cells, over a period , for example, of thirty two hours or less.
thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, f fteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or i 5 less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In another embodiment, the time and/or the dosage is sufficient to induce apoptosis in about 1 % to about 25% of the solid tissue cells, or, alternatively, about 1 to about 20%, about 1 % to about 17%, about 1 % to about 15 %, about 1 % to about 14%, about 5% to about 13%, about 5% to about 12%, about 1% to about 10%, over a period, for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
Apoptosis of the cells as well as their density can be measured using techniques discussed in Examples 1, 2, and 3.
in a third further embodiment, the apoptosis inducing agent is also the therapeutic agent. However, in this case, the therapeutic agent is typically administered in a separate dose or in a slow-release form.
Printed by VisuaIPatent WO OOJ6114I P'CT/USOOJ09329 In a fourth further embodiment, the apoptosis inducing agent and the therapeutic agent are administered simultaneously. In this embodiment, the therapeutic agent is typically a slow-release formulation that releases the therapeutic agent after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
In a yet another further embodiment, the apoptosis agent and the therapeutic agent are administered sequentially. In this method, the therapeutic agent is administered as a separate dose after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
In a second embodiment, the invention pertains to a method for delivering a therapeutic agent to a patient's tumor (e.g:, a cancerous or benign tumor).
The method includes administering a dose of an apoptosis inducing agent to a patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient. The tumor may be, for example, a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
Examples of the apoptosis inducing agent include paclitaxel and doxorubicin.
In a further embodiment, the method also comprises obtaining the apoptosis inducing agent.
In a further embodiment, the dose of the apoptosis inducing agent is sufficient to reduce the density of epithelial, exterior, or solid tumor cells, such that the therapeutic agent can be delivered to the interior of the tumor. For example, the dosage of the apoptosis inducing agent is sufficient to reduce the density of the cells, e.g., by about 1°/a, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%
or greater, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, f fteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or Less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or Iess, or one hour or less.
Printed by VisualPafent WO 00/61141 PCTlUS00109329 -2a-In another further embodiment, the apoptosis inducing agent induces apoptosis in about 1%, 2%, 3%, 4%, 5%, 6%, 7%, $%, 9%, 10%, 12%, 15%, 20%, 25% or more of the solid tissue cells, over a period , fox example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or.
less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less. In one particular instance when the apoptosis inducing agent is paclitaxel, the suff cient time can be, for example, between about 16 to about 24 hours, when it is administered at a dose of about, 50 nM over about I hour.
In a second further embodiment, the apoptosis inducing agent is also the therapeutic agent. However, in this case, the therapeutic agent is either administered in a separate dose or in a slow-release form of the apoptosis inducing agent.
Examples of apoptosis inducing agents which are also effective as therapeutic agents include, for example, paclitaxel and doxorubicin.
In a third further embodiment, the therapeutic agent comprises a gene therapy construct, a protein bound drug, a chemotherapeutic agent, or an antibiotic.
In a fourth further embodiment, the apoptosis inducing agent and/or the therapeutic agent can each be administered systemically, regionally, locoregionally, or locally. In an advantageous embodiment, the apoptosis inducing agent and/or the therapeutic agent are administered with a one or more pharmaceutically acceptable carriers. For example, the agents can be formulated in a manner suitable intravenous injection.
In yet another embodiment, the invention features a method for delivering a chemotherapeutic agent to a tumor in a patient, for example, a human (e.g., a cancer patient). The method includes administering a dose of an apoptosis inducing agent locally or regionally to a patient, allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor, and delivering a dose of a chemotherapeutic agent to said patient. In a further embodiment, the tumor is a cancerous tumor, e.g., a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor. In a further Printed by VisuaiPafent embodiment, the invention also comprises the step of obtaining the apoptosis inducing agent.
In a second further embodiment, the apoptosis inducing agent comprises paclitaxel, doxorubicin, or another effective apoptosis inducing agent.
In a third further embodiment, the sufficient time is sufficient for the reduction of the density of the solid tissue cells such that the therapeutic agent can be delivered to the interior of the tumor. For example, the sufficient time may be sufficient to reduce the density of the cells by about 5%, 10%, 15%, 20%, 30%, 35% or more, over a period of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour ar less. In yet another further embodiment, the sufficient time is sufficient to induce apoptosis in the solid tissue cells, such that the therapeutic agent can be delivered to the interior of the tumor.
For example, the su~cient time can be su~cient to induce apoptosis of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%,.16%, 17%, 18%, 19%, or 20% or more of the solid tissue cells, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In a fourth further embodiment, the apoptosis inducing agent is also the chemotherapeutic agent. However, in this case, the chemotherapeutic agent is either administered as a separate dose or in a slow-release form.
Printed by VisuaIPatent In a fifth further embodiment, the apoptosis agent and/or the therapeutic agent are administered with a pharmaceutically acceptable carrier, e.g., a carrier suitable for systemic, regional, locoregional, or local administration. The carrier may be suitable for intravenous injection.
In a sixth further embodiment, the apoptosis inducing agent and the therapeutic agent are administered simultaneously. In this embodiment, the therapeutic agent is slow-release formulated such that it is released after sufficient time for the apoptosis inducing agent to induce apoptosis.
In a seventh further embodiment, the apoptosis agent and the therapeutic agent are administered sequentially. In this embodiment, the therapeutic agent is administered after sufficient time, to allow the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
In another embodiment, the invention pertains to a method for delivering a dose of a therapeutic agent to tissue of a patient.
The method includes administering a dose of an apoptosis inducing agent to the patient, wherein the dose of the apoptosis inducing agent either:
(i) does not comprise the dose of the therapeutic agent; or (ii) comprises the dose of the therapeutic agent in a slow release formulation;
allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient; and (a) when the dose of the apoptosis inducing agent does not comprise the dose of the therapeutic agent, administering the dose of the therapeutic agent to the patient such that the dose of therapeutic agent is delivered to the tissue of the patient; or (b) when the dose of the apoptosis inducing agent comprises the dose of the therapeutic agent in a slow release formulation, allowing sufficient time for the therapeutic agent to be released in the tissue such that the dose of the therapeutic agent is delivered to the tissue of the patient.
The invention also pertains to a method for treating an ovarian tumor, comprising administering a dose of an apoptosis inducing agent, such as paclitaxel or doxorubicin locoregionally, regionally, or locally to a patient and allowing for sufficient time for apoptosis agent to induce apoptosis, and delivering the therapeutic agent. In a Pri»ted by VisualPatent WO 00/61141 PCTlUS00109329 further embodiment, the apoptosis inducing agent is paclitaxel, the dose is 50 nM over 1 hour, and the sufficient time is 16 to 24 hours.
The invention also pertains to a method.for treating a breast cancer tumor, comprising administering a dose of an apoptosis inducing agent, such as paclitaxel or doxorubicin Iocoregianally, regionally, or locally, to a patient and allowing for sufficient time for the apoptosis agent to induce apoptosis, and delivering the therapeutic agent. In a further embodiment, the apoptosis inducing agent is doxorubicin, and the dose is 5 :M for 1 to 4 hour, and the sufficient time is 16-30 hours.
III. PHARMACEUTICAL COMPOSTIONS OF THE INVENTION
The invention also pertains to a composition for delivering a therapeutic agent to a patient. The composition includes a quick release formulation of an apoptosis inducing agent, a slow release formulation of a therapeutic agent, and a pharmaceutically acceptable carrier.
In a further embodiment, the apoptosis inducing agent is paclitaxel. For example, one quick release formulation advantageously releases about 50 nM of paclitaxel over about 1 hour or less.
In a second further embodiment, the apoptosis inducing agent is doxorubicin.
In a third further embodiment, the apoptosis inducing agent is provided in an amount su~cient to reduce the density of the tumor cells of a solid tLUnor by about 30%
or greater, within about 16-24 hours after administration. The apoptosis inducing agent may also be provided in an amount sufficient to induce apoptosis in 10% or more of the tumor cells of a.solid tumor; within about 16-30 hours after administration.
In a fourth further embodiment, the therapeutic agent is paclitaxel or doxorubicin, protein-bound drug, a chemotherapeutic agent, an antibiotic or a gene delivery construct, e.g., a gene delivery construct comprising a tumor suppressor gene, e.g., p53.
In a fifth further embodiment, the pharmaceutical composition is suitable for intravenous injection. The composition may also be suitable for local, locoregional, regional or systemic administration.
In another embodiment, the pharmaceutical composition may comprise one or more pharmaceutical acceptable carriers.
Printed by VisuaiPatent In yet another embodiment, the invention pertains to nanoparticles, which comprise a cross linked gelatin and a therapeutic agent or an apoptosis inducing agent, such as, for example, paclitaxel, or doxorubicin. In a further embodiment, the invention pertains to a compositions containing the nanoparticles and a pharmaceutically acceptable carrier. The Garner can be, for example, suitable for systemic, regional, locoregional, or local administration. In another embodiment, the invention pertains to a method of treating a patient comprising administering the nanoparticles of the invention.
In one embodiment, the nanoparticles are about 500 to about 1 pm, or about 600 nm to about 800 nm in diameter.
The invention also pertains to microparticles comprising a therapeutic agent or an apoptosis inducing agent, such as paclitaxel or doxorubicin. In one embodiment, the microparticle is about 500 nm to about 100 Vim, about 500 nm to about 50 Vim, about 500 nm to about 25 pm, about 500 nm to about 20 pm, about 500 nm to about 15 pm, about 500 nm to about 10 Nxn, about 750 nm to about 10 pm, about 1 pm to about pm, about 750 nm to about 7.5 p,m, about 1 p,m to about 7.5 pm, about 2 ~zn to about 7.5 Vim, 3 pm to about 7 pm, or about 5 ~m in diameter. In another embodiment;
the invention pertains to a composition which comprises the microparticles and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be, for example, suitable for administraxion to a patient locally, regionally, or locoregionally. The invention also pertains to a method for treating a patient, comprising administering to the patient microparticles of the invention and a pharmaceutically acceptable carrier. In a further embodiment, the administration can be local, regional, or locoregional.
In another embodiment, the invention features microparticle suitable for administration to a patient locally, regionally, or locoregionally, comprising paclitaxel, wherein said microparticle has a diameter of about 5 Eun. In another further embodiment, the invention features microparticles suitable for administration to a patient locally, regionally, or locoregionally, comprising doxorubicin, wherein said microparticle has a diameter of about 5 pm.
The invention also pertains to a kit for the treatment of tumors. The kit contains an apoptosis inducing agent in a pharmaceutically acceptable carrier, a therapeutic agent in a pharmaceutically acceptable carrier, a container, and directions Printed by VisualPatent for using said apoptosis inducing agent and said therapeutic agent for the treatment of tumors. For example, a kit of the invention may comprise an apoptosis inducing agent and a therapeutic agent for subsequent intravenous injection. The kit may also provide the apoptosis inducing agent and/or the therapeutic agent formulated in dosages and carriers appropriately for local, locoregional, or regional administration.
Pharmaceutical compositions comprising compounds of the invention may contain wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring arid perfuming agents, and preservatives.
Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration.
The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about IO per cent to about 30 per cent.
Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the Garner and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
Printed by VisualPatent WO 00/61141 1'CT/US00/093Z9 A compound of the present invention may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, andlor silicic acid; binders, such as, for example, carboxymethylceiiulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose andlor acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate;
solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay;
lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release Printed by VisualPatent WO 00!61141 PCTIUS00l093Z9 profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile watex, or some other sterile injectable medium immediately before use.
These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredients) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
Examples of embedding compositions which can be used include polymeric substances and waxes.
The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water 15 or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
20 Besides inert dilutents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and 25 sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. ,_,_ Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating 30 excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at Printed by VlsuaIPatent body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin, The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel:
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may Printed by VisualPatent contain buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sarbic acid, and the like.
It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms axe made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemuIsions which are compatible with body tissue.
Printed by VisuaIPafenf The preparations of the present invention may be given orally, parenterally, topically, rectally, intralesionally, intraorbitally, intracapsularly, directly instilled into a cavity, or by inhalation. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories.
These compounds may be administered to humans and other animals for therapy by any suitable mute of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
Z 5 Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
Printed by VisualPatent WO 00/61141 1'CTlLT500109329 In general, a suitable dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect; i. e., treat a condition in a subject, e.g., cancer. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, will range from about 0.0001 to about 100 mg per kilogram of body weight, more preferably from about 0.01 to about 10 mg per kg, and still more preferably from about .10 to about 4 mg per kg. If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
As set out above, certain embodiments of the present compounds can contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
In other cases, the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
Exemplification of the Invention The invention is further illustrated by the following examples that should not be construed as limiting.
Materials and Methods:
Chemicals and reagents:
Paclitaxel and doxorubicin were obtained from the Bristol Myers Squibb Co.
(Wallingford, CT), the Phannacia & Upjohn Co. (Milan, Italy), and/or the National Cancer Institute (Bethesda, MD), and 3"-[3H]paclitaxel (specific activity 19.3 Ci/mmol) from the National Cancer Institute. Cefotaxime sodium was purchased from Hoechst-Roussel Inc. (Somerville, NJ); gentamicin from Solo Pak Laboratories (Franklin Park, IL); fetal bovine serum (FBS), Dulbecco's modified Eagle medium (DMEM), minimum essential medium (MEM), RPMI-1640, non-essential amino acids, L-Printed by VisuaIPatent glutamine and trypsin from GIBCO Laboratories (Grand Island, NY); sterile pigskin collagen gel (Spongostan standard) from Health Designs Industries (Rochester, NY);
Solvable tissue gel solubilizer and Atomlight scintillation fluid from Dupont Biotechnology Systems (Boston, MA); Hyperfilm 3H from Amersham Life Science Inc.
(Arlington Heights, IL); autoradiographic supplies from Kodak (Rochester, NY);
Cremophor EL from Sigma (St. Louis, MO); LKB 2208 Ultrofilm from Leica (Deerfield, IL), autoradiographic supplies from Kodak (Rochester, NY), cryotome imbedding polymer (O.C.T.) was obtained from Miles Inc. (Ellchart, IN); and monoclonal antibody (JSB-1) and polyclonal antibody (ab-1) against Pgp from BioGenex (San Racoon, CA) and Oncogene (Cambridge, MA), respectively.
Anirrials Male nulnu balb/c mice, weighing 18-21 g, were purchased from the National Cancer Institute, male Copenhagen rats, weighing 190 to 210 g, from Harlan Biomedicals (Dawely, OH), and female nu/nu balb/c mice, weighing 18-22 g, from the National Cancer Institute. Animal care was provided by the Laboratory Animal Resources in our institution.
Tumor procurement Surgical specimens of patient tumors (i.e., prostate, head and neck, ovarian) were obtained via the Tumor Procurement Service at The Ohio State University Comprehensive Cancer Center. Prostate tumor specimens were placed in MEM, and head and neck and ovarian tumor specimens in Hanks balanced salt solution within 10 to 30 min after surgical excision, stored on ice and prepared for culturing within one hour after excision.
Establishment of human xenograft tumors in mice Three human xenograft tumors; i.e., human pharynx FaDu tumor, human mammary MCF7 tumor, and the human prostate PC3 tumor, were used in the following three examples. FaDu cells were obtained from American Type Culture Collection (Rockville, MA). MCF7 cells were obtained from Dr. Kenneth Cowan at the National Cancer Institute. Cells were harvested from subconfluent cultures using trypsin and Prinfed by VisuaiPatent WO 00!61141 PCTIUSQO/09329 resuspended in fresh medium before plating. Cells with greater than 90%
viability, as determined by trypan blue exclusion, were used for tumor implantation. Cells were centrifuged and resuspended in Matrigel ( 1:1 v/v). Matrigel is a solubilized tissue basement membrane preparation extracted from the Engelbreth-Holmswarm mouse tumor and has been shown to support the growth of human tumoxs in immunodeficient mice (Kleinman H et al. (1990) Proc Am Assoc Cancer Res 31:490-491 ). The tumor establishment was achieved by subcutaneously injecting 106 cells (0.1 - 0.2 ml) with a 18 gauge needle at left and right sides of the upper back. The tumor was removed when it reached a size of 0.5 to 1 g and used for experiments.
Establishment of the MCF7 tumor was similar as described for tine FaDu tumor, with the except that a sustained release pellet of 17-beta-estradiol was implanted subcutaneously behind the neck of a mouse. Tumors were harvested when the tumor reached a size of about 0.5 in two weeks.
The androgen-independent human prostate PC3 cells were maintained as xenograft tumors in male nude mice according to the previously published procedures (Pretlow et al., 1993; Nagabhushan et al., 1996). Briefly, minced tumor tissue mixed with the same volume of Matrigel was implanted into both flanks of the nude mice at 0.3 ml per site. Tumors were harvested when they reached a size of 1 g at about 1.5 to 2 months after implantation.
Histocultures Patient tumors or xenograft tumor specimens were processed as previously described (Kuh, et al. (1999) J. Pharmcod. Exper. Therap. 290:871-880). The specimens were washed with culture medium for three times and dissected into about 1 mm3 fragments under sterile conditions. The culture medium consisted of a 1:1 mixture of MEM/DMEM for patient tumors, MEM for FaDu xenografts, and ItPMI1640 for PC3 xenografts, supplemented with 9% heat-inactivated FBS, 2 mM glutamine, 0.1 mM non-essential amino acids (only for MEM/DMEM), 90 :g/ml gentamicin and 90 :g/ml cefotaxime sodium. Five histoculture fragments were placed on a 1 cmZ
piece of presoaked collagen gel and incubated with 4 ml culture medium in 6-well plates. After 2 to 4 days, tumor histocultures were used to study the kinetics of drug penetration.
Printed by VisuaIPatent EXAMPLE 1: Determinants of Paclitaxel Penetration and Accumulation in Human Solid Tumors This study was performed using head and neck tumors from human patients and the human pharynx FaDu xenograft tumors maintained in athymic mice. The study used [3H]paciitaxel. The penetration of paclitaxel into tumor histocultures was visualized using autoradiography and the drug concentration in tumor tissues was measured using liquid scintillation counting.
Methods to study drug uptake and efflux in histocultures Tumor histocultures were incubated with 4 ml of culture medium containing 12 to 12,000 nM of mixture of radiolabeled and unlabeled paclitaxel. The final concentration of [3Hjpaclitaxel was 2.6 nM at 0.05 ~,Ci/ml or 5.2 nM at 0.1 p.Cilml.
These paclitaxel concentrations are within the range of clinical achievable concentrations in plasma (i.e. up to 13,000 nM, Kearns et al. (1995) Sem Oncol (Suppl.6):16-23). For the efflux study, tumor histocultures were incubated with paclitaxel for 24 hr, which was the longest time before substantial apoptosis occurs (Au JLS et al. (1998) Cancer Res 58:2141-2148), and then transferred to new plates and maintained in drug-free medium. At predetermined times, 100 p1 of medium was taken from each well and the histocultures were removed from the plates. The histocultures 24 were blot-dried on a filter paper and their weights were measured. One hundred :1 of medium or tumor samples were mixed with 0.5 ml of Solvable tissue/gel soiubilizer, incubated at 50°C in an oven overnight, and analyzed for total radioactivity using liquid scintillation counting. A preliminary study determined that 95% of the radioactivity in culture medium, analyzed by high pressure liquid chromatographic fractionation using a previous described method (Royer I et al. (1995) Rapid Commun Mass Spectrom 9:495-502), was represented by paclitaxel and its epimerization product, 7-epitaxol.
The ratio of 7-epitaxol to paclitaxel, in culture medium containing FaDu cells, was affected by the incubation time and the drug concentration in the medium, increasing from 2°!o at 3 hr to 7% in 24 hr and from 7% at 100 nM to 25% at 5,000 nM after 24 hr. Because 7-epitaxol has similar microtubule binding affinity and cytotoxicity as paclitaxel (Ringel I et al.
(1987) JPharmacol Exp Ther 242:692-698), the total radioactivity was expressed in Printed by VISUaIPafant w0 00/b1141 PCTIUS00/09329 paclitaxel equivalents. Drug concentration in tissue was calculated as (drug amount) divided by (tissue weight) and was expressed in molar terms.
For each tumor category, l, e, patient head and neck tumors, patient ovarian tumors, and FaDu xenograft tumors, three tumors were used per experiment, and 30 to 35 tumor histocultures were used for each concentration and each time point.
The study design of experiments using patient tumors was dictated by the size of the specimens.
On some occasions, specimens from an individual patient were only sufficient to study drug uptake and efflux at one or more but not all drug concentrations. A total of 7 head and neck tumors and 3 ovarian tumors were used. For the FaDu xenograft tumor, specimens from individual animals were sufficiently large that each tumor was used for studying uptake and ei~lux at ail four drug concentrations.
Accumulation of paclitaxel in tumor histocultures The increase of paclitaxel concentration in histocultures of patient tumors (head and neck, ovarian) and xenograft tumor is depicted in Figure l and in Table 1. For all three tumor types, the drug concentration in tumor histocultures increased with time, reaching a pseudo steady state between 48 to 72 hr, with <5% increase in the next 24 to 48 hr. During this time period, the drug concentration in the medium decreased by about 25%. Analysis of the mass balance indicates that about 90% of the dose was accounted for. The tumor-to-medium concentration ratios at steady state ranged from 20 to 120, indicating significant drug accumulation in tumors.
Figure 1 and Table 1 show the results of an experiment designed to test the uptake of paclitaxel into histocultures of FaDu xenograft and patient tumors.
The concentration-time profiles of paclitaxel in tumor histocultures obtained after incubation with different initial drug concentrations in culture medium (Cmedium)~ as depicted in Figure 1, were analyzed for the time for the tumor concentration to reach one-half of the pseudo steady state level (T~n,"pt~e) and for the tumor-to-medium concentration ratio at steady state. The statisticaY significance of the differences among patient (head and neck and ovarian, n=6) and FaDu (n=3) tumors, at equal initial medium concentrations, were analyzed by the two-tailed unpaired Student's t-test.
Printed by VisuaiPatent WO 00/61141 PCT/US001093x9 Table 1 initial Tumor Cm~~;"",Steady Steady stateSteady T,~Z,"Pe~eMass (nM) state Cc"mr (:M) state (h) baiance Cmedium C~,m~ to- (%) (nM) Cmedium ratio 12 10.911.0 1.0610.21 97.8115.2 24.213.4 91.213.5 Head 120 83.0 t 5.77 ~ 1.5264.5 t 19.8 t 83.8 ~
and 0.7 18.4 4.5 7.6 neck 1,200 925 t 22.0 t 6.2 23.1 t 10.4 t 87.5 t 25 7.1 3.8 6.5 patient12,000 9,870 341 t 125 34.8 t 5.81 ~ 91.5 ~
tumor t 59 14.5 2.31 3.5 12 10.610.7 1.3210.31 109122 i 8.4 89.315.4 t 9.6 Ovarian120 86.4 t 2.86 t 1.2832.8 t 1 I .l 84.5 t 2.3 I4.2 t 6.6 7.3 patient1,200 870 t 30.1 ~ I 32.3 t 14.2 t 85.2 t 2.6 1.7 13.7 7.3 2.5 tumor 12,000 10,500920211 t 80 I9.8 ~ 7.17 ~ 93.3 t 8.4 3.8I 4.5 12 9.090.27 1.01 ~ 0.21124 t 25 35.3 t 92.5 t 2.08 5.1 FaDu 120 89.7113.39.51 ~ 2.88115 t 3~ 27.8 t $6.5 t 3.7a 2.8 xenograft1,200 887 ~ 48.8 t 6.6853.7 t 18.9 ~ 89.4 t 131 14.8 3.2 5.7 12,000 8,910 433 ~ 15a 48.5 ~ 21.6 t 90.2 t t 267 0.58 6.98 5.4 pw.v~.
The steady state paclitaxel concentration in tumors increased while the steady state tumor-to-medium concentration ratio decreased with the initial drug concentrations in culture medium, although the relationships were not linear. In general, TI,~,upca~e~
which is the time to reach 50% of the pseudo steady state level, decreased with increasing initial medium concentration (p<0.01, regression analysis): These data.
indicate that drug accumulation is partly saturable, and show a more rapid attainment of steady state at higher initial extracellular drug concentration.
Efflux of paclitaxel from histocultures Figure 2 and Table 2 compare the kinetics of drug efflux from patient and xenograft tumors. In all three tumor types, the drug concentration declined to a pseudo steady state level at 48 hr. The extent of efflux was also dependent on the initial concentration, ranging from 29% to 60% at 120 nM and from 41 % to 81 % at 1,200 nM
in the first 24 hr. The decreases in drug concentration in the next 48 hr was several fold lower, ranging from 1% to 12% at 120 nM and from 3% to 13% at 1,200 nM.
Tnz,er~ux~
Printed by VisuaIPatent WO 00/61141 PC'rIC1S00109329 which is the time to reach 50% of the pseudo steady state level, ranged from 3 to 7.5 hr.
The decreases in tumor concentrations were accompanied by increases in medium concentrations. The tumor-to-medium concentration ratios ranged from 400 to 4;000 at 24 hr and from 250 to 2,700 at 72 hr. These ratios exceed the steady state tumor-to-medium concentration ratios achieved during the uptake study (i. e. 20 to 120) by 8- to 38-fold, indicating that a sink condition was maintained during the efflux study. Hence, the high steady state tumor-to-medium concentration ratios indicate a significant retention of the drug in tumors, i. e. 19% to 71 % of initial drug concentration was retained after 24 hr, and 16 to 72% retained after 72 hr. In general, the fractions retained and the tumor-to-medium concentration ratios attained at the lower initial medium concentration of 120 nM were significantly higher than those attained at the higher initial concentration of 1,200 nM (p<0.05, unpaired two-tailed Student's t-test). But the differences between the apparent Tli2,etnux at these two initial medium concentrations are not statistically significant. Collectively, these data indicate significant drug retention in tumors and that the extent of retention but not the rate of efflux is inversely related to drug concentration.
Figure 2 and Table 2 show the results of an experiment designed to measure the paclitaxel efflux from histocultures of FaDu xenograft and patient tumors.
Tumors were incubated with paclitaxel for 24 hr. After replacing the drug-containing medium with drug-free medium, the drug concentration remaining in histocultures at 24 and 72 hours post-treatment were analyzed to determine the time to reach 50% of the pseudo steady state level (TI~,e~ux). The statistical significance of the differences among patient (head and neck and ovarian, n=6) and FaDu (n=3) tumors, at equal initial medium concentrations, were analyzed using a unpaired t-test. Different units were used for the medium and tumor concentrations.
Printed by VisuaIPatent WO 00!61141 PCT/US00I09329 Table 2 At At 72 T,~2.ett~mc 24 hr hr post-treatment post-treatment Initial rn~
TUmOTCm~iumCmediomCwmor Cmmor't0"% CmedtumCtumor Cmmoi t0"
(~) (~) (:M) Cmeammremaining(nM) (:M) Cm~i"",remaining ratioin ratio in tumor tumor 120 I 1.70 1560 54.8 1.32 1.19 880 43.3 7.45 .13 t t t t 0.14 t 0.50 ~ t f 3.02 f 3.1 300 16.3 Head d 1,2007.69 4.38 550 18,7 10.9 4.17 376 16.0 3.33 t t t t 1l. t 2.77 ~ t t 2.62 88 6.2 I 250 5.3 120 1:1910.6151518 39.81 1.6010.260.5201 318 35.71 4.3010.54 x= f 18.5 Ovarian 0.24 0.149 14.2 ~ 0.196' patient1,20012.8 5.13 398 25.9 16.7 4.20 245 19.8 ~ 5.00 f t t f t 2.9 f 1.79 t f t 2.93 21 8.3 99 6.6 3.41 1.32 120 0.9893.88 4359 71.0 1.42 3,84 2660 71.8 6.42 t t t t f 0.18 t 1.04 t f t 3.51 1.7a FaDu 0.2281.27 1230'6.8a 473a xeno-1,20012.2123.215.41800158.61 18.915.517.713.71010 45.0 4.0S
t t t 1.21 5.8 1.3 3008 5.48 339a p<0.05, unpaired two-tailed Student's t-test.
Differences between patient and xenograft tumors Of the patient tumors, the head and neck tumors show a trend of higher accumulation (i. e. high steady state tumor-to-medium concentration ratio) and a slower uptake rate (i.e. longer apparent TIi2,uptaie) compared to the ovarian tumors (Tables 1 and 2). However, the differences are not statistically significant, due to the large variability between individual tumors. In contrast, there are significant differences in the rate of drug uptake, extent of drug accumulation and extent of drug retention between patient tumors and the xenograft tumor (Tables 1 and 2). When compared to patient tumors, the xenograft tumor showed a slower uptake and a greater extent of accumulation when the initial drug concentrations were >_120 nM, but not at the lbwer medium concentration of 12 nM. The xenograft tumor also showed a 3- to 4-times greater drug retention compared to patient tumors. The differences in the drug uptake and accumulation between patient and xenograft tumors were used to study the determinants of paclitaxel uptake and efflux in solid tumors.
Printed by VisualPatent Determinants of paclitaxel uptake and efflux The rate of paclitaxel uptake in tumors involves multiple kinetic processes;
i. e.
movement from media to collagen gel matrix, to tumor histocultures and then through interstitial space to cells, as well as binding to tubulins and microtubules and possibly other macromolecules (Jord n MA et al. (1993) Proc Natl Acad Sci USA 90:9552-9556;
Manfredi JJ et al. (1982) J Cell Biol 94:688-696). The binding to macromolecules determines the extent of drug accumulation; the plateau drug accumulation attained at higher drug concentration in culture medium reflects a saturation of binding sites (Jordan MA et al. (1996) Cancer Res 56:816-825; Kang et al. (1997) Proc Am Assoc Cancer Res 38:604). During efflux; the free drug including the drug dissociated from binding sites txavels sequentially from intracellular space to interstitial space by diffusion and/or transport by the drug efflux rndrl p-glycoprotein, to collagen gel matrix and to surrounding culture medium. Drug retention in tumors is determined by its binding to macromolecules and the rate of efflux is determined by the dissociation of drug from binding sites. The pseudo steady state attained during efflux reflects a slow dissociation of paclitaxel from binding sites.
Three studies were performed to identify the key determinants of paclitaxel uptake and efflux from solid tumors. These studies include (a) evaluation of drug diffusion from culture medium to histocultures, (b) evaluation of the role of the drug efflux mdrl p-glycoprotein, and (c) evaluation of the role of cellularity and apoptosis.
Diffusion of paciitaxel from culture medium to 3-dimensional tumor histocultures This study determined the rate of drug diffusion from culture medium into the collagen gel matrix supporting the histocultures, to evaluate whether slow drug diffusion contributed to the slow drug penetration into solid tumors. One cm2 collagen gel pieces were presoaked and placed in a well of a 6-well plate, containing 4 ml of complete culture medium. No tumors were added. After incubation for 3 to 4 days, the medium was replaced with 4 m1 of 120 nM [3H]paclitaxel-containing medium and incubated at 37°C for 24 hr. At predetermined times, 100 :1 of medium was removed from each well.
For the sampling of medium trapped in the porous collagen gels, one piece of collagen geI was transferred to a new plate and the medium was obtained by squeezing the gel with a pair of forceps. These procedures required less than 20 sec. The radioactivity in Printed by VisuaIPatent medium was determined. The results show that immediately (i.e., <12 min) after adding drug solution to the medium, the drug concentration in the culture medium trapped in the collagen gel matrix (Cgel) was about 50% of the initial drug concentration in the culture medium. The more rapid increase in Cge~ compared to the increase in drug concentration in the histocultures suggests that drug diffusion from the medium through the collagen gel matrix is not the rate-limiting factor for the slow drug penetration into tumor histocultures in the first 24 hours.
Effect of expression of the mdrl p-gl_ycoprotein (Pgp) on drug accumulation in patient and xenograft tumors.
The difference in Pgp expression in tumors was a factor that was considered in relation to the differential drug accumulation. The expression of Pgp was measured by immunohistochemical methods, using procedures described previously (Toth K et al.
(1994) Am JPathol 144:227-236). Briefly, tissue sections were de-waxed and rehydrated sequentially in xylene, ethanol and water. Tissue sections were boiled in a 0.1 M citrate buffer, pH 6.0, in a microwave oven, then cooled and washed in phosphate-buffered saline (PBS}. The tissue sections were incubated with Dako blocking solution for 10 min and subsequently with the following antibody solutions for 2 hr: a mouse anti-human Pgp antibody (JSB-1, 1:200 dilution) and a rabbit antihuman Pgp polyclonal antibody (ab-1, 1:100 dilution). JSB-1 does not cross-react with MDR3 (Schinkel AH et al. (1991) Cancer Res 51:2628-2635). The incubation was carried out in a humidified chamber at room temperature. The antibodies were diluted in PBS
containing 5 mg/ml bovine serum albumin. For negative controls, we used mouse IgG
as the primary antibody. For positive controls, we used human adrenal gland which shows high Pgp expression (Pavelic ZP ef al. (1993) Arch Otolaryngol Head Neck Surg 119:753-7S7). After washing with PBS, the tissue sections were covered with the linker solution, and then with peroxidase-conjugated streptavidin solution. After washing twice with PBS, tissue sections were incubated for 5 to 7 minutes with diaminobenzidine and counterstained with hematoxylin.
Only tumors that were stained by two Pgp antibodies and showed Pgp proteins in at least two-third of the histocultures were considered Pgp-positive. By these criteria, the xenograft tumor, three head and neck tumors, and two ovarian tumors were Pgp-Printed by VlsualPatenf positive, whereas four head and neck tumors and one ovarian tumor were Pgp-negative.
The accumulation of paclitaxel in these tumors was compared, at two initial medium concentrations of 120 and 12,000 nM. The results are shown in Table 3. The statistical significance of the differences between groups was analyzed by the two-tailed unpaired Student's t-test. Groups with statistically significant differences are also noted in Table 3.
umor-to-medium concentration ratio 120 12,000 Tumor Pgp nM nM
statusn 24 h n 24 h 48 h 72 h 96 h ~
FaDu + 3 53110 3 2913 4616 51+1 50+8 ~
Patient+ 3 3011 5 21+5 26+3 2411 25+4 Patient 3 383 5 311i 1 32+9 3318 31110 a Comparison between FaDu xenograft and Pgp-positive patient tumors, p<0.05.
b Comparison between Fa.Du xenograft and Pgp-negative patient tumors, p<0.05.
The xenograft tumor showed a higher accumulation than the Pgp-positive patient tumors. Within the patient tumors, Pgp expression did not always result in a lower drug accumulation. For example, while the Pgp-positive patient tumors showed a trend of lower drug accumulation compared to the Pgp-negative patient tumors at the higher drug concentration of 12,000 nM, the difference was small (i.e. average of <25%) and not statistically significant. Furthermore, no difference between the two groups was observed at the lower drug concentration of 120 nM. These data indicate that Pgp expression, while it might have contributed to the lower drug accumulation in some tumors, is not the major determinant of drug accumulation and did not fully account for the 50 to 100% difference in drug accumulation between patient and xenograft tumors.
Printed by VisuaIPatent Role of cellularity and apoptosis in paclitaxel penetration, accumulation and retention in histocultures The rate of [3H]paclitaxel penetration in tumors and the spatial relationship between drug penetration, tumor architecture and tumor cell distribution were evaluated using autoradiographic techniques and image analysis. The autoradiographic method was as described previously (Lesser GJ et al. (1995) Cancer Chemother Pharmacol 37:173-178). After incubation with [3H]paclitaxel (0.231 and 2.31 ~,Ci/mI, corresponding to 12 and 120 nM) for 1 hour to 3 days, tumor histocultures were collected and washed two times by dipping in ice-cold drug-free medium. Tissue samples were mounted on cryostat chucks with embedding matrix (O.C.T.
Compound, Miles Inc., Ellchart, IN) and cut into 10 pm thick sections in a cryostat at -20°C.
Sections were thaw-mounted on a glass slide and heat-fixed on a slide warmer for 15 min. The slides containing the tissue sections were placed against tritium-sensitive film (Ultrofilm) in an X-ray cassette and exposed for one to two weeks at room temperature.
The films were developed for 3-5 minutes at room temperature (D-19 Developer), placed in a stop bath for 30 seconds, immersed in fixer for 3 minutes and exposed to running room temperature water for 15 minutes. The films were then rinsed in Photo-flo 200 and allowed to air-dry. Separately, the tissue section slides were stained with hematoxylin and eosin.
Image analysis was then used to capture the autoradiographic image (where the grains indicated the location of the radiolabeled drug) and the histologic image of the tissue section slide stained with hematoxylin and eosin (which showed the tissue structure and distribution of tumor cells). The threshold for the autoradiographic image was adjusted to minimize the background signal. The autoradiographic image was overlaid on the histologic image to visualize the distribution of [3HJpaclitaxel in tumor histocultures.
Head and neck tumors and a xenograft tumor were treated with 120 nM
paclitaxel. The drug uptake rate in the xenograft tumor was about 50 to 80%
slower than in patient tumors and the accumulation was twice that in patient tumors (Table 1).
In the xenograft tumor, paclitaxel penetrated only a few cell layers in the periphery after 4 hours, 10 to 15 cell layers after 24 hours, and became evenly distributed throughout the tumor (>80 cell layer thick) at and after 48 hours. These data indicate an abrupt Printed by VisuaIPatent increase in the drug penetration rate after 24 hours. The drug penetration in the patient tumor was more rapid, reaching about one-half of the tumor histoculture at 4 hours and becoming evenly distributed at 24 hours. In both xenograft and patient tumors, a comparison of the radioactivity in areas with high and low cell density indicates a higher localization of radioactivity in cells compared to interstitial space. In addition, the rapid distribution of radioactivity to the areas with a low epithelial cell density at earlier time points, together with the observation of a more rapid drug penetration in patient head and neck tumors which has a lower tumor cell fraction (i.e., 5118% of the histocultures was represented by tumor cells) as compared to the FaDu xenograft tumor which has a higher tumor cell fraction (i.e., 797.0% of the histocultures was represented by tumor cells), suggest that reduced cellularity corresponds to a more rapid drug penetration.
The above observations suggest that drug penetration may be enhanced by a loss of cellularity, e.g. following apoptosis induced by paclitaxel treatment which occurs after a 16 to 24 hour delay (Saunders DE et al. (1997) Int J Cancer 70:214-220). This hypothesis was confirmed by evaluating the changes in tissue composition with time, for the xenograft tumor. The xenograft tumor was treated with two concentrations of paclitaxel, i. e. 120 nM which caused significant apoptosis and 12 nM which did not cause significant apoptosis.. The fractions of stromal tissue and tumor cells in each histoculture were measured using image analysis. Briefly, stromal and tumor cells of a 100x magnification field were outlined with the computer mouse. The sizes of each of these regions were determined via image analysis by counting the number of pixels in the region. To determine the fraction of apoptotic cells in a tumor, the tumor cell density and the fraction of apoptotic cells were determined by counting the number of total tumor cells and apoptotic cells in nonnecrotic regions at 400x magnification (3 microscopic fields/tumor). Apoptotic cells were determined based on morphological changes in tumor cells such as chromatin condensation and margination, disappearance of nucleoli, formation of membrane blebs, apoptotic bodies and/or cell shrinkage (Kerr JFR et al. (1994) Cancer 73:2013). This method has been shown to yield the same results as the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TLJNEL) method (Gan Y et al. (1996) Cancer Res 56:2086; Gold R et al. (1994) Lab Invest 71:219-225). For each tumor piece, 50 to 100 images were processed, and the Printed by VisualPatent fractions of the tumor represented by tumor cells, stromal tissue, and interstitial space were calculated.
When xenograft tumor histocultures were treated with 120 nM paclitaxel, there was a significant reduction in tumor cell density and increase in apoptotic cells. This effect was first detected at 24 hours and progressively increasing with time.
The fraction of apoptotic cells in the treated tumors was ~30% at 24 hours and increased to ~50% at 72 hours, whereas the untreated controls showed a <5% apoptotic cells. The onset of apoptosis and expansion of interstitial space at 24 hours coincided with the abrupt increase in drug penetration, i. e. the drug penetrated >80 cell layers during the second 24 hours opposed to 15 cell layers during the first 24 hours. When tumors were treated with 12 nM paclitaxel, it did not produce significant reduction in cellularity nor increase in apoptotic cells; the fraction of apoptotic cells remained relatively constant at <_7%.
Under these conditions, drug penetration was restricted to the periphery.
These results indicate that the drug-induced apoptosis causes a reduction in tumor cell density and thereby enhances drug penetration into the inner layers of the solid tumor.
5.'ummarY
In summary, this example shows that (a) the penetration of paclitaxel in tumors is more rapid but the accumulation is lower as the density of epithelial tumor cells decreases, (b) drug-induced apoptosis enhances drug penetration into the inner cell layers of solid tumors, (c) the concentration-dependent drug penetration rate is related to the concentration-dependent apoptotic effect, and (d) the time-dependent drug penetration is related to the kinetics of apoptosis.
EXAMPLE Z: Effect of Apoptosis-Inducing Pretreatment on Drug Penetration and Accumulation in Tissues using Paclitaxel as the Apoptosis Inducing Agent This example consists of in vitro and in vivo studies. The in vitro study was performed using the human pharynx FaDu xenograft tumor -maintained in athymic mice. The in vivo study was performed using a syngeneic animal tumor, i.e., the MAT-LyLu prostate tumor maintained in Copenhagen rats.
Printed by VisuaJPatent Drug treatment-In vitro studies Drug treatment was as previously described. The histocultures were transferred to a collagen gel presoaked with drug-containing medium for at Ieast 8 hr. The latter was to ascertain that the drug concentration in the medium inside the collagen gel was at equilibrium with the surrounding medium, in order to eliminate the delay in drug transport from medium through the collage gel. Drug treatment was terminated by transferring histocultures to a collagen gel presoaked with drug-free medium.
Histocultures were transferred using a pair of hooked forceps and care was exercised to avoid squeezing or pinching.
Effect of apoptosis-inducing pretreatment on drug deliver in tumor-In vitro studies.
The spatial distribution of [3H]paclitaxel in histocultures was studied using autoradiography and imaging techniques as described in Example 1. The total drug concentration in tumor histocultures was measured as described in Example 1.
Briefly, after incubating with 4 ml of culture medium containing a mixture of radiolabeled and nonradiolabeled paclitaxel (specific activity, 0.301 :Ci/ml), histocultures were harvested and analyzed for total radioactivity using liquid scintillation counter.
Thirty to 35 tumor histocultures were used for each time point.
Two studies were performed. In the first study, two groups of histocultures were incubated with the same concentration of [3H]paclitaxel, 10 or 50 nM for 72 hr. These two groups received identical total exposure to radialabeled paclitaxel, except the pretreated group also received an additional exposure of 3000 nM~hr nonradiolabeled paclitaxel (i.e., 1,000 nM of nonradiolabeled paclitaxel for 3 hr), initiated at 24 hr prior to the radiolabeled dose. The drug concentration and the timing of the pretreatment was found in a preliminary study to cause significant apoptosis (~30%) at 24 hr.
The second study used the same total drug exposure, i.e., 1,200 nM~hr, but by different schedules as described below For both studies, histocultures were collected at predetermined intervals after [3H]paclitaxel treatment, and analyzed for drug penetration.
The first study was used to demonstrate qualitatively the effect of pretreatment on the rate of drug penetration in solid tumor. Drug accumulation was evaluated only in the second study, because in the first study, the dilution of [3H]paclitaxel by nonradiolabeled drug was expected to alter the Printed by VisualPatent specific activity of [3H)paclitaxel and, therefore, affect data accuracy.
The results shows the effect of pretreatment with 1 :M nonradiolabeled paclitaxel on [3H)paclitaxel penetration in FaDu tumor histocultures. The nonradiolabeled paclitaxel was not detected by autoradiography and did not interfere with the detection of [3H]paclitaxel. The example used two concentrations of [~H]paclitaxel that differed in their ability in inducing apoptosis and reducing tumor cell density, with the 50 nM concentration being more effective than the 10 nM
concentration (Table 4). Without the pretreatment, tumor penetration of [3H]paclitaxel at 10 nM was limited to the periphery of the histocultures throughout 72 hr, whereas penetration at 50 nM concentration in the first 24 hr was limited to the periphery but subsequently increased, along with increased apoptotic fraction and reduced cell density, such that drug distributed evenly throughout the tumor by 72 hr. The paclitaxel pretreatment induced apoptosis and reduced the cell density by the time the [3H]paclitaxel treatment was applied. The pretreatment enhanced the penetration of [3H]paclitaxel at both 10 and 50 nM concentrations such that even distribution in tumor was attained at 72 and 24 hr, respectively. These findings suggest that the fractionated doses separated by an interval that allows for apoptosis to occur would have result in greater drug penetration and accumulation than a continuous treatment schedule of the same total drug exposure (i.e., product of concentration and time, CxT) Table 4 shows the results of an experiment where tumor histocultures were treated with different concentration of j3H]paclitaxel with or without pretreatment by 1 :M
nonradiolabeled paclitaxel. The fraction of apoptotic cells and the tumor cell density were determined by counting the number of total and apoptotic tumor cells in 400x microscopic fields (3 fields per tumor).
Printed by VisuaIPatent Drug concentrationApoptotic Cell density ~ fraction, % ~
and treatment Without I With Without With ~
duration I pretreatment~ PretreatmentpretreatmentPretreatment 1Q nM
4 hr ~ 3.930.87 ~ 23.61.3 86.314,0 64.23.5 ~
( ~
16 hr ~ 4.980.84 24.614.8 80.212.9 64.311.8 24 hr ~ 7.3211.80 26.62.4 ' 81.612.5 64.015.2 32 hr ~ 6.64 1.07 t 30.113.4 79.92.1 60.1 X4.2 48 hr 9.1811.31 ~ 34.915.2 77.8f3.0 62.33.1 ~
72 .hr ~ 11.01.7 ~ 31.014.4 82.612.2 61.012.2 50 nM t 4 hr t 2.7410.12 , 26.315.4 85.83.6 63.14.5 16 hr 7.9712.03 36.013.9 83.9f3.3 60.84.9 ~
24 hr I7.Ot2.8 ~ 36.412.0 77.013.8 58.31.1 32 hr 19.12.5 37.44.5 71.214.6 53.22.1 48 hr ~ 28.32.9 ~ 39.813.1 68.82.5 53.6f2.4 ~
72 hr I 27.213.0 37.913.4 61.12.8 47.813.2 To evaluate the effect of treatment schedule on paclitaxel delivery in tumors, a second study examined the drug penetration and accumulation in two groups that were treated with the same CxT (i.e., 1,200 nM~hr), given by two schedules. The pretreatment group received fractionated doses, i.e., 600 nM [~H]paclitaxel for 1 hr, followed by incubation in drug-free culture medium for additional 23 hr to allow apoptosis to occur, and then treated with 50 nM [3H]paclitaxel for 12 hr. The control group was incubated with 50 nM [3H]paclitaxel continuously for 24 hr. In the control group, paclitaxel penetration was restricted to the 5 to 10 cell layers in the periphery of the histocultures in the first 24 hr, at which time drug-induced apoptosis began to appear. While drug penetration increased simultaneously with an increase in apoptotic fraction and reduction in cell density during the next 12 hr, drug penetration remained 1 S . confined to less than 20 cell layers in the periphery. In comparison, the pretreatment Printed by VisuaIPatent group showed a higher apoptotic fraction, a lower cell density, and a more rapid penetration, resulting in even drug distribution throughout histocultures at 35 hr (Table 5). A comparison of drug accumulation in the two groups showed a 40% higher drug accumulation in the pretreatment group at the end of drug treatment (i.e., at 36 hr in pretreatment group vs at 24 hr in control group; Table S), in agreement with the more extensive drug penetration as shown by autoradiography. The results of this study confirm that a fractionated treatment separated at an interval for drug-induced apoptosis and reduction in cell density will result in greater drug penetration and accumulation into tumors than a single continuous treatment.
Table 5, listed below, shows the result of the experiment, in which tumor histocultures were treated with equal CxT of [3H)paclitaxel, i.e., 1,200 nM~hr, by two different schedules. One schedule used 50% of the total CxT to induce apoptosis, whereas the other schedule used continuous treatment. Concentrations of [3H]paclitaxel in tumor histocultures were determined, by liquid scintillation counting. The fraction of apoptotic cells and cell density were determined by counting the number of total and apoptotic tumor cells in 400x microscopic fields (3 fields per tumor).
Treatment Time (hr) after ; Apoptotic ~ Cell ~ Paclitaxel Schedule initiation of ! fraction (%) , density ; in tumor treatment x 1 hr ~ 24 j 20.34.3 ; 60.91.3 -X23 hr later I 36 I 25 ~SOnMx l2 hr .34 ~ 71.312.9 i 3.1110.31 50 nM x 24 hr , 36 i 17.03.94 ; 72.613.2 i 2.010.3 Collectively, these results indicate that under i~ vitro conditions, (a) an apoptosis-inducing pretreatment enhanced the drug penetration during subsequent treatments, and (b) treatments at higher drug concentrations that induced appreciable Printed by VisualPatent apoptosis and reduced tumor cell density resulted in more rapid drug penetration compared to treatments at lower concentration.
Effect of apoptosis-inducing pretreatment on drug accumulation in tumors- In vivo studies The rat MAT-LyLu tumor cells were originally obtained from Dr. J. Isaacs (Johns Hopkins University, Baltimore, MD), and has been maintained in RPMI-medium supplemented with 9% heat-inactivated FBS, 2 mM L-glutamine, 90 :g/ml gentamicin and 90 :g/ml cefotaxime sodium. Tumor cells (5x 106 cells in 0.1 rnl medium, >90% viability, as determined by trypan blue exclusion) were injected subcutaneously in the right and left upper backs of a male Copenhagen rat with a 21 G
needle. Experiments were initiated when the tumor was between 0.3 to 0.5 g in size.
The jugular vein and carotid artery of tumor-bearing rats were catheterized, under light ether anesthesia, with polyethylene tubing (PE-50; Becton Dickinson Co., Sparks, MD) for drug administration and for blood sampling, respectively. Each catheter was exteriorized to the dorsal side of the neck and attached to a second polyethylene tubing (PE-50), respectively. The catheters and tubings were covered with a metal coil tubing. Animals were allowed to recover for 4-5 hr, and then given an intravenous infusion of paclitaxel using an infusion pump (Harvard Apparatus, Southnatick, MA). Paclitaxel was dissolved in Cremophor ELlethanol (1:1, v/v) and diluted with 0.9% NaCI. The total infusion volume was 2 to 3 ml and the final Cremophor EL concentration in dosing solution was 10 to 15%. Five groups of animals were treated as described in the Results. Blood samples (0.12 or 0:22 ml) were obtained at predetermined times. Plasma fraction was obtained by centrifugation at 2,OOOg for 3 min, and stored at -70°C for HPLC analysis. At the end of the experiment, tumors were harvested. One quarter of a tumor was fixed in 10% neutralized formalin solution and processed for tissue morphology evaluation. Tumor cell density and the fraction of apoptotic cells were determined by counting the number of tumor cells and apoptotic cells in nonnecrotic regions at 400x magnification (5 microscopic fieldsltumor). The remainder of the tumor was stored at -70°C until HPLC analysis for drug concentration.
Printed by VlsualPatent The concentration of nonradiolabeled paclitaxel in plasma and tumor was analyzed by our previously reported HPLC assay using a column switching method (Song D et al. (1995) J Chromatogr B Biomed Appl. 663:337). Preweighed tumors were homogenized, mixed with the internal standard, 100 :1 cephalomanine (10 :g/ml in methanol). The HPLC stationary phase consisted of a cleaning column (NovaPak Cg, 75 x3.9 mm ID, 4 :m particle size, Waters Associates, Milford, MA) and an analytical column (Bakerbond Octadecyl, 250 x 4.6 mm ID, 5 :m particle size, J.T. Baker, Phillipsburg, NJ). Samples were injected onto the clean-up column and eluted with the clean-up mobile phase (37.5% acetonitrile in Water) at 1 ml/min. Concurrently, the analytical mobile phase (49% acetonitrile in Water) was directed through the analytical column at a flow rate of 1.2 ml/min. The fraction from 5 to 12 min containing paclitaxel and cephalomanine was transferred from the clean-up column onto the analytical column. Detection of paclitaxel and cephalomanine was at 229 nm, with a detection limit of 1 ng paclitaxel per injection.
Pharmacokinetic and tissue morphology studies were conducted to identify potential doses and times for administration of the drugs. The results, listed in Table 6, show that a pretreatment dose of 5 mg/kg infused over 1 hour is sufficient to induce apoptosis and reduce tumor cell density. These changes in tissue composition, as shown in the in vitro studies described above, are sufficient to enhance drug penetration in tumors. The pharmacokinetic data further showed a major half life of 1.1 hour for paclitaxel in rats, indicating that drug cancentration in plasma and tumor will be, theoretically, within 97% of a steady state following an infusion of six hours or longer (i. e., >_5 half lives). The latter is conf rmed by the plasma concentration-time profiles showing that the concentrations approached plateau values at the end of 6 and 12 hr infusions (13% diff'erence).
Table 6 shows the results of an experiment where animals received the indicated treatrnent (Tx). Concentrations of paclitaxel in tumors and plasma were determined by HPLC. Fraction of apoptotic cells and cell density were determined by counting the number of total and apoptotic cells in 400x microscopic fields (5 fields per tumor).
Mean ~ SD.
Printed by VisuaIPatent i ~ 1 i j . I
Group Infusion Total N Tumor Plasma Tumor-to-ApoptoticCell density ' : ~ ~ ; ~ i ~
' rate dose ~ conc. conc. plasma fraction, ' At ~ i (mglkg/hr)(mglkg~ (:glg) end of conc. % i . f at Tx i ratio ~
& schedule) ~ ~ specified(:g/ml) at end I . ~ I ' of i , i I , time i Tx ; y , x 1 10 5 3.9410.351.4210.112.80f0.2814.512:5 hr ~ , , ~ ~
at 30 a ~ ~ 83 ~ 4.69b 1 ! 0.83 x ~ = hra I
6 hr ~
~
at 24 I ~ i hr ~
', 5 5 ~ 4 2.7610.576.010.640.4610.09I .510.9120 t x I ; i ? ; ~ 4.35 hr at i 2A ~ 0 hr ' ~ at 1 . at 1 hr hr ' i 5 5 j 4 <0.35 ND NA ; 11.212.385 t 4.52 x 1 at .
hr at I
2B ; ' i 24 hr i ~ ~ at 24 0 hr hr' i 3 I 0.83 x 5 4 2.2610.131.310.121.7310.183.511.5 112 t 6 hr ' ' ' ; j 6.08 ~
at0hr ~ at6hr j 5 x 10 4 3.2410.312.9810.601.20+0.305.812.2 108 t I hr f i ; 5.78 at ~
4 j Ohr+0.83 ~ at7.2hr ~ i x6hrai j i 1.2 hr 5 ~ 0.83 10 5 2.9510.34' 1.5010.06i 1.9810.236.51.6 t 115 x 12 ' ~ t 5.18 I
hr ~ I at 12 ~ .
i i ~ hr I
~
' p<0.05. compared to all other groups.
b: p<0.01, compared to all other groups except Group 2B.
5 ': p<0.01, compared to all other groups except Group Z.
Three in vivo studies were performed. The first study examined the effect of pretreatment on drug delivery to tumor tissue, in three groups of animals.
Group 1 received a pretreatment of 5 mglkg over 1 hour and, at 24 hours, a second dose infused at a slower rate (i.e., 5 mglkg over 6 hours). To obtain the baseline measurements of drug delivery to tumor at each of the two doses, Group 2 received only the pretreatment, and Group 3 received only the second treatment. In the absence of enhanced drug delivery due to apoptosis. the drug concentration in Group 1 should be Printed by VisualPatent WO 00161141 PCTlUSOOI09329 lower than the sum of the concentrations in Groups 2 and 3, because the concentration derived from the pretreatment dose in Group 1 was measured at the end of the 30 hr total treatment time which, due to the continuing decline with time, should be lower . than the concentration in Group 2 which was measured immediately after the 1 hr S pretreatment. Conversely, in the presence of a substantially enhanced drug delivery due to apoptosis, the concentration in Group 1 may exceed the sum of concentrations in Groups 2 and 3. The results show a SO% higher tumor concentration in Group 1 at 30 hr or at the end of treatment compared with the sum of the concentration derived from Group 2 at 24 hr plus the concentration derived from Group 3 at 6 hr (Table 6), thus supporting our hypothesis of enhanced drug delivery due to apoptosis induced by the pretreatment.
The second study compared the tissue morphology and tumor concentration in Group 1 with those in Group 4 which received the same two doses by the same infusion schedules as Group 1, with the exception that the two doses were separated by only 10 1 S min (time required to change and reset the infusion syringe and pump) as opposed to the 23 hr in Group 1. As shown above, 24 hr was the duration needed for apoptosis and reduction in cell density to occur. At the end of treatment (30 hr for Group 1 and 7.2 hr for Group 4), Group 4 showed a 60% lower apoptosis, 30% higher cell density and 18%
lower drug concentration, compared to Group 1 (Table 6). These results indicate the importance of timing on drug-induced changes in tissue morphology and on drug delivery.
The third study compared the tissue morphology and tumor concentration in Group 1 to those in Group S which received the same total dose as Group 1 with the .exception that the dose was delivered at a slower rate continuously over a longer 2S duration, a. e. , 12 hr. At the end of treatment (30 hr for Group 1 and 12 hr for Group S), Group S showed a 3S% lower apoptosis and 2S% higher cell compared to Group l, and the drug concentration at 12 hr in Group S was 25% lower than the concentration at 30 hr in Group 1 (Table 6).
Another measurement of drug penetration in tumor is the tumor-to-plasma concentration ratio at the end of drug treatment when the plasma concentration in Groups 1, 4 and S were at an apparent steady state. A comparison of the tumor-to-plasma concentration ratio in these three groups shows a i30% and 40% higher ratios in Printed by VisuaIPatent -53=
Group 1 compared to Groups 4 and 5, respectively (Table 6), confirming the higher drug delivery in the group receiving the apoptosis-inducing pretreatment.
Collectively; the results of the in vivo studies confirm the findings in tumor histocultures, and further suggest a requirement of >10% apoptosis and >25%
reduced cell density for enhancing drug delivery to tumor under in vivo conditions.
EXAMPLE 3: Effect of Apoptosis-Inducing Pretreatment on Drug Penetration and Accumulation in Tissues using Doxorubicin as the Apoptosis Inducing Agent In this example, the penetration of doxorubicin into multilayer tissue was monitored using prostate tumor specimens obtained from human cancer patients and using the human prostate PC3 xenograft tumor maintained in athymic mice.
Doxorubicin was monitored by fluorescence.
Accumulation of doxorubicin in tumor histocultures Histocultures of tumors were incubated with 1, 5 or 20 :M doxorubicin as described in Example 1. These concentrations were chosen based on the previously published data which demonstrate that 0.4 :M doxorubicin was sufficient to produce, in patient prostate tumors, a 90% inhibition of tumor cell proliferation, and that 2.1 :M and 4.2 :M doxorubicin were sufficient to produce 50 and 90% cell death, respectively (Chen et al., (1998) Clin. Cancer Res. 4:277-282; 1998). At 4; 12, 24, 36, 48, and 72 hours, histocultures were collected and processed as described in Example 1. The fluorescence emitted by doxorubicin was visualized using fluorescence microscopy. The excitation and emission wavelengths were 546 nm and 565 nm, respectively. Microscopic images were captured using a Charged Couple Device (CCD) camera and the captured images were analyzed using Optimas image analysis software (Silver spring, MD). The doxorubicin concentration in tissues was quantified using standard curves (each curve contained six data points), established as follows. Samples for the standard curves were prepared by applying known amounts of doxorubicin in solution to microscope sections of blank dog prostate tissue. The standard doxorubicin solutions (2 :1) were pipetted on 10 :m-thick blank tissue sections, and carefully spread over a surface area of approximately 1.5 - 2 cmz. The standard slides were scanned using the same conditions as the samples. The average fluorescence intensity per area were measured.
Plots of the Printed by VisualPatent fluorescence readings against the applied doxorubicin concentrations in the standard curve samples provided the standard curves used to quantify the doxorubicin in the actual samples. For the latter, at least three sections were used to abtain the mean value in one tumor, and at least three tumors were used to obtain the mean value at each time point.
Figure 3 summarizes the accumulation of doxorubicin in tumor tissues, expressed as tissue-to-medium concentration ratio, as a function of time and initial extracellular drug concentrations. The results show that drug concentration in the periphery of tumor (i.e., 75 N.m) and in the far end of the tumor (i.e., 325 prn from the periphery of the tumor in contact with the culture medium) rose more rapidly in patient tumors than in the PC3 xenograft tumor. The ratios reached at 72 hr increased with the extracellular drug concentrations, but the increase was not linear with concentration. The latter may be due to the nonlinear drug binding which became saturated at the higher drug concentration, as described for paclitaxel in Example 1. At the lower drug concentration of 1 N,M, the drug concentration in the far end of the tumor remained several fold-lower compared to the concentration in the periphery. In contrast, at the higher drug concentrations of 5 and 20 ~M, the drug concentrations in the far end of the tumors approached the concentrations in the periphery of the tumors.
Collectively, these data indicate that the rate and extent of drug accumulation in solid tumors are dependent on time and initial drug concentration.
Table 7 shows the results of doxorubicin accumulation in patient tumors and the PC3 xenograft tumor, after 72 hr incubation with doxorubicin at 1, 5 and 20 N.M.
Printed by VTsuaIPatent Table 7 Tumor Drug Tissue Tissue-to- PC3 CeII density concentrationconcentrationmedium xenograft-to-in untreated in culture at 72 hr concentrationpatient tumortumor (cells medium, ratio at concentrationper mm2) ~M 72 hr ratio at 72 hr Patient 1 29.217.8 29.21?.8 1.15 1864125*
tumors 5 15 8170.9 31.6 14.2 1.3 5 20 7391531 36.9126.5 1.5 PC3 1 33.63.9 33.613.9 Not 2418t66~
xenograft5 213116.4 42.713:3 applicable tumor 20 1107193 55.39.6 *p<0.05, unpaired two-tailed Student's t-test.
Doxorubicin concentration in both patient tumors and the PC3 xenograft tumor increased with incubation time and with the initial drug concentration in the culture medium. The findings on the rate and extent of doxorubicin accumulation in patient and xenograft tumors are similar to the findings on paclitaxel described in Example 1. For example, drug accumulation in the xenograft tumor is slower compared to patient tumors (Figure 3). Drug concentration in the xenograft tumor shows a higher tumor-to-medium concentration ratio compared to patient tumors, although the difference is not statistically significant (Figure 3 & Table 7). The tumor cell density in the xenograft tumor without drug treatment is 1.3 fold-higher compared to patient tumors.
Collectively, these data indicate that the slower drug uptake rate and the higher drug accumulation in the PC3 xenograft tumor, compared to patient tumors, is due to the higher tumor cell density in the xenograft tumor.
Rate of doxorubicin ~~~enetration into tumors The rate of doxorubicin penetration into patient and PC3 xenograft tumors was monitored using fluorescence microscopy. The presence of fluorescence corresponds to the presence of doxorubicin and, hence, indicates the spatial distribution of doxorubicin Printed by VisualPatant in tumor tissue. The findings on doxorubicin penetration and distribution in tumor tissues are similar to the findings on paclitaxel as described in Example 1.
For example, the patient and xenograft tumors show different rate and pattern of doxorubicin penetration, and the rate of drug penetration was also dependent on the drug concentration. For the patient tumors treated with 5 or 20 ~.M, the fluorescence signal was confined to the periphery (about 75 pm thick) during the first 12 hr, but became evenly distributed throughout the histoculture (about 325 pm thick) after 24 hr: For the xenograft tumor treated with the same drug concentrations (i. e., 5 or 20 p.M), the fluorescence signal was confined to the periphery during the first 24 hr, and became evenly distributed only after 36 hr. At the lower drug concentration of 1 p.M, the drug was distributed evenly throughout the patient tumors by 72 hr but remained confined to the periphery of the xenograft tumor at 72 hr.
Figure 4 summarizes the drug concentration in tumor tissue, expressed as tissue-to-medium concentration ratio, as a function of the distance from the periphery of the tumor histocultures. The results show that the attainment of an equilibrium between the drug concentration in the far end of the tumor (i. e., 325 ~m from the periphery of the tumor in contact with the culture medium) with the drug concentration in the periphery of the tumor (i. e. , 75 Vim) depends on the initial drug concentration in the culture medium. At the lower drug concentration of 1 uM, the drug concentration in the far end of the tumor did not reach equilibrium with the concentration in the periphery. For the higher concentrations of 5 and 20 ~,M, the equilibrium was attained at 36 hr.
Collectively, these results indicate that rate and extent of doxorubicin penetration into tumor is dependent on the treatment time and the extracellular drug concentration.
These data are similar to the findings for paclitaxel, as described in Example 1, and suggest that doxorubicin-induced apoptosis enhances the rate and extent of drug penetration into tumors.
Roles of cell death in drug penetration Tumor cell density was monitored as described in Example 1. The cell death and therefore the reduction of cell density induced by doxorubicin treatment were dependent on the initial drug concentration. For example, the cell density in the periphery of the PC3 xenograft tumor (i.e., about 75 pm thick) decreased with time after treatment with 5 Printed by VisualPatent or 20 wM doxorubicin, but not after treatment with 1 pM doxorubicin. Figure 5 shows the inverse correlation of the average drug concentration in the PC3 xenograft tumor and the tumor cell density in the periphery of the tumor, after treatment with 20 p.M
doxorubicin.
S
In summary, this example shows that (a) the penetration of doxorubicin in tumors is more rapid but the accumulation is lower as the density of epithelial tumor cells decreases, (b) drug-induced apoptosis enhances drug penetration into the inner cell layers of solid tumors, (c) the concentration-dependent drug penetration rate is related to the concentration-dependent apoptotic effect, and (d} the time-dependent drug penetration is related to the kinetics of apoptosis. These findings are qualitatively identical to the findings for paclitaxel (described in Example 1 ), and indicate apoptosis-inducing pretreatment as a generally applicable principle for enhancing drug penetration into multilayer tissues.
EXAMPLE 4: Apoptosis-Inducing Pretreatment Enhances Penetration of Large Particles in Multilayer Tissues Two studies were performed to evaluate the ability of apoptosis-inducing pretreatment to enhance the penetration of large molecules in multilayer tissues. The first study used fluorescence-tagged (i.e., FITC-labeled) nanoparticies, which are between 600-800 nm in diameter. The penetration of the nanoparticles was monitored by fluorescence microscopy. The second study used microparticles (about 5 micron in diameter). The penetration of the microparticles was monitored by scanning electron microscopy.
The muitilayer tissue model for both studies was the human breast xenograft tumor derived from subcutaneous implantation of MCF7 cells. Tumors were removed from mice; fragmented and grown as histocultures on collagen gel matrix. One group received a pretreatment with 100 nM paclitaxel for 24 hr. The histocultures were then moved to a second culture flask, and incubated in paclitaxel-free culture medium with FITC-nanoparticles or microparticles for additional 48 hr. The control group was treated similarly, except no paclitaxel was added to the culture medium.
Samples of Printed by VisuaIPatent _ 58 -histocultures were removed at 0, 4, 6, 12, 24 and 48 hr after exposure to nanoparticles or microparticles. Histocultures were frozen, cut into 10 micron sections. The frozen sections were mounted on microscopic slides and examined microscopically.
The results show that in the control groups, penetration of nanoparticles and microparticles in tumor histocultures in the 48 hour exposure period was limited to the periphery. In the pretreated groups, nanoparticles and microparticles penetrated the center of the histocultures by 24 hr and became evenly distributed throughout the histocultures by 48 hr.
1 U Summary 1n summary, apoptosis-inducing pretreatment enhances penetration of particles of about 5 micron diameter in multilayer tissues.
EXAMPLE 5: Nanoparticle and microparticle formulations Poly(lactide-co-glycolide) (PLGA) microspheres were prepared by a standard oil-in-water emulsion-solvent evaporation method (Thies C., 1991, In Donbrow M. (Ed.) Microcapsules and Nahoparticles in Medicine and Pharmacy, CRC Press, Ann Arbor, pp. 47-71). For doxorubicin-containing microspheres, doxorubicin in its free base form, and PLGA were dissolved in a 1:6 mixture of methanol in methylene chloride.
'Polymer and drug solutions were emulsified in an aqueous solution containing 1°l0 (w/v) polyvinylalcohol and 10 mM boric acid, pH 8.8 by brief vortexing.
Subsequently, the emulsion was diluted, and the organic solvents allowed to evaporate. The microspheres were harvested by filtration, and lyophilized. For paclitaxel microspheres, PLGA and paclitaxel were dissolved in methylene chloride. The solution was emulsified with a glycerinlwater mixture containing Tv~reen.80. The microspheres were harvested by centrifugation and lyophilized. The average particle size was 1 Vim.
Nanoparticles .containing paclitaxel were prepared by the phase separation methods. An aqueous solution of gelatin and Tween 20 was heated and sodium sulfate added until turbidity'was obsexved. Paclitaxel-containing isopropanol solution was then added until the turbidity disappeared. Glutaraldehyde and potassium meta-bisulfate were added in sequence. The resulting nanoparticles were harvested by,centrifugation and . ' lyo..plzilized. The average particle size was 620 nm.
Printed by VisuaiPatent WO 00!61141 PCTJIJS00109329 Nanocapsules containing paclitaxel were prepared by the oil-in-water-in-oil method. Tween 20 was added to 10 acres solution of gelatin. Paclitaxel was dissolved in methylene chloride. The two solutions were emulsified to form an oil-in-water emulsion. Mineral oil containing glutaraldehyde was then added. After teaching the mixture, potassium meta-bisulfate was added. The resulting microparticles were harvested by centrifugation and lyophilized. The average particle size was 13 Vim.
Liposomes containing paclitaxel were prepared by mixing triasterin, paclitaxel and Tween 80. Phosphate buffered saline was added while vortexing, to form an emulsion. The lipospheres were harvested by centrifugation. Addition of egg phosphatidylcholine to the mixture improves the smoothness of the particle surface. The average particle size was 10 ~,m.
Incorporation by Reference The entire contents of all patents, published patent applications and other references cited herein are hereby expressly incorporated herein in their entireties by reference.
Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
Printed by VisualPatent
THERAPEUTIC AGENTS TO TISSUES
Background Paclitaxel, one of the most important anticancer drugs developed in the past two decades, is active against multiple types of human solid tumors (Rowinsky EK
(1993) J
Natl Cancer ~nst Monogr 15:25-37). Paclitaxel has pleiotropic effects; for example, it enhances tubulin polymerization, promotes microtubule assembly, binds to microtubules, stabilizes microtubule dynamics, induces mitotic block at the metaphase/anaphase transition, and induces apoptosis (Parness J and Horwitz SB
(1981) JCell Biol 91:479-487;.Manfredi JJ et al. (1982) JCell Biol. 94:688-696; Jordan MA, et al. (1993) Proc Natl Acad Sci USA 90:9552-9556; Jordan MA et al. (1996) Cancer Res 56:816-825; Derry WB et al. (1996) Biochemistry 34:2203-2211). The intracellular concentration of paclitaxel is critical for its pharmacological effect; drug resistance in several resistant sublines is correlated with reduced intracellular drug accumulation compared with the sensitive parent cell lines (Lopes NM et al.
(1993) Cancer Chemother Pharmacol 32:235-242; Bhalla K et al. (1994) Leukemia 8: 466-476; Jekunen AP et al. (1994) Br J Cancer 69:299-306; Riou JF et al. (1994) Proc Am Assoc Cancer Res 36:160; Speicher LA et al. (1994) JNatl Cancer Inst 86:688-694).
Doxorubicin is an anticancer drug with a wide spectrum of clinical activities.
It has been used clinically to treat leukemias, lymphomas, and solid tumors including breast, lung, prostate, and ovarian cancers and sarcomas (Oesterling et al.
(1997) In:
Cancer: Principles and Practice of Oncology (Eds, DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A., 1997); Doroshow, J.H. (1996) In: Cancer Chemotherapy and 26 Biotherapy: Principles and Practice (Eds, Chabner, B.A. and Longo, D.L.)).
Doxorubicin is one of the most effective agents against hormone-refractory prostate cancer (Smith, D.C. (1999) Urol. Clin. North Am. 26:323-331). It has been shown that in human prostate tumor histocultures, doxorubicin can induce complete inhibition of tumor cell growth with ICSO of 61 nM and complete tumor cell death with LCSO
of 2.1 ~.M (Chen et al., (1998) Clin. Cancer Res. 4:277-282, 1998).
Printed by VfsuaIPatent Drug delivery to the tumor core is necessary to prevent tumor regrowth (Erlanson M et al. ( 1992) Cancer Chemother Pharmacol 29:343-353; Durand RE
(1990) Cancer Chemother Pharmacol 26:198-204) and is, therefore, an important determinant of treatment efficacy (Jain RK (1996) Science 271:1079-1080).
Following a systemic intravenous injection, drug delivery to the tumor core involves three processes, i.e., distribution through vascular space, transport across microvascuiar wall, and diffusion through interstitial space in tumor tissue (Jain RK (1987) Cancer Res 47:3039-3051). When the drug is directly injected into a tumor such as by intratumoral injection or by direct instillation into peritumoral space such as in intravesical therapy of superficial bladder cancer and in the intraperitoneal dialysis of ovarian cancer, drug delivery to the tumor is primarily by diffusion through interstitial space (Nativ O et al.
(1997) Int JCancer 70:297-301; Song D et al. (1997) Cancer Chemother Pharmacol 40:285-292; Markman M (1998) Semin Oncol 25:356-360; Markman M et al. (1995) Semin Oncol 22:84-87). Movement of paclitaxel in interstitial space, in spite of its relatively low molecular weight (853 Dalton), is likely to behave as a protein because of its extensive binding to proteins in interstitial fluid (Baguley BC et al.
(1995) Clin Exp Pharmacol Physiol 22:825-828).
A recent study indicates that drug delivery to a tissue during regional therapy depends on the ability of the drug to penetrate the solid tissue. T'he study indicates that paclitaxel distribution in multicellular spheroids is limited to the periphery, but the barriers to paclitaxel penetration are not known (Nicholson et al. (1997) Eur.
J. Cancer 33:1291-1298). Accordingly, approaches to delivering therapeutic agents to tissues that allow for penetration of the drug into the tissue are still needed.
Summary This invention provides methods, and compositions for use therein, for delivering therapeutic agents to tissues, wherein the methods allaw for enhanced penetration of the therapeutic agent into the interior of multilayer tissues, such as solid tissues or tumors. The methods involve use of an apoptosis inducing agent, such as paclitaxel, in doses and for periods of time sufficient to cause apoptosis in the tissue to thereby allow for enhanced penetration of the therapeutic agent into the tissue (e.g., by creating channels within the tissues). Thus, the apoptosis inducing agent is used as a Printed by VisualPatent pretreatment before the therapeutic dose of the therapeutic agent is delivered to the tissue, and this pretreatment allows for enhanced penetration of the therapeutic agent into the tissue as compared to when the pretreatment is not used. The apoptosis inducing agent may also have therapeutic activity and thus may also be used as the therapeutic agent (i. e., the same drug may be used as the apoptosis inducing agent and the therapeutic agent). Alternatively, the apoptosis inducing agent may be used to enhance delivery of other types of drugs into tissues (i.e., the apoptosis inducing agent and the therapeutic agent may be different drugs).
Accordingly, in one embodiment, the invention pertains to a method for delivering a therapeutic agent to tissue of a patient, e.g., a mammal, e.g., a human. The method includes administering an apoptosis inducing agent to the patient, and allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the patient's tissue. The tissue can be, for example, liver, muscle (e.g., cardiac, smooth, or skeletal muscle), neuronal, skin or adipose tissue, or a tumor, such as a brain, breast, ovarian, bladder, prostate, skin, colon, lung, liver, or uterine tumor. The apoptosis agent can be administered systemically, locally, regionally, or any combination thereof, such as both locally and regionally-(locoregionally).
In a second embodiment, the invention pertains to a method for delivering a therapeutic agent to a patient's tumor (e.g., a cancerous or benign tumor).
The method includes administering a dose of an apoptosis inducing agent to a patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient. The tumor may be, for example, a brain, breast, ovarian, bladder, prostate, skin, colon, lung, liver, or uterine tumor.
Examples of the apoptosis inducing agent include paclitaxel and doxorubicin.
In yet another embodiment, the invention features a method for delivering a chemotherapeutic agent to a tumor in a patient, for example, a human (e.g., a cancer patient). The method includes administering a dose of an apoptosis inducing agent locally or regionally to a patient, allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor, and delivering a dose of a chemotherapeutic agent to said patient. In a further embodiment, the tumor is a cancerous tumor, e.g., a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
Printed by VisualPatent The invention also pertains to a composition for delivering a therapeutic agent to a patient. The composition includes a quick release formulation of an apoptosis inducing agent, a slow release formulation of a therapeutic agent, and a pharmaceutically acceptable carrier.
The invention also includes microparticles and nanoparticles comprising therapeutic or apoptosis inducing agents. It also includes methods of treating patients using the microparticles or nanoparticles.
The invention also pertains to a kit for the treatment of tumors The kit contains an apoptosis inducing agent in a pharmaceutically acceptable carrier, a therapeutic agent in a pharmaceutically acceptable carrier, a container, and directions for using the apoptosis inducing agent and the therapeutic agent for the treatment of tumors.
Brief Description of the Drawings:
Figure 1 is a line graph depicting the kinetics of paclitaxel uptake in patient and xenograft tumor histocultures. Patient head and neck tumors are represented by ~, patient ovarian tumors are represented by ~, and FaDu xenograft tumors are represented by O.
Figure 2 is a line graph depicting the kinetics of paclitaxel efflux in patient and xenograft tumor histocultures. Patient head and neck tumors are represented by ~, patient ovarian tumors are represented by ~, and FaDu xenograft tumors are represented by O.
Figure 3 is a graph depicting the accumulation of doxorubicin in tumor tissues, expressed as tissue-to-medium concentration ratio, as a function of time and initial extracellular drug concentrations. The average drug concentration in the periphery of tumor (i.e., 75 ~1VI) and in the far end of the tumor (i. e., 325 pM from the periphery of the tumor in contact with the culture medium) are shown. (A) Top panels:
patient prostate tumors. (B) Bottom panels: PC3 xenograft tumors. Tumors treated with doxorubicin are represented by 1. Tumors treated with 5 p,M doxorubicin are represented by O. Tumors treated with 20 pM doxorubicin are represented by ~.
Printed by VisualPatent WO 00/61141 PCTlUSOOI09329 Figure 4 is a graph depicting the doxorubicin concentration in tumor tissue, expressed as tissue-to-medium concentration ratio, as a function of the distance from the edge of the tumor in contact with the culture medium. (A) Top panels:
patient prostate tumors. (B) Bottom panels: PC3 xenograft tumors. Tumors were treated with 1 (right panels), 5 (middle panels) and 20 (left panels) :M doxorubicin. The treatment times are directed noted on the graph.
Figure 5 is a graph depicting the effect of cell density in the periphery of the tumor (i. e., 100 ~tm distance from the edge in contact with the culture medium). Percent cell density is the ratio between the cell density in the treated tumors and the cell density in the untreated control samples.
Detailed Description of the Invention The invention, at least in part, is directed to methods for enhancing delivery of therapeutic agents, such as macromolecules and drugs, into the interior of multilayer tissues, such as solid tissues yr tumors. The method initially uses an apoptosis inducing agent, such as paclitaxel, in doses which create channels within the tissues, and enhance the penetration of therapeutic agents to the interior of the tissue. Current methods of treating tissues are often not effective because the therapeutic agents are not delivered to the interior of the tissue. By using the methods and the compositions of the current invention, therapeutic agents can be delivered to the interior of the tissue.
At least in part, the invention pertains to the penetration of therapeutic drugs into tissues and tumors of a patient, by treating the tissue or tumor with an apoptosis inducing agent such that the permeability of the tissue or tumor to a therapeutic agent is enhanced. The therapeutic agent can be a protein bound drug, a chemotherapeutic agent, a gene therapy construct, or another agent which may be advantageously delivered to the interior of a tissue, such as a tumor.
In one embodiment, the invention pertains to a method for delivering a therapeutic agent to tissue of a patient. The method includes administering an apoptosis inducing agent to the patient, and allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
Printed by VisualPatent I DEFINITIONS
Before further description of the invention, certain terms employed in the specification, examples and appended claims are, for convenience, collected here.
The term "apoptosis inducing agent" includes agents which induce apoptosis in cells, e.g., tumor cells. Cells, including cancer cells, can be induced to undergo programmed cell death, also known as apoptosis. Apoptosis is characterized by the selective programmed destruction of cells into relatively small fragments with DNA
becoming highly fragmented (i. e. the resulting fragments typically have no more than about 200 bases). During apoptosis, cell shrinkage and internucleosomal DNA
cleavage occurs, which results in the fragmentation of the DNA. Eventually the cell disintegrates into small fragments. Examples of apoptosis inducing agents include agents such as paclitaxel, doxorubicin, vincristine, vinblastine, vindesine, vinorelbin, taxotere (DOCETAXEL), topotecan, camptothecin, irinotecan hydrochloride (CAMPTOSAR), etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, 1 S merbarone, piroxantrone hydrochloride, S-fluorouracil, methotrexate, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, cytarabine (ARA,-C), trimetrexate, gemcitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L- Asparate (PALA), pentostatin, 5-azacitidine, 5-Aza-2'-deoxycytidine, adenosine arabinoside (ARA-A), cladribine, ftorafur, UFT (combination of uracil and ftorafur), 5-fluoro-2'-deoxyuridine, fluorouridine, 5'-deoxy-5-fluorouridine, hydroxyurea, dihydrolenchlorambucil, tiazofurin, cisplatin, carboplatin, oxaliplatin, mitomycin C, BCNU
(Carmustine), melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4-ipomeanol, dihydrolenperone, spiromustine, geldanamycin, cytochalasins, depsipeptide, Lupron, ketoconazole, tamoxifen, goserelin (Zoledax), flutamide, 4'- cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide, Herceptin, anti-CD20 (Rituxan), interferon alpha, interferon beta, interferon gamma, interleukin 2, interleukin 4, interleukin 12, tumor necrosis factors, and radiation.
The language "chemotherapeutic agent" includes agents such as drugs which can advantageously be administered to the tissue, such as anti-tumor drugs such as paclitaxel, doxorubicin, and other drugs which have been known to affect tumors. It also includes agents which modulate other states which are related to tissues which can Printed by VisualPatent -be permeabilized using the methods and compositions of the invention. The chemotherapeutic agent can be, for example, a steroid, an antibiotic, or another pharmaceutical composition. Examples of chemotherapeutic agents include agents such as paclitaxel, doxorubicin, vincristine, vinblastine, vindesine, vinorelbin, taxotere (DOCETAXEL), topotecan, camptothecin, irinotecan hydrochloride (CAMPTOSAR), doxorubicin, etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, merbarone, piroxantrone hydrochloride, 5-fluorouracil, methotrexate, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, cytarabine (ARA-C), trimetrexate, gemcitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L-Asparate (PALA), pentostatin, 5-azacitidine, 5-Aza-2'-deoxycytidine, adenosine arabinoside (ARA-A), cladribine, ftorafur, UFT (combination of uracil and ftorafur), 5-fluoro-2'-deoxyuridine, 5- fluorouridine, 5'-deoxy-5-fluorouridine, hydroxyurea, dihydrolenchlorambucil, tiazofurin, cisplatin, carboplatin, oxaliplatin, mitomycin C, BCNU (Carmustine), melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4-ipomeanol, dihydrolenperone, spiromustine, geldanamycin;
cytochalasins, depsipeptide, Lupron, ketoconazole, tamoxifen, goserelin (Zoledax), flutamide, 4'- cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide, Herceptin, anti-CD20 (Rituxan), interferon alpha, interferon beta, interferon gamma, interleukin 2, interleukin 4, interleukin 12, tumor necrosis factors, and radiation.
The term "delivering" refers to making the therapeutic agent available to the interior of the tissue (e.g., tumor) to be treated such that the therapeutic agent is capable of having a therapeutic effect on the interior of the tissue and includes, for example, contacting the tissue with the agent. The term "delivering" is intended to include administering the therapeutic agent to the patient as a separate dose (after administration of the apoptosis inducing agent), as well as administering the therapeutic agent to the patient together with (i.e., at the same time as or in the same dose as) the apoptosis inducing agent, wherein the therapeutic agent is formulated such that the tissue is contacted with the therapeutic agent after the sufficient time has elapsed for apoptosis to occur in the interior of the tissue (i. e., the therapeutic agent is delivered to the tissue after sufl'icient time has elapsed for apoptosis to occur).
Printed by VisualPatent _g-The term "dose" refers to an amount of an apoptosis inducing agent or a therapeutic agent which is sufficient to perform its intended function, e.g., induce apoptosis and treat the tissue, respectively. In one embodiment, the dose of the apoptosis inducing agent may be, for example, between about 0.01 nM to about nM over about 0.01 to about 5.0 hours, between about 0.1 nM to about 500 nM
over about 0.1 to about 4.0 hours, between about 1 nM to about 250 nM over about 0.5 to about 3.0 hours, between about 10 nM to about 150 nM over about 0.5 to about 2.0 hours, between about 30 nM to about 100 nM over about 0.75 to about 1.5 hours, between about 40 nM to about 70 nM over about 1 hour, and, advantageously, about 50 nM of paclitaxel over about l hour. The dose of the therapeutic agent can be, for example, administered for three hours, starting 24 hour after administration of the apoptosis-inducing agent. The target concentration of the therapeutic agent, can be, for example, about 50 nM. In another embodiment, the dose of the apoptosis inducing agent, can be, for human patients about one-half of the usual clinical dose (135-225 mg/m2), administered by intravenous infusion over about, for example, 3 hours.
The dose of the therapeutic agent can be, far example, the remaining one-half of the usual clinical dose, and could be administered, for example, between 16 to 30 hour after administration or delivery of the dose of the apoptosis inducing agent.
The term "gene therapy construct" includes constructs useful for gene therapy purposes, in treatments for either genetic or acquired diseases, e.g. cancer.
The general approach of gene therapy involves the introduction of nucleic acid into cells such that one or more gene products encoded by the introduced genetic material are produced in the cells to restore or enhance a functional activity. For reviews on gene therapy approaches see Anderson, W.F. (1992) Science 256:808-813; Miller, A.D. (1992) Nature 357:455-460; Friedmann, T. (1989) Sciehce 244:1275-1281; and Cournoyer, D., et al. (1990) Curr. Opin. Biotech. 1:196-208.
Genes of particular interest to be expressed in cells of a subject for treatment of genetic or acquired diseases include those encoding adenosine deaminase, Factor VIII, Factor IX, dystrophin, j3-globin, LDL receptor, CFTR, insulin, erythropoietin, anti-angiogenesis factors, growth hormone, glucocerebrosidase, (3-glucouronidase, al-antitrypsin, phenylalanine hydroxylase, tyrosine hydroxylase, ornithine transcarbamylase, arginosuccinate synthetase, UDP-glucuronysyl transferase, apoAl, Printed by VisuaIPatent WO 00/61141 P'CTlUS00/09329 TNF, soluble TNF receptor, interleukins (e.g., IL-2), interferons (e.g., a- or y-IFN) and other cytokines and gmwth factors. Cells types which can be modified for gene therapy purposes include tumor cells, hematopoietic stem cells, myoblasts, hepatocytes, lymphocytes, skin epithelium and airway epithelium. For further descriptions of cell types, genes and methods for gene therapy see e.g., Wilson, J.M et al. (1988) Proc: Natl.
Acad. Sci. USA 85:3014-3018; Armentano, D. et al. (1990) Proc. Natl. Acad.
Sci. USA
87:6141-6145; Wolff, J.A. et al. (1990) Science 247:1465-1468; Ghowdhury, J.R.
et al.
(1991) Science 254:1802-1805; Ferry, N, et al. (1991) Proc. Natl. Acac~ Sci.
USA
88:83??-8381; Wilson, J.M. et al. (1992) J. Biol. Chem. 267:963-967; Quantin, B. et al.
(1992) Proc. Natl. Acad. Sci. USA 89:2581-2584; Dai, Y. et al. (1992) Proc.
Natl. Acad.
Sci. USA 89:10892-10895; van Beusechem, V.W. et al. (1992) Proc. Natl. Acad.
Sci.
USA 89:7640-7644; Rosenfeld, M.A. et al. (1992) Cell 68:143-155; Kay, M.A. et al.
(1992) Human Gene Therapy 3:641-647; Cristiano, R.J. et al. (1993) Proc. Natl.
Acad.
Sci. USA 90:2122-2126; Hwu, P. et al. (1993) J. Immunol. 150:4104-4115; and Herz, J.
and Gerard, R.D. (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816.
Gene therapy applications of particular interest in cancer treatment include overexpression of a cytokine gene (e.g., TNF-a) in tumor infiltrating lymphocytes or ectopic expression of cytokines in tumor cells to induce an anti-tumor immune response at the tumor site), expression of an enzyme in tumor cells which can convert a non-toxic agent into a toxic agent, expression of tumor specific antigens to induce an anti-tumor immune response, expression of tumor suppressor genes (e.g., p53 or Rb) in tumor cells, expression of a multidrug resistance gene (e.g., MDR1 and/or MRP) in bone marrow cells to protect them from the toxicity of chemotherapy.
Gene therapy applications of particular interest in treatment of viral diseases include expression of traps-dominant negative viral transactivation proteins, such as traps-dominant negative tat and rev mutants for HIV ar traps-dominant ICp4 mutants for HSV (see e.g., Balboni, P.G. et al. (1993) J. Med. Yirol. 41:289-295; Liem, S.E. et al.
(1993) Hum. Gene Tyrer. 4:625-634; Malim, M.H. et al. (1992) J. Exp. Med.
176:1197-1201; Daly, T.J, et al. (1993) Biochemistry 32:8945-8954; and Smith, C.A. et al. (1992) Virology 191:581-588), expression of traps-dominant negative envelope proteins, such as env mutants for HIV (see e.g., Steffy, K.R. et al. (1993) J. Virol. 67:1854-1859), intracellular expression of antibodies, or fragments thereof, directed to viral products Printed by VisuaIPatent ("internal immunization", see e.g., Marasco, W.A. et al. (1993) Proc. Natl.
Acad. Sci.
USA 90:7889-7893) and expression of soluble viral receptors, such as soluble CD4.
Additionally, the system of the invention can be used to conditionally express a suicide gene in cells, thereby allowing for elimination of the cells after they have served an intended function.
The term "liposomes" or "lipid vesicles" refer to substantially spherical structures made of materials having a high lipid content in which the lipids are organized in the form of lipid bilayers. Unilamellar vesicles have a single lipid bilayer surrounding an amorphous central cavity which can encapsulate an aqueous volume.
Uniiamellar vesicles can be prepared as either large unilamellar vesicles (LUVs; diameter greater than about l p,) or small unilamellar vesicles (SUV s; diameter less than about 0.2 pm).
Multilamellar vesicles (MLVs) have many onion-like shells of lipid bilayers.
Because of their high lipid content, MLVs have use for carrying certain small lipophilic molecules but have a low carrying capacity for aqueous material. Paucilamellar vesicles I S (PLVs) have about two-ten bilayers arranged in the form of substantially spherical shells separated by aqueous layers surrounding a central cavity free of lipid bilayers. PLVs can encapsulate both aqueous and hydrophobic material and thus can carry a wide variety of materials. Unilamellar vesicles composed of a single bilayer of phospholipids and/or glycolipids are the most commonly used lipid vesicles for modeling of cell membrane structures since phospholipids are the primary structural component of natural membranes, including the outer cell membrane. Liposomes (e.g., phospholipid vesicles) can be used as carrier vehicles for delivering biologically active materials to tissues using the methods of the invention. For reviews of phospholipid vesicle-mediated transfer of materials see Mannino, BioTechniques, 6:682 (1988);
Litzinger, D.C. Biochim. et Biophys. Acta, I 113:201 (1992). Methods for preparing liposomes as carrier vesicles for delivery of biologically active materials are known in the art (see, for example, U.S. 4,522,811).
The term "locally" includes administration, e.g., injection, directly into the tissue to be treated. Examples of local treatment include intratumoral and intralesional injection.
Printed by VisuaIPatent The term "locoregionally" includes administration both locally and regionally.
For example, the compound may be administered in the fluid surrounding the tissues and directly injected into the tissues, e.g., intraperitoneal treatment of ovarian cancer, intravesical instillation of drug into urinary bladder for the treatment of diseased bladder, intraprostatic injection, intrahepatic infusion, perfusion of isolated organs (e.g., lung), intrathecal treatment of brain tumors, implants of drug release devices in brain for the treatment of brain cancer, and intralesional injection (e.g., into a skin lesion or a tumor). Locoregional treatments may also apply to other diseases, e.g., viral or bacterial infection, interstitial cystitis.
The term "microparticles" includes particles which comprise apoptasis inducing agents, therapeutic agents or other substances which can be advantageously delivered using methods of the invention to the interior of a tissue, e.g., a tumor. The term refers to particles of about 0.1 l.un to about 100 ~.m, about 0.5 ~m to about 50 pm, 0.5 pxn to about 20 ~m in size, advantageously, particles of about 1 pm to about 10 p,m in size, about 5 pm in size, or mixtures thereof. The microparticles may comprise macromolecules, gene therapy constructs, chemotherapeutic agents, or protein bound drugs, for example. Typically microparticles can be administered locally, locoregionally, or regionally, for example.
The term "nanoparticles" includes particles which comprise apoptasis inducing agents, therapeutic agents or other substances which can be advantageously delivered using methods of the invention to the interior or a tissue, e.g., a tumor. The term refers to particles of about 0.1 nm to about 1 ~,m, 1 nm to about 1 pm, about 10 nm to about 1 Vim, about 50 nm to about l pm, about 100 nm to about 1 p,m, about 250-900 nm in size, or, advantageously, about 600-800 nm. The nanoparticles may comprise macromolecules, gene therapy constructs, chemotherapeutic agents, or protein bound drugs, for example. Typically, nanoparticles can be administered to a patient via local, locoregional, regional, or systemic administration. In one embodiment, the nanoparticles may comprise cross-linked gelatin.
The term "patient" includes animals which can be treated using the methods of the invention. Examples of animals include mammals, such as mice, rabbits, rats, horses, goats, dogs, cats, pigs, cattle, sheep, and primates (e.g., chimpanzees, gorillas;
Printed by VlsualPatent and, preferably, humans). In a further embodiment, the patient is a cancer patient, e.g., a human suffering from cancer.
The phrase "pharmaceutically acceptable carrier" is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, diluent, excipient,, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt;
gelatin; talc;
excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water;
isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions;
and other non-toxic compatible substances employed in pharmaceutical formulations. In one embodiment, the pharmaceutically acceptable carrier is suitable for intravenous administration. In another embodiment, the pharmaceutically acceptable carrier is suitable for Iocoregional injection.
The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. Hydroxyls can be converted into esters via treatment with an esterifying agent such as alkanoyl halides. The term also includes lower hydrocarbon groups capable of being solvated under physiological conditions, Printed by VfsualPatent WO 00/61141 PCTiL1S00109329 e.g., alkyl esters, methyl, ethyl and propyl esters. (See, for example, Berge et al., supra. ) The term "pharmaceutically acceptable salts" is art recognized and includes relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. {19'77) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).
The language "pharmaceutical composition" includes preparations suitable for administration to mammals, e.g., humans. When the compounds of the present invention are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a pharmaceutical composition containing, fox example, 0.1 to 99.5%
(more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
The term "protein bound drug" includes drugs bound to or capable of binding to proteins. Examples of protein bound drugs include paclitaxel, doxorubicin, cisplatin, carboplatin, oxaliplatin, vinca alkaloids, suramin, amitriptyline, amphotericin B, cefazolin, chlorothiazide, chlorpromazine, clindamycin, clofibrate, depsipeptide, desipramine, diazepam, dicloxacillin, digitoxin, doxycycline, furosemide, heparin, indomethacin, lorazepam, nafcillin, nortriptyline, phenytoin, prazosin, prednisolone, propranolol, protriptyline, rifampin, sulfisoxazole, warfarin.
The term "quick-release formulation" refers to a formulation of a drug, wherein the drug is delivered to a site of interest in an already-active form or a form that becomes active, in a relatively short period of time, e.g., within one or a few hours and includes formulations which allow the apoptosis inducing agent to be released in a dose of about 50 nM or more over about a 1 hour time. Examples of quick-release Printed by VisualPatent formulations include micro- and nanoparticle formulations. Methods used to prepare these formulation are described in Example 5.
The term "regionally" includes administration to a region of tissue where the tissue to be treated is located, e.g., intraperitoneal administration for the peritoneal organs (such as the bladder, ovaries, etc); intracranial administration for the brain; intra-spinal administration for spinal column tissue; infra peri-cordially for the cardiac tissue;
and the like.
The term "simultaneously" includes administrations which occur together. In one embodiment, the therapeutic agent and the apoptosis inducing agent are formulated together. In such an embodiment, the apoptosis agent is typically in a quick formulation and the therapeutic agent is typically in a slow release formulation, such that the therapeutic agent is released, for example, about sixteen to twenty four hours after the apoptosis inducing agent.
The term "slow-release formulation" refers to a formulation of a drug wherein 1 S the drug is delivered to a site of interest for a sustained period of time and includes formulations whichrelease the therapeutic agent after a sufficient time has elapsed for the apoptosis inducing agent to induce apoptosis. In one embodiment, the slow release formulation releases the therapeutic agent in about six to about 120 hours after administration, about six to 96 hours after administration, about six to about seventy two hours after administration, about six to about forty-eight hours after administration, about twelve to about thirty six hours after administration, about twelve to about thirty hours after administration, or, advantageously, about sixteen to about twenty four hours after administration.
The term "solid tissue cells" describes the cells that comprise a solid tumor or tissue and include, but are not limited to, "solid tumor cells." They includes cells in the outer or exterior cell layers which can be treated with an apoptosis inducing agent such that a therapeutic agent can be delivered to the interior of the tumor or tissue, and the inner cell layers of a mufti-layer tissue. Solid tumor or tissue cells can be derived from epithelial or non-epithelial lineages. The term "solid tumor cells" includes cells that comprise a solid tumor, and also includes that cells in the outer or exterior cell layers.
Printed by VlsualPatent WO 00/61141 PCTlUS00/093Z9 The term "sufficient time" includes the length of time which is necessary for the apoptosis inducing agent to induce apoptosis, such that the tissue is permeabilized to the therapeutic agent. Far example, the sufficient time may be when the density of the epithelial, exterior or solid tissue or tumor cells have.been reduced, e.g., reduced by 1%, 2%, 3%, 4%, 5%, 10%, 20 %; 25%, 30%, 35%, 40%; 45%, 50% or greater. In another example, the sufficient time may be when apoptosis has been induced in some, e.g., 1°/a, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 15%, 17%, 20% or more of the solid tissue cells. In Example 3, it has been shown that, in at least in certain situations, the sufficient time for a apoptosis inducing agent such as paclitaxel when administered at a dose of 50 nM over one hour, is about sixteen to twenty four hours.
The sufficient time may vary. 'according to the identity and the dose of the apoptosis inducing agent and can be determined using such methods as those described in the Examples.
In a further embodiment, the sufficient time is, for example, seventy two hours or more, seventy two hours or less, sixty hours or less, fifty five hours or less, fifty hours or less, forty five hours or less, forty hours or less, thirty five hours or less, thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
The language "therapeutic agent" encompasses any agent that can confer a therapeutic benefit on a patient and includes gene therapy constructs, chemotherapeutic agents, antibiotics, macromolecules, and protein bound drugs. The language also includes any agents which can be delivered to the interior of the tissue using the methods described herein. In one embodiment, the therapeutic agent is paclitaxel or doxorubicin, or analogues or derivatives thereof. In one embodiment, the therapeutic agent comprises the same active component as the apoptosis inducing agent. For example, both the apoptosis inducing agent and the therapeutic agent can be compounds such as, but not limited to, paciitaxel or doxorubicin. The therapeutic agent may be Printed by VisuaiPatent WO 00!61141 PCT/US00l09329 formulated as microparticles or nanoparticles. Other examples of therapeutic agents include macromolecules, such as, liposomes, nanoparticles, plasmid, viral vectors, non-viral vectors, chemotherapeutics, and oligonucleotides.
The term "tissue" includes both normal mammalian tissues such as liver, muscle (e.g., cardiac, skeletal; or smooth muscle), skin, neuronal, and adipose tissue, as weal as both benign and cancerous tumors.
The term "tumor" refers to abnormally growing tissue of any tissue type and includes both benign and malignant tumors, such as cancerous tumors. Examples of cancerous tumors include sarcomas, carcinomas, adenocarcinomas, lymphomas, and leukemias. The cancerous tumor may comprise metastatic lesion. It also includes any other tumors which can be advantageously treated using the methods and compositions of the invention. The cancerous tumor may be, for example, a fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesotheIioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastric cancer, esophageal cancer, colon carcinoma, rectal cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of the head and neck, skin cancer, brain cancer, squamous cell carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, non-small cell dung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, rneningioma, melanoma, neuroblastoma, retinoblastorna, leukemia, lymphoma, or Kaposi's sarcoma.
The term "tumor suppressor genes" include genes known to suppress tumors, e.g., tumors which are treatable by using the methods of the invention.
Examples of tumor suppressor genes include, for example, p53.
Printed by VisuaIPatent _ 17 .
II. METHODS OF THE INVENTION
In one embodiment, the invention pertains to a method for delivering a therapeutic agent to tissue (e.g., the interior of a multilayer tissue) of a patient, e.g., a mammal, e.g., a human. The method includes administering an apoptosis inducing agent to the patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the patient's tissue, and delivering a therapeutic agent to tlxe tissue. The tissue can be, for example, liver, muscle (e.g., cardiac, skeletal, or smooth muscle), skin, neuronal, yr adipose tissue, or a tumor, such as a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor. The apoptosis agent can be administered systemicahy, locally, regionally, or any combination thereof, such as both locally and regionally (locoregionally). In a further embodiment, the method further comprises obtaining the apoptosis inducing agent prior to administration to the patient.
In a further embodiment, the apoptosis inducing agent is paclitaxel or doxorubicin. The therapeutic agent can be a gene therapy construct, a I5 chemotherapeutic agent, a protein bound drug or an antibiotic.
In a second further embodiment, the sufficient time and/or dosage is sufficient to reduce the density of the epithelial, exterior, or solid cells of the tissue. For example, the density of the solid tissue cells may be reduced by about 1 %; 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12 %, 13%, 14%, 15%, 16%, 17,%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or greater, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In another example, the density of the solid tissue cells may be reduced by about 0.1% to about 50%, about 1% to about 45%, about 2% or about 45%, about 1% to about 40%, 5% to about 40%, 10% to about 40%, 20% or about 40%, 25% to about 40%, or about 30% to about 35%, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours Printed by VisuaIPatent or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In another, the time is sufficient to induce apoptosis in about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25% or more of the solid tissue cells, over a period , for example, of thirty two hours or less.
thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, f fteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or i 5 less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In another embodiment, the time and/or the dosage is sufficient to induce apoptosis in about 1 % to about 25% of the solid tissue cells, or, alternatively, about 1 to about 20%, about 1 % to about 17%, about 1 % to about 15 %, about 1 % to about 14%, about 5% to about 13%, about 5% to about 12%, about 1% to about 10%, over a period, for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
Apoptosis of the cells as well as their density can be measured using techniques discussed in Examples 1, 2, and 3.
in a third further embodiment, the apoptosis inducing agent is also the therapeutic agent. However, in this case, the therapeutic agent is typically administered in a separate dose or in a slow-release form.
Printed by VisuaIPatent WO OOJ6114I P'CT/USOOJ09329 In a fourth further embodiment, the apoptosis inducing agent and the therapeutic agent are administered simultaneously. In this embodiment, the therapeutic agent is typically a slow-release formulation that releases the therapeutic agent after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
In a yet another further embodiment, the apoptosis agent and the therapeutic agent are administered sequentially. In this method, the therapeutic agent is administered as a separate dose after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
In a second embodiment, the invention pertains to a method for delivering a therapeutic agent to a patient's tumor (e.g:, a cancerous or benign tumor).
The method includes administering a dose of an apoptosis inducing agent to a patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient. The tumor may be, for example, a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
Examples of the apoptosis inducing agent include paclitaxel and doxorubicin.
In a further embodiment, the method also comprises obtaining the apoptosis inducing agent.
In a further embodiment, the dose of the apoptosis inducing agent is sufficient to reduce the density of epithelial, exterior, or solid tumor cells, such that the therapeutic agent can be delivered to the interior of the tumor. For example, the dosage of the apoptosis inducing agent is sufficient to reduce the density of the cells, e.g., by about 1°/a, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%
or greater, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, f fteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or Less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or Iess, or one hour or less.
Printed by VisualPafent WO 00/61141 PCTlUS00109329 -2a-In another further embodiment, the apoptosis inducing agent induces apoptosis in about 1%, 2%, 3%, 4%, 5%, 6%, 7%, $%, 9%, 10%, 12%, 15%, 20%, 25% or more of the solid tissue cells, over a period , fox example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or.
less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less. In one particular instance when the apoptosis inducing agent is paclitaxel, the suff cient time can be, for example, between about 16 to about 24 hours, when it is administered at a dose of about, 50 nM over about I hour.
In a second further embodiment, the apoptosis inducing agent is also the therapeutic agent. However, in this case, the therapeutic agent is either administered in a separate dose or in a slow-release form of the apoptosis inducing agent.
Examples of apoptosis inducing agents which are also effective as therapeutic agents include, for example, paclitaxel and doxorubicin.
In a third further embodiment, the therapeutic agent comprises a gene therapy construct, a protein bound drug, a chemotherapeutic agent, or an antibiotic.
In a fourth further embodiment, the apoptosis inducing agent and/or the therapeutic agent can each be administered systemically, regionally, locoregionally, or locally. In an advantageous embodiment, the apoptosis inducing agent and/or the therapeutic agent are administered with a one or more pharmaceutically acceptable carriers. For example, the agents can be formulated in a manner suitable intravenous injection.
In yet another embodiment, the invention features a method for delivering a chemotherapeutic agent to a tumor in a patient, for example, a human (e.g., a cancer patient). The method includes administering a dose of an apoptosis inducing agent locally or regionally to a patient, allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor, and delivering a dose of a chemotherapeutic agent to said patient. In a further embodiment, the tumor is a cancerous tumor, e.g., a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor. In a further Printed by VisuaiPafent embodiment, the invention also comprises the step of obtaining the apoptosis inducing agent.
In a second further embodiment, the apoptosis inducing agent comprises paclitaxel, doxorubicin, or another effective apoptosis inducing agent.
In a third further embodiment, the sufficient time is sufficient for the reduction of the density of the solid tissue cells such that the therapeutic agent can be delivered to the interior of the tumor. For example, the sufficient time may be sufficient to reduce the density of the cells by about 5%, 10%, 15%, 20%, 30%, 35% or more, over a period of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour ar less. In yet another further embodiment, the sufficient time is sufficient to induce apoptosis in the solid tissue cells, such that the therapeutic agent can be delivered to the interior of the tumor.
For example, the su~cient time can be su~cient to induce apoptosis of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%,.16%, 17%, 18%, 19%, or 20% or more of the solid tissue cells, over a period , for example, of thirty two hours or less, thirty hours or less, twenty seven hours or less, twenty four hours or less, twenty three hours or less, twenty two hours or less, twenty one hours or less, twenty hours or less, nineteen hours or less, eighteen hours or less, seventeen hours or less, sixteen hours or less, fifteen hours or less, fourteen hours or less, thirteen hours or less, twelve hours or less, eleven hours or less, ten hours or less, nine hours or less, eight hours or less, seven hours or less, six hours or less, five hours or less, four hours or less, three hours or less, two hours or less, or one hour or less.
In a fourth further embodiment, the apoptosis inducing agent is also the chemotherapeutic agent. However, in this case, the chemotherapeutic agent is either administered as a separate dose or in a slow-release form.
Printed by VisuaIPatent In a fifth further embodiment, the apoptosis agent and/or the therapeutic agent are administered with a pharmaceutically acceptable carrier, e.g., a carrier suitable for systemic, regional, locoregional, or local administration. The carrier may be suitable for intravenous injection.
In a sixth further embodiment, the apoptosis inducing agent and the therapeutic agent are administered simultaneously. In this embodiment, the therapeutic agent is slow-release formulated such that it is released after sufficient time for the apoptosis inducing agent to induce apoptosis.
In a seventh further embodiment, the apoptosis agent and the therapeutic agent are administered sequentially. In this embodiment, the therapeutic agent is administered after sufficient time, to allow the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
In another embodiment, the invention pertains to a method for delivering a dose of a therapeutic agent to tissue of a patient.
The method includes administering a dose of an apoptosis inducing agent to the patient, wherein the dose of the apoptosis inducing agent either:
(i) does not comprise the dose of the therapeutic agent; or (ii) comprises the dose of the therapeutic agent in a slow release formulation;
allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient; and (a) when the dose of the apoptosis inducing agent does not comprise the dose of the therapeutic agent, administering the dose of the therapeutic agent to the patient such that the dose of therapeutic agent is delivered to the tissue of the patient; or (b) when the dose of the apoptosis inducing agent comprises the dose of the therapeutic agent in a slow release formulation, allowing sufficient time for the therapeutic agent to be released in the tissue such that the dose of the therapeutic agent is delivered to the tissue of the patient.
The invention also pertains to a method for treating an ovarian tumor, comprising administering a dose of an apoptosis inducing agent, such as paclitaxel or doxorubicin locoregionally, regionally, or locally to a patient and allowing for sufficient time for apoptosis agent to induce apoptosis, and delivering the therapeutic agent. In a Pri»ted by VisualPatent WO 00/61141 PCTlUS00109329 further embodiment, the apoptosis inducing agent is paclitaxel, the dose is 50 nM over 1 hour, and the sufficient time is 16 to 24 hours.
The invention also pertains to a method.for treating a breast cancer tumor, comprising administering a dose of an apoptosis inducing agent, such as paclitaxel or doxorubicin Iocoregianally, regionally, or locally, to a patient and allowing for sufficient time for the apoptosis agent to induce apoptosis, and delivering the therapeutic agent. In a further embodiment, the apoptosis inducing agent is doxorubicin, and the dose is 5 :M for 1 to 4 hour, and the sufficient time is 16-30 hours.
III. PHARMACEUTICAL COMPOSTIONS OF THE INVENTION
The invention also pertains to a composition for delivering a therapeutic agent to a patient. The composition includes a quick release formulation of an apoptosis inducing agent, a slow release formulation of a therapeutic agent, and a pharmaceutically acceptable carrier.
In a further embodiment, the apoptosis inducing agent is paclitaxel. For example, one quick release formulation advantageously releases about 50 nM of paclitaxel over about 1 hour or less.
In a second further embodiment, the apoptosis inducing agent is doxorubicin.
In a third further embodiment, the apoptosis inducing agent is provided in an amount su~cient to reduce the density of the tumor cells of a solid tLUnor by about 30%
or greater, within about 16-24 hours after administration. The apoptosis inducing agent may also be provided in an amount sufficient to induce apoptosis in 10% or more of the tumor cells of a.solid tumor; within about 16-30 hours after administration.
In a fourth further embodiment, the therapeutic agent is paclitaxel or doxorubicin, protein-bound drug, a chemotherapeutic agent, an antibiotic or a gene delivery construct, e.g., a gene delivery construct comprising a tumor suppressor gene, e.g., p53.
In a fifth further embodiment, the pharmaceutical composition is suitable for intravenous injection. The composition may also be suitable for local, locoregional, regional or systemic administration.
In another embodiment, the pharmaceutical composition may comprise one or more pharmaceutical acceptable carriers.
Printed by VisuaiPatent In yet another embodiment, the invention pertains to nanoparticles, which comprise a cross linked gelatin and a therapeutic agent or an apoptosis inducing agent, such as, for example, paclitaxel, or doxorubicin. In a further embodiment, the invention pertains to a compositions containing the nanoparticles and a pharmaceutically acceptable carrier. The Garner can be, for example, suitable for systemic, regional, locoregional, or local administration. In another embodiment, the invention pertains to a method of treating a patient comprising administering the nanoparticles of the invention.
In one embodiment, the nanoparticles are about 500 to about 1 pm, or about 600 nm to about 800 nm in diameter.
The invention also pertains to microparticles comprising a therapeutic agent or an apoptosis inducing agent, such as paclitaxel or doxorubicin. In one embodiment, the microparticle is about 500 nm to about 100 Vim, about 500 nm to about 50 Vim, about 500 nm to about 25 pm, about 500 nm to about 20 pm, about 500 nm to about 15 pm, about 500 nm to about 10 Nxn, about 750 nm to about 10 pm, about 1 pm to about pm, about 750 nm to about 7.5 p,m, about 1 p,m to about 7.5 pm, about 2 ~zn to about 7.5 Vim, 3 pm to about 7 pm, or about 5 ~m in diameter. In another embodiment;
the invention pertains to a composition which comprises the microparticles and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be, for example, suitable for administraxion to a patient locally, regionally, or locoregionally. The invention also pertains to a method for treating a patient, comprising administering to the patient microparticles of the invention and a pharmaceutically acceptable carrier. In a further embodiment, the administration can be local, regional, or locoregional.
In another embodiment, the invention features microparticle suitable for administration to a patient locally, regionally, or locoregionally, comprising paclitaxel, wherein said microparticle has a diameter of about 5 Eun. In another further embodiment, the invention features microparticles suitable for administration to a patient locally, regionally, or locoregionally, comprising doxorubicin, wherein said microparticle has a diameter of about 5 pm.
The invention also pertains to a kit for the treatment of tumors. The kit contains an apoptosis inducing agent in a pharmaceutically acceptable carrier, a therapeutic agent in a pharmaceutically acceptable carrier, a container, and directions Printed by VisualPatent for using said apoptosis inducing agent and said therapeutic agent for the treatment of tumors. For example, a kit of the invention may comprise an apoptosis inducing agent and a therapeutic agent for subsequent intravenous injection. The kit may also provide the apoptosis inducing agent and/or the therapeutic agent formulated in dosages and carriers appropriately for local, locoregional, or regional administration.
Pharmaceutical compositions comprising compounds of the invention may contain wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring arid perfuming agents, and preservatives.
Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration.
The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about IO per cent to about 30 per cent.
Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the Garner and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
Printed by VisualPatent WO 00/61141 1'CT/US00/093Z9 A compound of the present invention may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, andlor silicic acid; binders, such as, for example, carboxymethylceiiulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose andlor acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate;
solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay;
lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release Printed by VisualPatent WO 00!61141 PCTIUS00l093Z9 profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile watex, or some other sterile injectable medium immediately before use.
These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredients) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
Examples of embedding compositions which can be used include polymeric substances and waxes.
The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water 15 or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
20 Besides inert dilutents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and 25 sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. ,_,_ Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating 30 excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at Printed by VlsuaIPatent body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin, The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel:
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may Printed by VisualPatent contain buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sarbic acid, and the like.
It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms axe made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemuIsions which are compatible with body tissue.
Printed by VisuaIPafenf The preparations of the present invention may be given orally, parenterally, topically, rectally, intralesionally, intraorbitally, intracapsularly, directly instilled into a cavity, or by inhalation. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories.
These compounds may be administered to humans and other animals for therapy by any suitable mute of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
Z 5 Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
Printed by VisualPatent WO 00/61141 1'CTlLT500109329 In general, a suitable dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect; i. e., treat a condition in a subject, e.g., cancer. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, will range from about 0.0001 to about 100 mg per kilogram of body weight, more preferably from about 0.01 to about 10 mg per kg, and still more preferably from about .10 to about 4 mg per kg. If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
As set out above, certain embodiments of the present compounds can contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
In other cases, the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
Exemplification of the Invention The invention is further illustrated by the following examples that should not be construed as limiting.
Materials and Methods:
Chemicals and reagents:
Paclitaxel and doxorubicin were obtained from the Bristol Myers Squibb Co.
(Wallingford, CT), the Phannacia & Upjohn Co. (Milan, Italy), and/or the National Cancer Institute (Bethesda, MD), and 3"-[3H]paclitaxel (specific activity 19.3 Ci/mmol) from the National Cancer Institute. Cefotaxime sodium was purchased from Hoechst-Roussel Inc. (Somerville, NJ); gentamicin from Solo Pak Laboratories (Franklin Park, IL); fetal bovine serum (FBS), Dulbecco's modified Eagle medium (DMEM), minimum essential medium (MEM), RPMI-1640, non-essential amino acids, L-Printed by VisuaIPatent glutamine and trypsin from GIBCO Laboratories (Grand Island, NY); sterile pigskin collagen gel (Spongostan standard) from Health Designs Industries (Rochester, NY);
Solvable tissue gel solubilizer and Atomlight scintillation fluid from Dupont Biotechnology Systems (Boston, MA); Hyperfilm 3H from Amersham Life Science Inc.
(Arlington Heights, IL); autoradiographic supplies from Kodak (Rochester, NY);
Cremophor EL from Sigma (St. Louis, MO); LKB 2208 Ultrofilm from Leica (Deerfield, IL), autoradiographic supplies from Kodak (Rochester, NY), cryotome imbedding polymer (O.C.T.) was obtained from Miles Inc. (Ellchart, IN); and monoclonal antibody (JSB-1) and polyclonal antibody (ab-1) against Pgp from BioGenex (San Racoon, CA) and Oncogene (Cambridge, MA), respectively.
Anirrials Male nulnu balb/c mice, weighing 18-21 g, were purchased from the National Cancer Institute, male Copenhagen rats, weighing 190 to 210 g, from Harlan Biomedicals (Dawely, OH), and female nu/nu balb/c mice, weighing 18-22 g, from the National Cancer Institute. Animal care was provided by the Laboratory Animal Resources in our institution.
Tumor procurement Surgical specimens of patient tumors (i.e., prostate, head and neck, ovarian) were obtained via the Tumor Procurement Service at The Ohio State University Comprehensive Cancer Center. Prostate tumor specimens were placed in MEM, and head and neck and ovarian tumor specimens in Hanks balanced salt solution within 10 to 30 min after surgical excision, stored on ice and prepared for culturing within one hour after excision.
Establishment of human xenograft tumors in mice Three human xenograft tumors; i.e., human pharynx FaDu tumor, human mammary MCF7 tumor, and the human prostate PC3 tumor, were used in the following three examples. FaDu cells were obtained from American Type Culture Collection (Rockville, MA). MCF7 cells were obtained from Dr. Kenneth Cowan at the National Cancer Institute. Cells were harvested from subconfluent cultures using trypsin and Prinfed by VisuaiPatent WO 00!61141 PCTIUSQO/09329 resuspended in fresh medium before plating. Cells with greater than 90%
viability, as determined by trypan blue exclusion, were used for tumor implantation. Cells were centrifuged and resuspended in Matrigel ( 1:1 v/v). Matrigel is a solubilized tissue basement membrane preparation extracted from the Engelbreth-Holmswarm mouse tumor and has been shown to support the growth of human tumoxs in immunodeficient mice (Kleinman H et al. (1990) Proc Am Assoc Cancer Res 31:490-491 ). The tumor establishment was achieved by subcutaneously injecting 106 cells (0.1 - 0.2 ml) with a 18 gauge needle at left and right sides of the upper back. The tumor was removed when it reached a size of 0.5 to 1 g and used for experiments.
Establishment of the MCF7 tumor was similar as described for tine FaDu tumor, with the except that a sustained release pellet of 17-beta-estradiol was implanted subcutaneously behind the neck of a mouse. Tumors were harvested when the tumor reached a size of about 0.5 in two weeks.
The androgen-independent human prostate PC3 cells were maintained as xenograft tumors in male nude mice according to the previously published procedures (Pretlow et al., 1993; Nagabhushan et al., 1996). Briefly, minced tumor tissue mixed with the same volume of Matrigel was implanted into both flanks of the nude mice at 0.3 ml per site. Tumors were harvested when they reached a size of 1 g at about 1.5 to 2 months after implantation.
Histocultures Patient tumors or xenograft tumor specimens were processed as previously described (Kuh, et al. (1999) J. Pharmcod. Exper. Therap. 290:871-880). The specimens were washed with culture medium for three times and dissected into about 1 mm3 fragments under sterile conditions. The culture medium consisted of a 1:1 mixture of MEM/DMEM for patient tumors, MEM for FaDu xenografts, and ItPMI1640 for PC3 xenografts, supplemented with 9% heat-inactivated FBS, 2 mM glutamine, 0.1 mM non-essential amino acids (only for MEM/DMEM), 90 :g/ml gentamicin and 90 :g/ml cefotaxime sodium. Five histoculture fragments were placed on a 1 cmZ
piece of presoaked collagen gel and incubated with 4 ml culture medium in 6-well plates. After 2 to 4 days, tumor histocultures were used to study the kinetics of drug penetration.
Printed by VisuaIPatent EXAMPLE 1: Determinants of Paclitaxel Penetration and Accumulation in Human Solid Tumors This study was performed using head and neck tumors from human patients and the human pharynx FaDu xenograft tumors maintained in athymic mice. The study used [3H]paciitaxel. The penetration of paclitaxel into tumor histocultures was visualized using autoradiography and the drug concentration in tumor tissues was measured using liquid scintillation counting.
Methods to study drug uptake and efflux in histocultures Tumor histocultures were incubated with 4 ml of culture medium containing 12 to 12,000 nM of mixture of radiolabeled and unlabeled paclitaxel. The final concentration of [3Hjpaclitaxel was 2.6 nM at 0.05 ~,Ci/ml or 5.2 nM at 0.1 p.Cilml.
These paclitaxel concentrations are within the range of clinical achievable concentrations in plasma (i.e. up to 13,000 nM, Kearns et al. (1995) Sem Oncol (Suppl.6):16-23). For the efflux study, tumor histocultures were incubated with paclitaxel for 24 hr, which was the longest time before substantial apoptosis occurs (Au JLS et al. (1998) Cancer Res 58:2141-2148), and then transferred to new plates and maintained in drug-free medium. At predetermined times, 100 p1 of medium was taken from each well and the histocultures were removed from the plates. The histocultures 24 were blot-dried on a filter paper and their weights were measured. One hundred :1 of medium or tumor samples were mixed with 0.5 ml of Solvable tissue/gel soiubilizer, incubated at 50°C in an oven overnight, and analyzed for total radioactivity using liquid scintillation counting. A preliminary study determined that 95% of the radioactivity in culture medium, analyzed by high pressure liquid chromatographic fractionation using a previous described method (Royer I et al. (1995) Rapid Commun Mass Spectrom 9:495-502), was represented by paclitaxel and its epimerization product, 7-epitaxol.
The ratio of 7-epitaxol to paclitaxel, in culture medium containing FaDu cells, was affected by the incubation time and the drug concentration in the medium, increasing from 2°!o at 3 hr to 7% in 24 hr and from 7% at 100 nM to 25% at 5,000 nM after 24 hr. Because 7-epitaxol has similar microtubule binding affinity and cytotoxicity as paclitaxel (Ringel I et al.
(1987) JPharmacol Exp Ther 242:692-698), the total radioactivity was expressed in Printed by VISUaIPafant w0 00/b1141 PCTIUS00/09329 paclitaxel equivalents. Drug concentration in tissue was calculated as (drug amount) divided by (tissue weight) and was expressed in molar terms.
For each tumor category, l, e, patient head and neck tumors, patient ovarian tumors, and FaDu xenograft tumors, three tumors were used per experiment, and 30 to 35 tumor histocultures were used for each concentration and each time point.
The study design of experiments using patient tumors was dictated by the size of the specimens.
On some occasions, specimens from an individual patient were only sufficient to study drug uptake and efflux at one or more but not all drug concentrations. A total of 7 head and neck tumors and 3 ovarian tumors were used. For the FaDu xenograft tumor, specimens from individual animals were sufficiently large that each tumor was used for studying uptake and ei~lux at ail four drug concentrations.
Accumulation of paclitaxel in tumor histocultures The increase of paclitaxel concentration in histocultures of patient tumors (head and neck, ovarian) and xenograft tumor is depicted in Figure l and in Table 1. For all three tumor types, the drug concentration in tumor histocultures increased with time, reaching a pseudo steady state between 48 to 72 hr, with <5% increase in the next 24 to 48 hr. During this time period, the drug concentration in the medium decreased by about 25%. Analysis of the mass balance indicates that about 90% of the dose was accounted for. The tumor-to-medium concentration ratios at steady state ranged from 20 to 120, indicating significant drug accumulation in tumors.
Figure 1 and Table 1 show the results of an experiment designed to test the uptake of paclitaxel into histocultures of FaDu xenograft and patient tumors.
The concentration-time profiles of paclitaxel in tumor histocultures obtained after incubation with different initial drug concentrations in culture medium (Cmedium)~ as depicted in Figure 1, were analyzed for the time for the tumor concentration to reach one-half of the pseudo steady state level (T~n,"pt~e) and for the tumor-to-medium concentration ratio at steady state. The statisticaY significance of the differences among patient (head and neck and ovarian, n=6) and FaDu (n=3) tumors, at equal initial medium concentrations, were analyzed by the two-tailed unpaired Student's t-test.
Printed by VisuaiPatent WO 00/61141 PCT/US001093x9 Table 1 initial Tumor Cm~~;"",Steady Steady stateSteady T,~Z,"Pe~eMass (nM) state Cc"mr (:M) state (h) baiance Cmedium C~,m~ to- (%) (nM) Cmedium ratio 12 10.911.0 1.0610.21 97.8115.2 24.213.4 91.213.5 Head 120 83.0 t 5.77 ~ 1.5264.5 t 19.8 t 83.8 ~
and 0.7 18.4 4.5 7.6 neck 1,200 925 t 22.0 t 6.2 23.1 t 10.4 t 87.5 t 25 7.1 3.8 6.5 patient12,000 9,870 341 t 125 34.8 t 5.81 ~ 91.5 ~
tumor t 59 14.5 2.31 3.5 12 10.610.7 1.3210.31 109122 i 8.4 89.315.4 t 9.6 Ovarian120 86.4 t 2.86 t 1.2832.8 t 1 I .l 84.5 t 2.3 I4.2 t 6.6 7.3 patient1,200 870 t 30.1 ~ I 32.3 t 14.2 t 85.2 t 2.6 1.7 13.7 7.3 2.5 tumor 12,000 10,500920211 t 80 I9.8 ~ 7.17 ~ 93.3 t 8.4 3.8I 4.5 12 9.090.27 1.01 ~ 0.21124 t 25 35.3 t 92.5 t 2.08 5.1 FaDu 120 89.7113.39.51 ~ 2.88115 t 3~ 27.8 t $6.5 t 3.7a 2.8 xenograft1,200 887 ~ 48.8 t 6.6853.7 t 18.9 ~ 89.4 t 131 14.8 3.2 5.7 12,000 8,910 433 ~ 15a 48.5 ~ 21.6 t 90.2 t t 267 0.58 6.98 5.4 pw.v~.
The steady state paclitaxel concentration in tumors increased while the steady state tumor-to-medium concentration ratio decreased with the initial drug concentrations in culture medium, although the relationships were not linear. In general, TI,~,upca~e~
which is the time to reach 50% of the pseudo steady state level, decreased with increasing initial medium concentration (p<0.01, regression analysis): These data.
indicate that drug accumulation is partly saturable, and show a more rapid attainment of steady state at higher initial extracellular drug concentration.
Efflux of paclitaxel from histocultures Figure 2 and Table 2 compare the kinetics of drug efflux from patient and xenograft tumors. In all three tumor types, the drug concentration declined to a pseudo steady state level at 48 hr. The extent of efflux was also dependent on the initial concentration, ranging from 29% to 60% at 120 nM and from 41 % to 81 % at 1,200 nM
in the first 24 hr. The decreases in drug concentration in the next 48 hr was several fold lower, ranging from 1% to 12% at 120 nM and from 3% to 13% at 1,200 nM.
Tnz,er~ux~
Printed by VisuaIPatent WO 00/61141 PC'rIC1S00109329 which is the time to reach 50% of the pseudo steady state level, ranged from 3 to 7.5 hr.
The decreases in tumor concentrations were accompanied by increases in medium concentrations. The tumor-to-medium concentration ratios ranged from 400 to 4;000 at 24 hr and from 250 to 2,700 at 72 hr. These ratios exceed the steady state tumor-to-medium concentration ratios achieved during the uptake study (i. e. 20 to 120) by 8- to 38-fold, indicating that a sink condition was maintained during the efflux study. Hence, the high steady state tumor-to-medium concentration ratios indicate a significant retention of the drug in tumors, i. e. 19% to 71 % of initial drug concentration was retained after 24 hr, and 16 to 72% retained after 72 hr. In general, the fractions retained and the tumor-to-medium concentration ratios attained at the lower initial medium concentration of 120 nM were significantly higher than those attained at the higher initial concentration of 1,200 nM (p<0.05, unpaired two-tailed Student's t-test). But the differences between the apparent Tli2,etnux at these two initial medium concentrations are not statistically significant. Collectively, these data indicate significant drug retention in tumors and that the extent of retention but not the rate of efflux is inversely related to drug concentration.
Figure 2 and Table 2 show the results of an experiment designed to measure the paclitaxel efflux from histocultures of FaDu xenograft and patient tumors.
Tumors were incubated with paclitaxel for 24 hr. After replacing the drug-containing medium with drug-free medium, the drug concentration remaining in histocultures at 24 and 72 hours post-treatment were analyzed to determine the time to reach 50% of the pseudo steady state level (TI~,e~ux). The statistical significance of the differences among patient (head and neck and ovarian, n=6) and FaDu (n=3) tumors, at equal initial medium concentrations, were analyzed using a unpaired t-test. Different units were used for the medium and tumor concentrations.
Printed by VisuaIPatent WO 00!61141 PCT/US00I09329 Table 2 At At 72 T,~2.ett~mc 24 hr hr post-treatment post-treatment Initial rn~
TUmOTCm~iumCmediomCwmor Cmmor't0"% CmedtumCtumor Cmmoi t0"
(~) (~) (:M) Cmeammremaining(nM) (:M) Cm~i"",remaining ratioin ratio in tumor tumor 120 I 1.70 1560 54.8 1.32 1.19 880 43.3 7.45 .13 t t t t 0.14 t 0.50 ~ t f 3.02 f 3.1 300 16.3 Head d 1,2007.69 4.38 550 18,7 10.9 4.17 376 16.0 3.33 t t t t 1l. t 2.77 ~ t t 2.62 88 6.2 I 250 5.3 120 1:1910.6151518 39.81 1.6010.260.5201 318 35.71 4.3010.54 x= f 18.5 Ovarian 0.24 0.149 14.2 ~ 0.196' patient1,20012.8 5.13 398 25.9 16.7 4.20 245 19.8 ~ 5.00 f t t f t 2.9 f 1.79 t f t 2.93 21 8.3 99 6.6 3.41 1.32 120 0.9893.88 4359 71.0 1.42 3,84 2660 71.8 6.42 t t t t f 0.18 t 1.04 t f t 3.51 1.7a FaDu 0.2281.27 1230'6.8a 473a xeno-1,20012.2123.215.41800158.61 18.915.517.713.71010 45.0 4.0S
t t t 1.21 5.8 1.3 3008 5.48 339a p<0.05, unpaired two-tailed Student's t-test.
Differences between patient and xenograft tumors Of the patient tumors, the head and neck tumors show a trend of higher accumulation (i. e. high steady state tumor-to-medium concentration ratio) and a slower uptake rate (i.e. longer apparent TIi2,uptaie) compared to the ovarian tumors (Tables 1 and 2). However, the differences are not statistically significant, due to the large variability between individual tumors. In contrast, there are significant differences in the rate of drug uptake, extent of drug accumulation and extent of drug retention between patient tumors and the xenograft tumor (Tables 1 and 2). When compared to patient tumors, the xenograft tumor showed a slower uptake and a greater extent of accumulation when the initial drug concentrations were >_120 nM, but not at the lbwer medium concentration of 12 nM. The xenograft tumor also showed a 3- to 4-times greater drug retention compared to patient tumors. The differences in the drug uptake and accumulation between patient and xenograft tumors were used to study the determinants of paclitaxel uptake and efflux in solid tumors.
Printed by VisualPatent Determinants of paclitaxel uptake and efflux The rate of paclitaxel uptake in tumors involves multiple kinetic processes;
i. e.
movement from media to collagen gel matrix, to tumor histocultures and then through interstitial space to cells, as well as binding to tubulins and microtubules and possibly other macromolecules (Jord n MA et al. (1993) Proc Natl Acad Sci USA 90:9552-9556;
Manfredi JJ et al. (1982) J Cell Biol 94:688-696). The binding to macromolecules determines the extent of drug accumulation; the plateau drug accumulation attained at higher drug concentration in culture medium reflects a saturation of binding sites (Jordan MA et al. (1996) Cancer Res 56:816-825; Kang et al. (1997) Proc Am Assoc Cancer Res 38:604). During efflux; the free drug including the drug dissociated from binding sites txavels sequentially from intracellular space to interstitial space by diffusion and/or transport by the drug efflux rndrl p-glycoprotein, to collagen gel matrix and to surrounding culture medium. Drug retention in tumors is determined by its binding to macromolecules and the rate of efflux is determined by the dissociation of drug from binding sites. The pseudo steady state attained during efflux reflects a slow dissociation of paclitaxel from binding sites.
Three studies were performed to identify the key determinants of paclitaxel uptake and efflux from solid tumors. These studies include (a) evaluation of drug diffusion from culture medium to histocultures, (b) evaluation of the role of the drug efflux mdrl p-glycoprotein, and (c) evaluation of the role of cellularity and apoptosis.
Diffusion of paciitaxel from culture medium to 3-dimensional tumor histocultures This study determined the rate of drug diffusion from culture medium into the collagen gel matrix supporting the histocultures, to evaluate whether slow drug diffusion contributed to the slow drug penetration into solid tumors. One cm2 collagen gel pieces were presoaked and placed in a well of a 6-well plate, containing 4 ml of complete culture medium. No tumors were added. After incubation for 3 to 4 days, the medium was replaced with 4 m1 of 120 nM [3H]paclitaxel-containing medium and incubated at 37°C for 24 hr. At predetermined times, 100 :1 of medium was removed from each well.
For the sampling of medium trapped in the porous collagen gels, one piece of collagen geI was transferred to a new plate and the medium was obtained by squeezing the gel with a pair of forceps. These procedures required less than 20 sec. The radioactivity in Printed by VisuaIPatent medium was determined. The results show that immediately (i.e., <12 min) after adding drug solution to the medium, the drug concentration in the culture medium trapped in the collagen gel matrix (Cgel) was about 50% of the initial drug concentration in the culture medium. The more rapid increase in Cge~ compared to the increase in drug concentration in the histocultures suggests that drug diffusion from the medium through the collagen gel matrix is not the rate-limiting factor for the slow drug penetration into tumor histocultures in the first 24 hours.
Effect of expression of the mdrl p-gl_ycoprotein (Pgp) on drug accumulation in patient and xenograft tumors.
The difference in Pgp expression in tumors was a factor that was considered in relation to the differential drug accumulation. The expression of Pgp was measured by immunohistochemical methods, using procedures described previously (Toth K et al.
(1994) Am JPathol 144:227-236). Briefly, tissue sections were de-waxed and rehydrated sequentially in xylene, ethanol and water. Tissue sections were boiled in a 0.1 M citrate buffer, pH 6.0, in a microwave oven, then cooled and washed in phosphate-buffered saline (PBS}. The tissue sections were incubated with Dako blocking solution for 10 min and subsequently with the following antibody solutions for 2 hr: a mouse anti-human Pgp antibody (JSB-1, 1:200 dilution) and a rabbit antihuman Pgp polyclonal antibody (ab-1, 1:100 dilution). JSB-1 does not cross-react with MDR3 (Schinkel AH et al. (1991) Cancer Res 51:2628-2635). The incubation was carried out in a humidified chamber at room temperature. The antibodies were diluted in PBS
containing 5 mg/ml bovine serum albumin. For negative controls, we used mouse IgG
as the primary antibody. For positive controls, we used human adrenal gland which shows high Pgp expression (Pavelic ZP ef al. (1993) Arch Otolaryngol Head Neck Surg 119:753-7S7). After washing with PBS, the tissue sections were covered with the linker solution, and then with peroxidase-conjugated streptavidin solution. After washing twice with PBS, tissue sections were incubated for 5 to 7 minutes with diaminobenzidine and counterstained with hematoxylin.
Only tumors that were stained by two Pgp antibodies and showed Pgp proteins in at least two-third of the histocultures were considered Pgp-positive. By these criteria, the xenograft tumor, three head and neck tumors, and two ovarian tumors were Pgp-Printed by VlsualPatenf positive, whereas four head and neck tumors and one ovarian tumor were Pgp-negative.
The accumulation of paclitaxel in these tumors was compared, at two initial medium concentrations of 120 and 12,000 nM. The results are shown in Table 3. The statistical significance of the differences between groups was analyzed by the two-tailed unpaired Student's t-test. Groups with statistically significant differences are also noted in Table 3.
umor-to-medium concentration ratio 120 12,000 Tumor Pgp nM nM
statusn 24 h n 24 h 48 h 72 h 96 h ~
FaDu + 3 53110 3 2913 4616 51+1 50+8 ~
Patient+ 3 3011 5 21+5 26+3 2411 25+4 Patient 3 383 5 311i 1 32+9 3318 31110 a Comparison between FaDu xenograft and Pgp-positive patient tumors, p<0.05.
b Comparison between Fa.Du xenograft and Pgp-negative patient tumors, p<0.05.
The xenograft tumor showed a higher accumulation than the Pgp-positive patient tumors. Within the patient tumors, Pgp expression did not always result in a lower drug accumulation. For example, while the Pgp-positive patient tumors showed a trend of lower drug accumulation compared to the Pgp-negative patient tumors at the higher drug concentration of 12,000 nM, the difference was small (i.e. average of <25%) and not statistically significant. Furthermore, no difference between the two groups was observed at the lower drug concentration of 120 nM. These data indicate that Pgp expression, while it might have contributed to the lower drug accumulation in some tumors, is not the major determinant of drug accumulation and did not fully account for the 50 to 100% difference in drug accumulation between patient and xenograft tumors.
Printed by VisuaIPatent Role of cellularity and apoptosis in paclitaxel penetration, accumulation and retention in histocultures The rate of [3H]paclitaxel penetration in tumors and the spatial relationship between drug penetration, tumor architecture and tumor cell distribution were evaluated using autoradiographic techniques and image analysis. The autoradiographic method was as described previously (Lesser GJ et al. (1995) Cancer Chemother Pharmacol 37:173-178). After incubation with [3H]paclitaxel (0.231 and 2.31 ~,Ci/mI, corresponding to 12 and 120 nM) for 1 hour to 3 days, tumor histocultures were collected and washed two times by dipping in ice-cold drug-free medium. Tissue samples were mounted on cryostat chucks with embedding matrix (O.C.T.
Compound, Miles Inc., Ellchart, IN) and cut into 10 pm thick sections in a cryostat at -20°C.
Sections were thaw-mounted on a glass slide and heat-fixed on a slide warmer for 15 min. The slides containing the tissue sections were placed against tritium-sensitive film (Ultrofilm) in an X-ray cassette and exposed for one to two weeks at room temperature.
The films were developed for 3-5 minutes at room temperature (D-19 Developer), placed in a stop bath for 30 seconds, immersed in fixer for 3 minutes and exposed to running room temperature water for 15 minutes. The films were then rinsed in Photo-flo 200 and allowed to air-dry. Separately, the tissue section slides were stained with hematoxylin and eosin.
Image analysis was then used to capture the autoradiographic image (where the grains indicated the location of the radiolabeled drug) and the histologic image of the tissue section slide stained with hematoxylin and eosin (which showed the tissue structure and distribution of tumor cells). The threshold for the autoradiographic image was adjusted to minimize the background signal. The autoradiographic image was overlaid on the histologic image to visualize the distribution of [3HJpaclitaxel in tumor histocultures.
Head and neck tumors and a xenograft tumor were treated with 120 nM
paclitaxel. The drug uptake rate in the xenograft tumor was about 50 to 80%
slower than in patient tumors and the accumulation was twice that in patient tumors (Table 1).
In the xenograft tumor, paclitaxel penetrated only a few cell layers in the periphery after 4 hours, 10 to 15 cell layers after 24 hours, and became evenly distributed throughout the tumor (>80 cell layer thick) at and after 48 hours. These data indicate an abrupt Printed by VisuaIPatent increase in the drug penetration rate after 24 hours. The drug penetration in the patient tumor was more rapid, reaching about one-half of the tumor histoculture at 4 hours and becoming evenly distributed at 24 hours. In both xenograft and patient tumors, a comparison of the radioactivity in areas with high and low cell density indicates a higher localization of radioactivity in cells compared to interstitial space. In addition, the rapid distribution of radioactivity to the areas with a low epithelial cell density at earlier time points, together with the observation of a more rapid drug penetration in patient head and neck tumors which has a lower tumor cell fraction (i.e., 5118% of the histocultures was represented by tumor cells) as compared to the FaDu xenograft tumor which has a higher tumor cell fraction (i.e., 797.0% of the histocultures was represented by tumor cells), suggest that reduced cellularity corresponds to a more rapid drug penetration.
The above observations suggest that drug penetration may be enhanced by a loss of cellularity, e.g. following apoptosis induced by paclitaxel treatment which occurs after a 16 to 24 hour delay (Saunders DE et al. (1997) Int J Cancer 70:214-220). This hypothesis was confirmed by evaluating the changes in tissue composition with time, for the xenograft tumor. The xenograft tumor was treated with two concentrations of paclitaxel, i. e. 120 nM which caused significant apoptosis and 12 nM which did not cause significant apoptosis.. The fractions of stromal tissue and tumor cells in each histoculture were measured using image analysis. Briefly, stromal and tumor cells of a 100x magnification field were outlined with the computer mouse. The sizes of each of these regions were determined via image analysis by counting the number of pixels in the region. To determine the fraction of apoptotic cells in a tumor, the tumor cell density and the fraction of apoptotic cells were determined by counting the number of total tumor cells and apoptotic cells in nonnecrotic regions at 400x magnification (3 microscopic fields/tumor). Apoptotic cells were determined based on morphological changes in tumor cells such as chromatin condensation and margination, disappearance of nucleoli, formation of membrane blebs, apoptotic bodies and/or cell shrinkage (Kerr JFR et al. (1994) Cancer 73:2013). This method has been shown to yield the same results as the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TLJNEL) method (Gan Y et al. (1996) Cancer Res 56:2086; Gold R et al. (1994) Lab Invest 71:219-225). For each tumor piece, 50 to 100 images were processed, and the Printed by VisualPatent fractions of the tumor represented by tumor cells, stromal tissue, and interstitial space were calculated.
When xenograft tumor histocultures were treated with 120 nM paclitaxel, there was a significant reduction in tumor cell density and increase in apoptotic cells. This effect was first detected at 24 hours and progressively increasing with time.
The fraction of apoptotic cells in the treated tumors was ~30% at 24 hours and increased to ~50% at 72 hours, whereas the untreated controls showed a <5% apoptotic cells. The onset of apoptosis and expansion of interstitial space at 24 hours coincided with the abrupt increase in drug penetration, i. e. the drug penetrated >80 cell layers during the second 24 hours opposed to 15 cell layers during the first 24 hours. When tumors were treated with 12 nM paclitaxel, it did not produce significant reduction in cellularity nor increase in apoptotic cells; the fraction of apoptotic cells remained relatively constant at <_7%.
Under these conditions, drug penetration was restricted to the periphery.
These results indicate that the drug-induced apoptosis causes a reduction in tumor cell density and thereby enhances drug penetration into the inner layers of the solid tumor.
5.'ummarY
In summary, this example shows that (a) the penetration of paclitaxel in tumors is more rapid but the accumulation is lower as the density of epithelial tumor cells decreases, (b) drug-induced apoptosis enhances drug penetration into the inner cell layers of solid tumors, (c) the concentration-dependent drug penetration rate is related to the concentration-dependent apoptotic effect, and (d) the time-dependent drug penetration is related to the kinetics of apoptosis.
EXAMPLE Z: Effect of Apoptosis-Inducing Pretreatment on Drug Penetration and Accumulation in Tissues using Paclitaxel as the Apoptosis Inducing Agent This example consists of in vitro and in vivo studies. The in vitro study was performed using the human pharynx FaDu xenograft tumor -maintained in athymic mice. The in vivo study was performed using a syngeneic animal tumor, i.e., the MAT-LyLu prostate tumor maintained in Copenhagen rats.
Printed by VisuaJPatent Drug treatment-In vitro studies Drug treatment was as previously described. The histocultures were transferred to a collagen gel presoaked with drug-containing medium for at Ieast 8 hr. The latter was to ascertain that the drug concentration in the medium inside the collagen gel was at equilibrium with the surrounding medium, in order to eliminate the delay in drug transport from medium through the collage gel. Drug treatment was terminated by transferring histocultures to a collagen gel presoaked with drug-free medium.
Histocultures were transferred using a pair of hooked forceps and care was exercised to avoid squeezing or pinching.
Effect of apoptosis-inducing pretreatment on drug deliver in tumor-In vitro studies.
The spatial distribution of [3H]paclitaxel in histocultures was studied using autoradiography and imaging techniques as described in Example 1. The total drug concentration in tumor histocultures was measured as described in Example 1.
Briefly, after incubating with 4 ml of culture medium containing a mixture of radiolabeled and nonradiolabeled paclitaxel (specific activity, 0.301 :Ci/ml), histocultures were harvested and analyzed for total radioactivity using liquid scintillation counter.
Thirty to 35 tumor histocultures were used for each time point.
Two studies were performed. In the first study, two groups of histocultures were incubated with the same concentration of [3H]paclitaxel, 10 or 50 nM for 72 hr. These two groups received identical total exposure to radialabeled paclitaxel, except the pretreated group also received an additional exposure of 3000 nM~hr nonradiolabeled paclitaxel (i.e., 1,000 nM of nonradiolabeled paclitaxel for 3 hr), initiated at 24 hr prior to the radiolabeled dose. The drug concentration and the timing of the pretreatment was found in a preliminary study to cause significant apoptosis (~30%) at 24 hr.
The second study used the same total drug exposure, i.e., 1,200 nM~hr, but by different schedules as described below For both studies, histocultures were collected at predetermined intervals after [3H]paclitaxel treatment, and analyzed for drug penetration.
The first study was used to demonstrate qualitatively the effect of pretreatment on the rate of drug penetration in solid tumor. Drug accumulation was evaluated only in the second study, because in the first study, the dilution of [3H]paclitaxel by nonradiolabeled drug was expected to alter the Printed by VisualPatent specific activity of [3H)paclitaxel and, therefore, affect data accuracy.
The results shows the effect of pretreatment with 1 :M nonradiolabeled paclitaxel on [3H)paclitaxel penetration in FaDu tumor histocultures. The nonradiolabeled paclitaxel was not detected by autoradiography and did not interfere with the detection of [3H]paclitaxel. The example used two concentrations of [~H]paclitaxel that differed in their ability in inducing apoptosis and reducing tumor cell density, with the 50 nM concentration being more effective than the 10 nM
concentration (Table 4). Without the pretreatment, tumor penetration of [3H]paclitaxel at 10 nM was limited to the periphery of the histocultures throughout 72 hr, whereas penetration at 50 nM concentration in the first 24 hr was limited to the periphery but subsequently increased, along with increased apoptotic fraction and reduced cell density, such that drug distributed evenly throughout the tumor by 72 hr. The paclitaxel pretreatment induced apoptosis and reduced the cell density by the time the [3H]paclitaxel treatment was applied. The pretreatment enhanced the penetration of [3H]paclitaxel at both 10 and 50 nM concentrations such that even distribution in tumor was attained at 72 and 24 hr, respectively. These findings suggest that the fractionated doses separated by an interval that allows for apoptosis to occur would have result in greater drug penetration and accumulation than a continuous treatment schedule of the same total drug exposure (i.e., product of concentration and time, CxT) Table 4 shows the results of an experiment where tumor histocultures were treated with different concentration of j3H]paclitaxel with or without pretreatment by 1 :M
nonradiolabeled paclitaxel. The fraction of apoptotic cells and the tumor cell density were determined by counting the number of total and apoptotic tumor cells in 400x microscopic fields (3 fields per tumor).
Printed by VisuaIPatent Drug concentrationApoptotic Cell density ~ fraction, % ~
and treatment Without I With Without With ~
duration I pretreatment~ PretreatmentpretreatmentPretreatment 1Q nM
4 hr ~ 3.930.87 ~ 23.61.3 86.314,0 64.23.5 ~
( ~
16 hr ~ 4.980.84 24.614.8 80.212.9 64.311.8 24 hr ~ 7.3211.80 26.62.4 ' 81.612.5 64.015.2 32 hr ~ 6.64 1.07 t 30.113.4 79.92.1 60.1 X4.2 48 hr 9.1811.31 ~ 34.915.2 77.8f3.0 62.33.1 ~
72 .hr ~ 11.01.7 ~ 31.014.4 82.612.2 61.012.2 50 nM t 4 hr t 2.7410.12 , 26.315.4 85.83.6 63.14.5 16 hr 7.9712.03 36.013.9 83.9f3.3 60.84.9 ~
24 hr I7.Ot2.8 ~ 36.412.0 77.013.8 58.31.1 32 hr 19.12.5 37.44.5 71.214.6 53.22.1 48 hr ~ 28.32.9 ~ 39.813.1 68.82.5 53.6f2.4 ~
72 hr I 27.213.0 37.913.4 61.12.8 47.813.2 To evaluate the effect of treatment schedule on paclitaxel delivery in tumors, a second study examined the drug penetration and accumulation in two groups that were treated with the same CxT (i.e., 1,200 nM~hr), given by two schedules. The pretreatment group received fractionated doses, i.e., 600 nM [~H]paclitaxel for 1 hr, followed by incubation in drug-free culture medium for additional 23 hr to allow apoptosis to occur, and then treated with 50 nM [3H]paclitaxel for 12 hr. The control group was incubated with 50 nM [3H]paclitaxel continuously for 24 hr. In the control group, paclitaxel penetration was restricted to the 5 to 10 cell layers in the periphery of the histocultures in the first 24 hr, at which time drug-induced apoptosis began to appear. While drug penetration increased simultaneously with an increase in apoptotic fraction and reduction in cell density during the next 12 hr, drug penetration remained 1 S . confined to less than 20 cell layers in the periphery. In comparison, the pretreatment Printed by VisuaIPatent group showed a higher apoptotic fraction, a lower cell density, and a more rapid penetration, resulting in even drug distribution throughout histocultures at 35 hr (Table 5). A comparison of drug accumulation in the two groups showed a 40% higher drug accumulation in the pretreatment group at the end of drug treatment (i.e., at 36 hr in pretreatment group vs at 24 hr in control group; Table S), in agreement with the more extensive drug penetration as shown by autoradiography. The results of this study confirm that a fractionated treatment separated at an interval for drug-induced apoptosis and reduction in cell density will result in greater drug penetration and accumulation into tumors than a single continuous treatment.
Table 5, listed below, shows the result of the experiment, in which tumor histocultures were treated with equal CxT of [3H)paclitaxel, i.e., 1,200 nM~hr, by two different schedules. One schedule used 50% of the total CxT to induce apoptosis, whereas the other schedule used continuous treatment. Concentrations of [3H]paclitaxel in tumor histocultures were determined, by liquid scintillation counting. The fraction of apoptotic cells and cell density were determined by counting the number of total and apoptotic tumor cells in 400x microscopic fields (3 fields per tumor).
Treatment Time (hr) after ; Apoptotic ~ Cell ~ Paclitaxel Schedule initiation of ! fraction (%) , density ; in tumor treatment x 1 hr ~ 24 j 20.34.3 ; 60.91.3 -X23 hr later I 36 I 25 ~SOnMx l2 hr .34 ~ 71.312.9 i 3.1110.31 50 nM x 24 hr , 36 i 17.03.94 ; 72.613.2 i 2.010.3 Collectively, these results indicate that under i~ vitro conditions, (a) an apoptosis-inducing pretreatment enhanced the drug penetration during subsequent treatments, and (b) treatments at higher drug concentrations that induced appreciable Printed by VisualPatent apoptosis and reduced tumor cell density resulted in more rapid drug penetration compared to treatments at lower concentration.
Effect of apoptosis-inducing pretreatment on drug accumulation in tumors- In vivo studies The rat MAT-LyLu tumor cells were originally obtained from Dr. J. Isaacs (Johns Hopkins University, Baltimore, MD), and has been maintained in RPMI-medium supplemented with 9% heat-inactivated FBS, 2 mM L-glutamine, 90 :g/ml gentamicin and 90 :g/ml cefotaxime sodium. Tumor cells (5x 106 cells in 0.1 rnl medium, >90% viability, as determined by trypan blue exclusion) were injected subcutaneously in the right and left upper backs of a male Copenhagen rat with a 21 G
needle. Experiments were initiated when the tumor was between 0.3 to 0.5 g in size.
The jugular vein and carotid artery of tumor-bearing rats were catheterized, under light ether anesthesia, with polyethylene tubing (PE-50; Becton Dickinson Co., Sparks, MD) for drug administration and for blood sampling, respectively. Each catheter was exteriorized to the dorsal side of the neck and attached to a second polyethylene tubing (PE-50), respectively. The catheters and tubings were covered with a metal coil tubing. Animals were allowed to recover for 4-5 hr, and then given an intravenous infusion of paclitaxel using an infusion pump (Harvard Apparatus, Southnatick, MA). Paclitaxel was dissolved in Cremophor ELlethanol (1:1, v/v) and diluted with 0.9% NaCI. The total infusion volume was 2 to 3 ml and the final Cremophor EL concentration in dosing solution was 10 to 15%. Five groups of animals were treated as described in the Results. Blood samples (0.12 or 0:22 ml) were obtained at predetermined times. Plasma fraction was obtained by centrifugation at 2,OOOg for 3 min, and stored at -70°C for HPLC analysis. At the end of the experiment, tumors were harvested. One quarter of a tumor was fixed in 10% neutralized formalin solution and processed for tissue morphology evaluation. Tumor cell density and the fraction of apoptotic cells were determined by counting the number of tumor cells and apoptotic cells in nonnecrotic regions at 400x magnification (5 microscopic fieldsltumor). The remainder of the tumor was stored at -70°C until HPLC analysis for drug concentration.
Printed by VlsualPatent The concentration of nonradiolabeled paclitaxel in plasma and tumor was analyzed by our previously reported HPLC assay using a column switching method (Song D et al. (1995) J Chromatogr B Biomed Appl. 663:337). Preweighed tumors were homogenized, mixed with the internal standard, 100 :1 cephalomanine (10 :g/ml in methanol). The HPLC stationary phase consisted of a cleaning column (NovaPak Cg, 75 x3.9 mm ID, 4 :m particle size, Waters Associates, Milford, MA) and an analytical column (Bakerbond Octadecyl, 250 x 4.6 mm ID, 5 :m particle size, J.T. Baker, Phillipsburg, NJ). Samples were injected onto the clean-up column and eluted with the clean-up mobile phase (37.5% acetonitrile in Water) at 1 ml/min. Concurrently, the analytical mobile phase (49% acetonitrile in Water) was directed through the analytical column at a flow rate of 1.2 ml/min. The fraction from 5 to 12 min containing paclitaxel and cephalomanine was transferred from the clean-up column onto the analytical column. Detection of paclitaxel and cephalomanine was at 229 nm, with a detection limit of 1 ng paclitaxel per injection.
Pharmacokinetic and tissue morphology studies were conducted to identify potential doses and times for administration of the drugs. The results, listed in Table 6, show that a pretreatment dose of 5 mg/kg infused over 1 hour is sufficient to induce apoptosis and reduce tumor cell density. These changes in tissue composition, as shown in the in vitro studies described above, are sufficient to enhance drug penetration in tumors. The pharmacokinetic data further showed a major half life of 1.1 hour for paclitaxel in rats, indicating that drug cancentration in plasma and tumor will be, theoretically, within 97% of a steady state following an infusion of six hours or longer (i. e., >_5 half lives). The latter is conf rmed by the plasma concentration-time profiles showing that the concentrations approached plateau values at the end of 6 and 12 hr infusions (13% diff'erence).
Table 6 shows the results of an experiment where animals received the indicated treatrnent (Tx). Concentrations of paclitaxel in tumors and plasma were determined by HPLC. Fraction of apoptotic cells and cell density were determined by counting the number of total and apoptotic cells in 400x microscopic fields (5 fields per tumor).
Mean ~ SD.
Printed by VisuaIPatent i ~ 1 i j . I
Group Infusion Total N Tumor Plasma Tumor-to-ApoptoticCell density ' : ~ ~ ; ~ i ~
' rate dose ~ conc. conc. plasma fraction, ' At ~ i (mglkg/hr)(mglkg~ (:glg) end of conc. % i . f at Tx i ratio ~
& schedule) ~ ~ specified(:g/ml) at end I . ~ I ' of i , i I , time i Tx ; y , x 1 10 5 3.9410.351.4210.112.80f0.2814.512:5 hr ~ , , ~ ~
at 30 a ~ ~ 83 ~ 4.69b 1 ! 0.83 x ~ = hra I
6 hr ~
~
at 24 I ~ i hr ~
', 5 5 ~ 4 2.7610.576.010.640.4610.09I .510.9120 t x I ; i ? ; ~ 4.35 hr at i 2A ~ 0 hr ' ~ at 1 . at 1 hr hr ' i 5 5 j 4 <0.35 ND NA ; 11.212.385 t 4.52 x 1 at .
hr at I
2B ; ' i 24 hr i ~ ~ at 24 0 hr hr' i 3 I 0.83 x 5 4 2.2610.131.310.121.7310.183.511.5 112 t 6 hr ' ' ' ; j 6.08 ~
at0hr ~ at6hr j 5 x 10 4 3.2410.312.9810.601.20+0.305.812.2 108 t I hr f i ; 5.78 at ~
4 j Ohr+0.83 ~ at7.2hr ~ i x6hrai j i 1.2 hr 5 ~ 0.83 10 5 2.9510.34' 1.5010.06i 1.9810.236.51.6 t 115 x 12 ' ~ t 5.18 I
hr ~ I at 12 ~ .
i i ~ hr I
~
' p<0.05. compared to all other groups.
b: p<0.01, compared to all other groups except Group 2B.
5 ': p<0.01, compared to all other groups except Group Z.
Three in vivo studies were performed. The first study examined the effect of pretreatment on drug delivery to tumor tissue, in three groups of animals.
Group 1 received a pretreatment of 5 mglkg over 1 hour and, at 24 hours, a second dose infused at a slower rate (i.e., 5 mglkg over 6 hours). To obtain the baseline measurements of drug delivery to tumor at each of the two doses, Group 2 received only the pretreatment, and Group 3 received only the second treatment. In the absence of enhanced drug delivery due to apoptosis. the drug concentration in Group 1 should be Printed by VisualPatent WO 00161141 PCTlUSOOI09329 lower than the sum of the concentrations in Groups 2 and 3, because the concentration derived from the pretreatment dose in Group 1 was measured at the end of the 30 hr total treatment time which, due to the continuing decline with time, should be lower . than the concentration in Group 2 which was measured immediately after the 1 hr S pretreatment. Conversely, in the presence of a substantially enhanced drug delivery due to apoptosis, the concentration in Group 1 may exceed the sum of concentrations in Groups 2 and 3. The results show a SO% higher tumor concentration in Group 1 at 30 hr or at the end of treatment compared with the sum of the concentration derived from Group 2 at 24 hr plus the concentration derived from Group 3 at 6 hr (Table 6), thus supporting our hypothesis of enhanced drug delivery due to apoptosis induced by the pretreatment.
The second study compared the tissue morphology and tumor concentration in Group 1 with those in Group 4 which received the same two doses by the same infusion schedules as Group 1, with the exception that the two doses were separated by only 10 1 S min (time required to change and reset the infusion syringe and pump) as opposed to the 23 hr in Group 1. As shown above, 24 hr was the duration needed for apoptosis and reduction in cell density to occur. At the end of treatment (30 hr for Group 1 and 7.2 hr for Group 4), Group 4 showed a 60% lower apoptosis, 30% higher cell density and 18%
lower drug concentration, compared to Group 1 (Table 6). These results indicate the importance of timing on drug-induced changes in tissue morphology and on drug delivery.
The third study compared the tissue morphology and tumor concentration in Group 1 to those in Group S which received the same total dose as Group 1 with the .exception that the dose was delivered at a slower rate continuously over a longer 2S duration, a. e. , 12 hr. At the end of treatment (30 hr for Group 1 and 12 hr for Group S), Group S showed a 3S% lower apoptosis and 2S% higher cell compared to Group l, and the drug concentration at 12 hr in Group S was 25% lower than the concentration at 30 hr in Group 1 (Table 6).
Another measurement of drug penetration in tumor is the tumor-to-plasma concentration ratio at the end of drug treatment when the plasma concentration in Groups 1, 4 and S were at an apparent steady state. A comparison of the tumor-to-plasma concentration ratio in these three groups shows a i30% and 40% higher ratios in Printed by VisuaIPatent -53=
Group 1 compared to Groups 4 and 5, respectively (Table 6), confirming the higher drug delivery in the group receiving the apoptosis-inducing pretreatment.
Collectively; the results of the in vivo studies confirm the findings in tumor histocultures, and further suggest a requirement of >10% apoptosis and >25%
reduced cell density for enhancing drug delivery to tumor under in vivo conditions.
EXAMPLE 3: Effect of Apoptosis-Inducing Pretreatment on Drug Penetration and Accumulation in Tissues using Doxorubicin as the Apoptosis Inducing Agent In this example, the penetration of doxorubicin into multilayer tissue was monitored using prostate tumor specimens obtained from human cancer patients and using the human prostate PC3 xenograft tumor maintained in athymic mice.
Doxorubicin was monitored by fluorescence.
Accumulation of doxorubicin in tumor histocultures Histocultures of tumors were incubated with 1, 5 or 20 :M doxorubicin as described in Example 1. These concentrations were chosen based on the previously published data which demonstrate that 0.4 :M doxorubicin was sufficient to produce, in patient prostate tumors, a 90% inhibition of tumor cell proliferation, and that 2.1 :M and 4.2 :M doxorubicin were sufficient to produce 50 and 90% cell death, respectively (Chen et al., (1998) Clin. Cancer Res. 4:277-282; 1998). At 4; 12, 24, 36, 48, and 72 hours, histocultures were collected and processed as described in Example 1. The fluorescence emitted by doxorubicin was visualized using fluorescence microscopy. The excitation and emission wavelengths were 546 nm and 565 nm, respectively. Microscopic images were captured using a Charged Couple Device (CCD) camera and the captured images were analyzed using Optimas image analysis software (Silver spring, MD). The doxorubicin concentration in tissues was quantified using standard curves (each curve contained six data points), established as follows. Samples for the standard curves were prepared by applying known amounts of doxorubicin in solution to microscope sections of blank dog prostate tissue. The standard doxorubicin solutions (2 :1) were pipetted on 10 :m-thick blank tissue sections, and carefully spread over a surface area of approximately 1.5 - 2 cmz. The standard slides were scanned using the same conditions as the samples. The average fluorescence intensity per area were measured.
Plots of the Printed by VisualPatent fluorescence readings against the applied doxorubicin concentrations in the standard curve samples provided the standard curves used to quantify the doxorubicin in the actual samples. For the latter, at least three sections were used to abtain the mean value in one tumor, and at least three tumors were used to obtain the mean value at each time point.
Figure 3 summarizes the accumulation of doxorubicin in tumor tissues, expressed as tissue-to-medium concentration ratio, as a function of time and initial extracellular drug concentrations. The results show that drug concentration in the periphery of tumor (i.e., 75 N.m) and in the far end of the tumor (i.e., 325 prn from the periphery of the tumor in contact with the culture medium) rose more rapidly in patient tumors than in the PC3 xenograft tumor. The ratios reached at 72 hr increased with the extracellular drug concentrations, but the increase was not linear with concentration. The latter may be due to the nonlinear drug binding which became saturated at the higher drug concentration, as described for paclitaxel in Example 1. At the lower drug concentration of 1 N,M, the drug concentration in the far end of the tumor remained several fold-lower compared to the concentration in the periphery. In contrast, at the higher drug concentrations of 5 and 20 ~M, the drug concentrations in the far end of the tumors approached the concentrations in the periphery of the tumors.
Collectively, these data indicate that the rate and extent of drug accumulation in solid tumors are dependent on time and initial drug concentration.
Table 7 shows the results of doxorubicin accumulation in patient tumors and the PC3 xenograft tumor, after 72 hr incubation with doxorubicin at 1, 5 and 20 N.M.
Printed by VTsuaIPatent Table 7 Tumor Drug Tissue Tissue-to- PC3 CeII density concentrationconcentrationmedium xenograft-to-in untreated in culture at 72 hr concentrationpatient tumortumor (cells medium, ratio at concentrationper mm2) ~M 72 hr ratio at 72 hr Patient 1 29.217.8 29.21?.8 1.15 1864125*
tumors 5 15 8170.9 31.6 14.2 1.3 5 20 7391531 36.9126.5 1.5 PC3 1 33.63.9 33.613.9 Not 2418t66~
xenograft5 213116.4 42.713:3 applicable tumor 20 1107193 55.39.6 *p<0.05, unpaired two-tailed Student's t-test.
Doxorubicin concentration in both patient tumors and the PC3 xenograft tumor increased with incubation time and with the initial drug concentration in the culture medium. The findings on the rate and extent of doxorubicin accumulation in patient and xenograft tumors are similar to the findings on paclitaxel described in Example 1. For example, drug accumulation in the xenograft tumor is slower compared to patient tumors (Figure 3). Drug concentration in the xenograft tumor shows a higher tumor-to-medium concentration ratio compared to patient tumors, although the difference is not statistically significant (Figure 3 & Table 7). The tumor cell density in the xenograft tumor without drug treatment is 1.3 fold-higher compared to patient tumors.
Collectively, these data indicate that the slower drug uptake rate and the higher drug accumulation in the PC3 xenograft tumor, compared to patient tumors, is due to the higher tumor cell density in the xenograft tumor.
Rate of doxorubicin ~~~enetration into tumors The rate of doxorubicin penetration into patient and PC3 xenograft tumors was monitored using fluorescence microscopy. The presence of fluorescence corresponds to the presence of doxorubicin and, hence, indicates the spatial distribution of doxorubicin Printed by VisualPatant in tumor tissue. The findings on doxorubicin penetration and distribution in tumor tissues are similar to the findings on paclitaxel as described in Example 1.
For example, the patient and xenograft tumors show different rate and pattern of doxorubicin penetration, and the rate of drug penetration was also dependent on the drug concentration. For the patient tumors treated with 5 or 20 ~.M, the fluorescence signal was confined to the periphery (about 75 pm thick) during the first 12 hr, but became evenly distributed throughout the histoculture (about 325 pm thick) after 24 hr: For the xenograft tumor treated with the same drug concentrations (i. e., 5 or 20 p.M), the fluorescence signal was confined to the periphery during the first 24 hr, and became evenly distributed only after 36 hr. At the lower drug concentration of 1 p.M, the drug was distributed evenly throughout the patient tumors by 72 hr but remained confined to the periphery of the xenograft tumor at 72 hr.
Figure 4 summarizes the drug concentration in tumor tissue, expressed as tissue-to-medium concentration ratio, as a function of the distance from the periphery of the tumor histocultures. The results show that the attainment of an equilibrium between the drug concentration in the far end of the tumor (i. e., 325 ~m from the periphery of the tumor in contact with the culture medium) with the drug concentration in the periphery of the tumor (i. e. , 75 Vim) depends on the initial drug concentration in the culture medium. At the lower drug concentration of 1 uM, the drug concentration in the far end of the tumor did not reach equilibrium with the concentration in the periphery. For the higher concentrations of 5 and 20 ~,M, the equilibrium was attained at 36 hr.
Collectively, these results indicate that rate and extent of doxorubicin penetration into tumor is dependent on the treatment time and the extracellular drug concentration.
These data are similar to the findings for paclitaxel, as described in Example 1, and suggest that doxorubicin-induced apoptosis enhances the rate and extent of drug penetration into tumors.
Roles of cell death in drug penetration Tumor cell density was monitored as described in Example 1. The cell death and therefore the reduction of cell density induced by doxorubicin treatment were dependent on the initial drug concentration. For example, the cell density in the periphery of the PC3 xenograft tumor (i.e., about 75 pm thick) decreased with time after treatment with 5 Printed by VisualPatent or 20 wM doxorubicin, but not after treatment with 1 pM doxorubicin. Figure 5 shows the inverse correlation of the average drug concentration in the PC3 xenograft tumor and the tumor cell density in the periphery of the tumor, after treatment with 20 p.M
doxorubicin.
S
In summary, this example shows that (a) the penetration of doxorubicin in tumors is more rapid but the accumulation is lower as the density of epithelial tumor cells decreases, (b) drug-induced apoptosis enhances drug penetration into the inner cell layers of solid tumors, (c) the concentration-dependent drug penetration rate is related to the concentration-dependent apoptotic effect, and (d} the time-dependent drug penetration is related to the kinetics of apoptosis. These findings are qualitatively identical to the findings for paclitaxel (described in Example 1 ), and indicate apoptosis-inducing pretreatment as a generally applicable principle for enhancing drug penetration into multilayer tissues.
EXAMPLE 4: Apoptosis-Inducing Pretreatment Enhances Penetration of Large Particles in Multilayer Tissues Two studies were performed to evaluate the ability of apoptosis-inducing pretreatment to enhance the penetration of large molecules in multilayer tissues. The first study used fluorescence-tagged (i.e., FITC-labeled) nanoparticies, which are between 600-800 nm in diameter. The penetration of the nanoparticles was monitored by fluorescence microscopy. The second study used microparticles (about 5 micron in diameter). The penetration of the microparticles was monitored by scanning electron microscopy.
The muitilayer tissue model for both studies was the human breast xenograft tumor derived from subcutaneous implantation of MCF7 cells. Tumors were removed from mice; fragmented and grown as histocultures on collagen gel matrix. One group received a pretreatment with 100 nM paclitaxel for 24 hr. The histocultures were then moved to a second culture flask, and incubated in paclitaxel-free culture medium with FITC-nanoparticles or microparticles for additional 48 hr. The control group was treated similarly, except no paclitaxel was added to the culture medium.
Samples of Printed by VisuaIPatent _ 58 -histocultures were removed at 0, 4, 6, 12, 24 and 48 hr after exposure to nanoparticles or microparticles. Histocultures were frozen, cut into 10 micron sections. The frozen sections were mounted on microscopic slides and examined microscopically.
The results show that in the control groups, penetration of nanoparticles and microparticles in tumor histocultures in the 48 hour exposure period was limited to the periphery. In the pretreated groups, nanoparticles and microparticles penetrated the center of the histocultures by 24 hr and became evenly distributed throughout the histocultures by 48 hr.
1 U Summary 1n summary, apoptosis-inducing pretreatment enhances penetration of particles of about 5 micron diameter in multilayer tissues.
EXAMPLE 5: Nanoparticle and microparticle formulations Poly(lactide-co-glycolide) (PLGA) microspheres were prepared by a standard oil-in-water emulsion-solvent evaporation method (Thies C., 1991, In Donbrow M. (Ed.) Microcapsules and Nahoparticles in Medicine and Pharmacy, CRC Press, Ann Arbor, pp. 47-71). For doxorubicin-containing microspheres, doxorubicin in its free base form, and PLGA were dissolved in a 1:6 mixture of methanol in methylene chloride.
'Polymer and drug solutions were emulsified in an aqueous solution containing 1°l0 (w/v) polyvinylalcohol and 10 mM boric acid, pH 8.8 by brief vortexing.
Subsequently, the emulsion was diluted, and the organic solvents allowed to evaporate. The microspheres were harvested by filtration, and lyophilized. For paclitaxel microspheres, PLGA and paclitaxel were dissolved in methylene chloride. The solution was emulsified with a glycerinlwater mixture containing Tv~reen.80. The microspheres were harvested by centrifugation and lyophilized. The average particle size was 1 Vim.
Nanoparticles .containing paclitaxel were prepared by the phase separation methods. An aqueous solution of gelatin and Tween 20 was heated and sodium sulfate added until turbidity'was obsexved. Paclitaxel-containing isopropanol solution was then added until the turbidity disappeared. Glutaraldehyde and potassium meta-bisulfate were added in sequence. The resulting nanoparticles were harvested by,centrifugation and . ' lyo..plzilized. The average particle size was 620 nm.
Printed by VisuaiPatent WO 00!61141 PCTJIJS00109329 Nanocapsules containing paclitaxel were prepared by the oil-in-water-in-oil method. Tween 20 was added to 10 acres solution of gelatin. Paclitaxel was dissolved in methylene chloride. The two solutions were emulsified to form an oil-in-water emulsion. Mineral oil containing glutaraldehyde was then added. After teaching the mixture, potassium meta-bisulfate was added. The resulting microparticles were harvested by centrifugation and lyophilized. The average particle size was 13 Vim.
Liposomes containing paclitaxel were prepared by mixing triasterin, paclitaxel and Tween 80. Phosphate buffered saline was added while vortexing, to form an emulsion. The lipospheres were harvested by centrifugation. Addition of egg phosphatidylcholine to the mixture improves the smoothness of the particle surface. The average particle size was 10 ~,m.
Incorporation by Reference The entire contents of all patents, published patent applications and other references cited herein are hereby expressly incorporated herein in their entireties by reference.
Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
Printed by VisualPatent
Claims (108)
1. A method for delivering a therapeutic agent to tissue of a patient, comprising:
administering an apoptosis inducing agent to the patient, and allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient, such that the therapeutic agent is delivered to tissue of the patient.
administering an apoptosis inducing agent to the patient, and allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient, such that the therapeutic agent is delivered to tissue of the patient.
2. The method of claim 1, wherein said tissue is a tumor.
3. The method of claim 1, wherein said tissue is liver, neuronal, muscle, skin or adipose tissue.
4. The method of claim 2, wherein said tumor is a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
5. The method of claim 1, wherein said apoptosis inducing agent is paclitaxel or doxorubicin.
6. The method of claim 1, wherein said sufficient time is sufficient to reduce the density of the solid cells of the tissue by about 30% or greater.
7. The method of claim 1, wherein said sufficient time is sufficient to induce apoptosis in 10% or more of the solid cells of the tissue.
8. The method of claim 1, wherein said apoptosis inducing agent is administered locally.
9. The method of claim 1, wherein said apoptosis inducing agent is administered regionally.
10. The method of claim 1, wherein said apoptosis inducing agent is also said therapeutic agent but wherein said therapeutic agent comprises a separate dose or a slow-release form of the apoptosis inducing agent.
11. The method of claim 1, wherein said therapeutic agent is a gene therapy construct, a chemotherapeutic agent, a protein bound drug or an antibiotic.
12. The method of claim 1, wherein said patient is a human.
13. The method of claim 1, wherein said apoptosis inducing agent and said therapeutic agent are administered simultaneously and the therapeutic agent is a slow-release formulation that releases the therapeutic agent after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
14. The method of claim 1, wherein said apoptosis agent and said therapeutic agent are administered sequentially, the therapeutic agent being administered after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
15. A method for delivering a therapeutic agent to tissue of a patient, comprising:
obtaining an apoptosis inducing agent;
administering the apoptosis inducing agent to the patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient; and delivering the therapeutic agent to the tissue of the patient, such that said therapeutic agent is delivered to tissue of the patient.
obtaining an apoptosis inducing agent;
administering the apoptosis inducing agent to the patient, allowing sufficient time for the apoptosis inducing agent to induce apoptosis in the tissue of the patient; and delivering the therapeutic agent to the tissue of the patient, such that said therapeutic agent is delivered to tissue of the patient.
16. A method for delivering a therapeutic agent to a tumor in a patient, comprising:
administering a dose of an apoptosis inducing agent to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient, such that the therapeutic agent is delivered to the tumor.
administering a dose of an apoptosis inducing agent to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient, such that the therapeutic agent is delivered to the tumor.
17. The method of claim 16, wherein said tumor is cancerous.
18. The method of claim 16, wherein said tumor is a benign tumor.
19. The method of claim 17; wherein said cancerous tumor is a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
20. The method of claim 16, wherein said apoptosis inducing agent is paclitaxel.
21. The method of claim 16, wherein said apoptosis inducing agent is doxorubicin.
22. The method of claim 16, wherein said dose of said apoptosis inducing agent is sufficient to reduce the density of the solid tumor cells.
23. The method of claim 22, wherein the reduction of the density of the solid tumor cells is about 10% or greater.
24. The method of claim 23, wherein the reduction of the density of the solid tumor cells is about 20% or greater.
25. The method of claim 24, wherein the reduction of the density of the solid tumor cells is about 30% or greater.
26. The method of claim 25, wherein the reduction of the density of the solid tumor cells is about 35% or greater.
27. The method of claim 16, wherein said dose of said apoptosis inducing agent induces apoptosis in about 5% or more of the solid tumor cells.
28. The method of claim 27, wherein said dose of said apoptosis inducing agent induces apoptosis in about 10% or more of the solid tumor cells.
29. The method of claim 28, wherein said dose of said apoptosis inducing agent induced apoptosis in about 15% or more of the solid tumor cells.
30. The method of claim 29, wherein said sufficient time is sufficient for the reduction of 20% or more of the density of the solid tumor cells.
31. The method of claim 20, wherein said sufficient time is sufficient for the reduction of 30% of more of the density of the solid tumor cells.
32. The method of claim 16, wherein said sufficient time is sufficient to induce apoptosis in more than 5% of said solid tumor cells.
33. The method of claim 31, wherein said sufficient time is sufficient to induce apoptosis in more than 10% of said solid tumor cells.
34. The method of claim 20, wherein said sufficient time is between about 16 to about 24 hours.
35. The method of claim 20, wherein said dose of said apoptosis inducing agent is about 50 nM over about 1 hour.
36. The method of claim 16, wherein said patient is a human.
37. The method of claim 16, wherein said apoptosis inducing agent is also said therapeutic agent but wherein said therapeutic agent comprises a separate dose or a slow-release form of the apoptosis inducing agent.
38. The method of claim 37, wherein said therapeutic agent and said apoptosis inducing agent comprise paclitaxel.
39. The method of claim 37, wherein said therapeutic agent and said apoptosis inducing agent comprise doxorubicin.
40. The method of claim 16, wherein said therapeutic agent comprises a gene therapy construct, a protein bound drug, a chemotherapeutic agent, or an antibiotic.
41. The method of claim 40, wherein said therapeutic agent is a gene therapy construct, wherein said construct comprises a tumor suppressor gene.
42. The method of claim 41, wherein said tumor suppressor gene is p53.
43. The method of claim 40, wherein said therapeutic agent is a protein bound drug.
44. The method of claim 16, wherein said apoptosis inducing agent is administered systemically.
45. The method of claim 16, wherein said apoptosis inducing agent is administered regionally.
46. The method of claim 16, wherein said apoptosis inducing agent is administered locoregionally.
47. The method of claim 16, wherein said apoptosis inducing agent is administered locally.
48. The method of claim 16, wherein said therapeutic agent is administered systemically.
49. The method of claim 16, wherein said therapeutic agent is administered regionally.
50. The method of claim 16, wherein said therapeutic agent is administered locoregionally.
51. The method of claim 16, wherein said therapeutic agent is administered locally.
52. The method of claim 16, wherein said apoptosis inducing agent or said therapeutic agent is administered with a pharmaceutically acceptable carrier.
53. The method of claim 52, wherein said pharmaceutically acceptable carrier is suitable for intravenous injection.
54. The method of claim 16, wherein said apoptosis inducing agent is formulated as a microparticle or a nanoparticle.
55. The method of claim 17, wherein said therapeutic agent is formulated as a microparticle or a nanoparticle.
56. A method for delivering a therapeutic agent to a tumor in a patient, comprising:
obtaining an apoptosis inducing agent;
administering a dose of the apoptosis inducing agent to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient, such that the therapeutic agent is delivered to the tumor.
obtaining an apoptosis inducing agent;
administering a dose of the apoptosis inducing agent to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a therapeutic agent to said patient, such that the therapeutic agent is delivered to the tumor.
57. A method for delivering a chemotherapeutic agent to a tumor in a patient, comprising:
administering a dose of an apoptosis inducing agent locally or regionally to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a chemotherapeutic agent to said patient, such that the chemotherapeutic agent is delivered to the tumor.
administering a dose of an apoptosis inducing agent locally or regionally to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a chemotherapeutic agent to said patient, such that the chemotherapeutic agent is delivered to the tumor.
58. The method of claim 57, wherein said tumor is cancerous.
59. The method of claim 58, wherein said cancerous tumor is a brain, breast, ovarian, bladder, prostate, colon, lung, liver, or uterine tumor.
60. The method of claim 57, wherein said apoptosis inducing agent is paclitaxel.
61. The method of claim 57, wherein said apoptosis inducing agent is doxorubicin.
62. The method of claim 57, wherein the reduction of the density of the solid tumor cells is about 30% or greater.
63. The method of claim 62, wherein the reduction of the density of the solid tumor cells is about 35% or greater.
64. The method of claim 63, wherein said sufficient time is sufficient for the reduction of 20% or more of the density of the solid tumor cells.
65. The method of claim 64, wherein said sufficient time is sufficient for the reduction of 30% of more of the density of the solid tumor cells.
66. The method of claim 57, wherein said sufficient time is sufficient to induce apoptosis in more than 5% of said solid tumor cells.
67. The method of claim 66, wherein said sufficient time is sufficient to induce apoptosis in more than 10% of said solid tumor cells.
68. The method of claim 60, wherein said sufficient time is between about 16 to about 24 hours.
69. The method of claim 60, wherein said dose of said apoptosis inducing agent is about 50 nM over about 1 hour.
70. The method of claim 57, wherein said patient is a human.
71. The method of claim 57, wherein said apoptosis inducing agent is also said chemotherapeutic agent but wherein said chemotherapeutic agent comprises a separate dose or a slow-release form of the apoptosis inducing agent.
72. The method of claim 57, wherein said chemotherapeutic agent and said apoptosis inducing agent comprises paclitaxel.
73. The method of claim 57, wherein said therapeutic agent and said apoptosis inducing agent comprises doxorubicin.
74. The method of claim 57, wherein said apoptosis inducing agent is formulated as microparticles or nanoparticles.
75. The method of claim 57, wherein said therapeutic agent is formulated as microparticles or nanoparticles.
76. The method of claim 57, wherein said apoptosis agent or said therapeutic agent are administered with a pharmaceutically acceptable carrier.
77. The method of claim 76, wherein said pharmaceutically acceptable carrier is suitable for intravenous injection.
78. The method of claim 57, wherein said apoptosis inducing agent and said therapeutic agent are administered simultaneously and the therapeutic agent is a slow-release formulation that releases the therapeutic agent after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
79. The method of claim 57, wherein said apoptosis agent and said therapeutic agent are administered sequentially, the therapeutic agent being administered after sufficient time to allow for the apoptosis inducing agent to induce apoptosis in the tissue of the patient.
80. The method of claim 57, wherein said patient is a human.
81. A method for delivering a chemotherapeutic agent to a tumor in a patient, comprising:
obtaining an apoptosis inducing agent;
administering a dose of the apoptosis inducing agent locally or regionally to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a chemotherapeutic agent to said patient, such that the chemotherapeutic agent is delivered to the tumor.
obtaining an apoptosis inducing agent;
administering a dose of the apoptosis inducing agent locally or regionally to a patient;
allowing sufficient time for said apoptosis inducing agent to induce apoptosis in the tumor; and delivering a dose of a chemotherapeutic agent to said patient, such that the chemotherapeutic agent is delivered to the tumor.
82. A composition for delivering a therapeutic agent to a patient comprising:
a quick release formulation of an apoptosis inducing agent;
a slow release formulation of a therapeutic agent; and a pharmaceutically acceptable carrier.
a quick release formulation of an apoptosis inducing agent;
a slow release formulation of a therapeutic agent; and a pharmaceutically acceptable carrier.
83. The composition of claim 82, wherein said apoptosis inducing agent is paclitaxel.
84. The composition of claim 82, wherein said quick release formulation releases about 50 nM of paclitaxel over about 1 hour or less.
85. The composition of claim 82, wherein said apoptosis inducing agent is doxorubicin.
86. The composition of claim 82, wherein said apoptosis inducing agent is provided in an amount sufficient to reduce the density of the solid tumor cells by about 30% or greater, within about 16-24 hours after administration.
87. The composition of claim 82, wherein said apoptosis inducing agent is provided in an amount sufficient to induce apoptosis in 10% or more of the solid tumor cells, within about 16-24 hours after administration.
88. The composition of claim 82, wherein said therapeutic agent is paclitaxel or doxorubicin.
89. The composition of claim 82, wherein said therapeutic agent is a protein-bound drug, a chemotherapeutic agent, an antibiotic or a gene delivery construct.
90. The composition of claim 89, wherein said gene delivery construct comprises a tumor suppressor gene.
91. The composition of claim 82, wherein said pharmaceutical composition is suitable for intravenous injection.
92. The composition of claim 82, wherein said pharmaceutical composition is suitable for local administration.
93. The composition of claim 82, wherein said pharmaceutical composition is suitable for regional administration.
94. The composition of claim 82, wherein said apoptosis inducing agent is formulated as a microparticle or nanoparticle.
95. The composition of claim 82, wherein said therapeutic agent is formulated as a microparticle or nanoparticle.
96. A kit for the treatment of tumors, comprising:
an apoptosis inducing agent in a pharmaceutically acceptable carrier;
a therapeutic agent in a pharmaceutically acceptable carrier;
a container; and directions for using said apoptosis inducing agent and said therapeutic agent for the treatment of tumors.
an apoptosis inducing agent in a pharmaceutically acceptable carrier;
a therapeutic agent in a pharmaceutically acceptable carrier;
a container; and directions for using said apoptosis inducing agent and said therapeutic agent for the treatment of tumors.
97. A nanoparticle comprising a cross linked gelatin and a therapeutic agent or an apoptosis inducing agent.
98. The nanoparticle of claim 97, wherein said nanoparticle is about 500 nm to about 1 µm in diameter.
99. The nanoparticle of claim 98, wherein said therapeutic agent or said apoptosis inducing agent is paclitaxel.
100. The nanoparticle of claim 97, wherein said therapeutic agent or said apoptosis inducing agent is doxorubicin.
101. A microparticle comprising a therapeutic agent or an apoptosis inducing agent, wherein said microparticle is suitable for administration to a patient locally, regionally, or locoregionally.
102. The microparticle of claim 101, wherein said microparticle is about 1 µm to about 10 µm in diameter.
103. The microparticle of claim 102, wherein said microparticle is about 3 µm to about 7 µm in diameter.
104. The microparticle of claim 103, wherein said microparticle is about 5 µm in diameter.
105. The microparticle of claim 101, wherein said therapeutic agent or said apoptosis inducing agent is paclitaxel.
106. The microparticle of claim 101, wherein said therapeutic agent or said apoptosis inducing agent is doxorubicin.
107. A microparticle suitable for administration to a patient locally, regionally, or locoregionally, comprising paclitaxel, wherein said microparticle has a diameter of about 5µm.
108. A microparticle suitable for administration to a patient locally, regionally, or locoregionally, comprising doxorubicin, wherein said microparticle has a diameter of about 5 µm.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12867499P | 1999-04-09 | 1999-04-09 | |
US60/128,674 | 1999-04-09 | ||
PCT/US2000/009329 WO2000061141A2 (en) | 1999-04-09 | 2000-04-07 | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2369263A1 true CA2369263A1 (en) | 2000-10-19 |
Family
ID=22436437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002369263A Abandoned CA2369263A1 (en) | 1999-04-09 | 2000-04-07 | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1171118A2 (en) |
JP (1) | JP2003524624A (en) |
AU (1) | AU777620B2 (en) |
CA (1) | CA2369263A1 (en) |
WO (1) | WO2000061141A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2462369C (en) * | 2001-10-03 | 2009-12-22 | Celator Technologies Inc. | Compositions for delivery of drug combinations |
EP1453537A1 (en) | 2001-12-12 | 2004-09-08 | FH Faulding & Co. Limited | Composition for viral preservation |
JP2004277379A (en) * | 2003-03-18 | 2004-10-07 | Medicos Hirata:Kk | Drug delivery system for inducing apoptosis |
EP1608359A4 (en) * | 2003-04-03 | 2011-08-17 | Jessie L-S Au | Tumor-targeting drug-loaded particles |
US8043631B2 (en) * | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
BRPI0502497A (en) * | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | use of protein-coupled receptor agonists and antagonists, but as modulators of apoptotic activity for the study, prevention and treatment of diseases |
WO2009116556A1 (en) * | 2008-03-19 | 2009-09-24 | 富士フイルム株式会社 | Pharmaceutical composition for injection |
KR101208587B1 (en) * | 2009-06-24 | 2012-12-06 | 여오영 | Anticancer composition for local injection comprising hydroxychloroquine |
US9775819B2 (en) * | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
RU2563997C2 (en) * | 2009-09-21 | 2015-09-27 | Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН | Oxaliplatin nanoparticles and method of obtaining thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08506317A (en) * | 1992-05-20 | 1996-07-09 | プロ − ニューロン,インコーポレーテッド | Combination of chemotherapeutic agents |
EP0727984B1 (en) * | 1993-11-18 | 2003-06-25 | Sirtex Medical Limited | Controlled release preparation |
DE4417865A1 (en) * | 1994-05-20 | 1995-11-23 | Behringwerke Ag | Two component tumour therapy using necrosis inducing agent |
US5900429A (en) * | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
BR9808109A (en) * | 1997-03-31 | 2000-03-08 | Neorx Corp | Therapeutic smooth muscle vascular cell inhibitor |
ATE219363T1 (en) * | 1997-06-20 | 2002-07-15 | Baker Norton Pharma | SOLUBLE PRODRUGS OF PACLITAXEL |
JPH11269065A (en) * | 1998-03-19 | 1999-10-05 | Microbial Chem Res Found | Agent for overcoming apoptosis resistance of cancer cells |
JPH11322602A (en) * | 1998-05-13 | 1999-11-24 | Kazuo Umezawa | Inhibitor of transcription factor nfkappab activation |
-
2000
- 2000-04-07 EP EP00921881A patent/EP1171118A2/en not_active Ceased
- 2000-04-07 CA CA002369263A patent/CA2369263A1/en not_active Abandoned
- 2000-04-07 WO PCT/US2000/009329 patent/WO2000061141A2/en active Application Filing
- 2000-04-07 AU AU42142/00A patent/AU777620B2/en not_active Ceased
- 2000-04-07 JP JP2000610474A patent/JP2003524624A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1171118A2 (en) | 2002-01-16 |
JP2003524624A (en) | 2003-08-19 |
WO2000061141A3 (en) | 2001-03-01 |
WO2000061141A2 (en) | 2000-10-19 |
AU777620B2 (en) | 2004-10-21 |
AU4214200A (en) | 2000-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7217735B1 (en) | Methods and compositions for enhancing delivery of therapeutic agents to tissues | |
Dave et al. | Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications | |
Papa et al. | Ultrasound-sensitive nanoparticle aggregates for targeted drug delivery | |
Kabanov et al. | New technologies for drug delivery across the blood brain barrier | |
Jain et al. | Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery | |
Singh et al. | Nanoparticle-based targeted drug delivery | |
Kuo et al. | Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor | |
Kasinathan et al. | Strategies for drug delivery to the central nervous system by systemic route | |
EP0740548B1 (en) | Drug targeting system, method for preparing same and its use | |
Gao et al. | UEA I-bearing nanoparticles for brain delivery following intranasal administration | |
US20040038406A1 (en) | Nanoparticle delivery systems and methods of use thereof | |
EP2106806A1 (en) | Nanoparticles for targeted delivery of active agents to the lung | |
Abdelaziz et al. | Inhalable lactoferrin/chondroitin-functionalized monoolein nanocomposites for localized lung cancer targeting | |
Martucci et al. | Nanoparticle-based strategy for personalized B-cell lymphoma therapy | |
AU777620B2 (en) | Methods and compositions for enhancing delivery of therapeutic agents to tissues | |
CA2623293A1 (en) | Nanoparticles for targeted delivery of active agents | |
Singh et al. | Nanocarrier mediated autophagy: an emerging trend for cancer therapy | |
US8449915B1 (en) | Pharmaceutical composition of nanoparticles | |
Sarwar et al. | Oral delivery and enhanced efficacy of antimonal drug through macrophage-guided multifunctional nanocargoes against visceral Leishmaniasis | |
Lahkar et al. | Surface modified polymeric nanoparticles for brain targeted drug delivery | |
KR20210053881A (en) | Polymer nanoparticles containing salinomycin | |
CN111617260A (en) | Fusion peptide-modified brain metastases-targeted nano-drug delivery system capable of avoiding LRP1-mediated reflux and preparation method and application thereof | |
TWI472341B (en) | Oligomeric nanoparticle complex release system | |
JP2018534244A (en) | Compositions and methods for improving nanoparticle distribution within brain stroma | |
Castro-Pastrana et al. | Recent Advances on Nanostructured Materials for Drug Delivery and Release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |